

PATIENT STRATIFICATION AND DETERMINING CLINICAL OUTCOME FOR CANCER PATIENTS

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 [0001] This application claims the benefit of priority of US provisional application No. 61/538,487, filed September 23, 2011, the contents of it being hereby incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

- 10 [0002] The present invention refers to the field of bioinformatics and biochemistry of cancer.

BACKGROUND OF THE INVENTION

- [0003] The hallmark of human cancer is heterogeneity. The heterogeneity of human cancer can be demonstrated in at least three aspects: diverse histopathological characteristics, different genetic traits,
15 and complex molecular events and signaling mechanisms. These factors reflect the complexity of the underlying molecular mechanisms governing carcinogenesis and carcinoma progression. Therefore, these factors contributing to heterogeneity also impose great challenges in designing effective therapeutic strategies to benefit cancer patients.

- [0004] To tackle this challenge, it is critical to take innovative approaches to identify patient
20 subgroups that share common molecular characteristics. This approach would further provide frameworks to assist in developing rational cancer diagnostics and therapeutic strategies. One of the best examples is the development of trastuzumab in treating Her2 positive breast cancers. Her2 is a growth promoting oncogene over-expressed in approximately 18% of breast cancer patients. A substantial body of work, including those using genome-scale gene expression measures, has
25 demonstrated that Her2 positive breast cancer is a distinct disease entity which is distinctive in phenotypic behaviours such as the tendency for distant metastasis. Trastuzumab, a monoclonal antibody against Her2, has been shown to be an effective treatment only for breast cancer patients that show Her2 amplification. Another example is the discovery of the positive correlation between EGFR mutation and the response to EGFR inhibitor Iressa in treating non-small cell lung cancer patients.

- 30 [0005] Innovations like these have not been rapidly and successfully translated to other cancer types. For example, the therapeutic innovation for epithelial ovarian cancer (EOC) is slow. One major reason for this slow innovation for novel therapeutics in EOC is the lack of strong evidence supporting the applicability of patient stratification by using robust molecular diagnostics in the prediction of survival or therapeutic response. The heterogeneity of EOC might be even more
35 complex which can be evident in at least four aspects.

[0006] Firstly, EOC represents a broad and heterogeneous entity which includes different invasive behavior (low malignant potential and invasive) as well as four major distinct histopathological subtypes, serous, mucinous, endometrioid, and clear cell carcinomas.

[0007] Secondly, EOC can occur in women harboring germline mutations of genes such as BRCA1/2 and mismatch repair genes as the hereditary trait, and in women without germline mutations as the sporadic trait.

[0008] Thirdly, the carcinogenesis process of EOC does not follow the step-wise model as in the colorectal cancer but rather has been proposed to follow two pathways: Type I and Type II. Type I diseases consist mainly of low-grade tumors with frequent KRAS or BRAF mutations and identifiable pre-malignant lesions (borderline malignancy). Type II diseases consist of high-grade tumors with predominant p53 mutations and potential precursor lesions harboring the same p53 mutations.

[0009] Finally, multiple signaling pathways contribute to growth promotion, insensitivity to antigrowth signals, inhibition of apoptosis and immune surveillance, enhanced angiogenesis, and promotion of invasion and metastasis in EOC. However, most EOC patients receive the same taxane/platinum-based chemotherapy regardless of the existing heterogeneity. For EOC, targeted therapies against VEGF (angiogenesis), EGFR (survival), or c-Kit (stem cell) pathways have not provided encouraging results from clinical trials. Therefore, the therapeutic modalities for EOC have remained at the primitive ground and have not provided additional benefits to the patients.

[0010] Genome-scale expression data has been utilized to characterize the complex biological diversity in human cancer. The substantial number of data points provides the robustness to detect not only common properties but also subtle biological differences across the whole variety of cancer samples. Several studies on breast cancer, glioblastoma multiforme (GBM), and diffuse large B-cell lymphoma have demonstrated this application on identifying patient subtypes.

[0011] Subtypes identified through expression microarray analyses are well linked with multiple important clinical parameters such as age, expression patterns of molecular markers, and patient survival prognosis. These efforts have helped advancing the understanding of cancer heterogeneity and designing potential diagnostic and therapeutic schemes which have made personalized medicine possible. For cancers that have not benefited from these advances, such as EOC, several microarray studies have been conducted to correlate the expression pattern with clinical features such as histological types, aggressiveness and patient outcomes. These studies have shed light that molecular subtyping might be able to provide hope of innovations in therapies for complex diseases such as EOC.

[0012] There have been accumulative evidences suggesting that epithelial-mesenchymal transition (EMT), a fundamental mechanism in embryonic development, plays a crucial role in promoting carcinoma progression. EMT describes the process driving epithelial cells to form cells

exhibiting a fibroblastic-like morphology (mesenchymal). This mechanism involves multiple steps including the loss of an apico-basolateral polarity. The loss of epithelial cell polarity is induced by the dissolution of junctional complexes (desmosomes and adherens junctions) and tight junctions, and the concomitant remodeling of the actin cytoskeleton. Epithelial cells also delocalize polarity gene products and modulate their integrin adhesome to favor cell substrate adhesions to eventually acquire a mesenchymal phenotype. This critical transdifferentiation program leads to cells with low intercellular adhesion and equipped with rear-front polarity favoring cell locomotion and invasion.

[0013] In cancer progression, EMT explains how carcinoma cells invade and metastasize by transforming the epithelial state via an intermediate potentially metastable state to the mesenchymal state. The EMT program could also contribute to the dissemination of carcinoma cells from solid tumors and to the formation of micrometastatic foci which subsequently develop into clinically detectable metastases. EMT is also involved in the acquisition of chemoresistance maintaining cancer stemness and causing immune escape. The proof of concept that EMT indeed is involved in human cancers arises from several recent genome-scale expression analyses. EMT signatures have been found in the claudin-low (Basal B) subtypes of breast cancers, a subgroup of GBM, and the C1 and C5 clusters of EOC. In EOC, the progression and dissemination have been suggested to involve a vicious EMT-MET cycle.

[0014] Unique features of ovarian carcinoma are the ability to spread by shedding from the primary tumour to the surrounding peritoneal cavity and to generate large amount of ascites. The shedding of ovarian carcinoma cells requires the loss of cell-cell and cell-matrix adhesions. The production of ascites is mainly due to increased vascular permeability and extravasation of the intravascular fluid to the peritoneal cavity resulting from the presence of angiogenic factors such as VEGF. Some of the shed cells escape from apoptosis and survive as aggregates and form floating spheroids in the ascitic fluids. Cytokines and growth factors (ex. IL-6, IL-8, HB-EGF, TGF- α , VEGF, b-FGF, LPA, etc.) secreted from the cancer spheroids, reactive immune cells, and peritoneal mesothelial cells provide an autocrine and paracrine milieu for the survival of spheroids. These spheroids then adhere to and invade the peritoneum resulting in extensive dissemination of the disease. Transcriptional repressors such as SNAIL and SNAIL2 have been shown to govern the EMT process in ovarian cancer cells. Recent data have also demonstrated that pathway related to EMT is associated with platinum-based chemotherapy resistance (Helleman, Smid et al. 2010). Also, EMT is also related to a "migratory cancer stem cell-like" phenotype in recurrent ovarian cancers. In GBM, a mesenchyme like subtype was found by unsupervised clustering but not extensively. In breast cancer, several molecular subtypes are exhibiting a mesenchymal like phenotype. They include a newly described subtype named claudin-low. The basal subtype is also a mesenchymal-like phenotype; it includes sporadic tumors, BRCA1 tumors and sarcomatoid carcinoma.

[0015] EMT is best demonstrated at the tumor invasive fronts of colorectal cancers where in-transit mesenchymal-like cells can be identified. The invasive fronts indicate the interface between the main tumor mass and the microenvironment milieu. This frontline can be regarded as the starting point of the pressure gradient generated by the microenvironment. Signals of EMT thus follow a gradient from the invasive front toward the inner tumor mass. Also, within the inner tumor mass, pressures coming from hypoxia and nutrient depletion create another gradient for EMT. Therefore, EMT contributes to tumor heterogeneity. In fact, the different degree of EMT involvement provides a novel aspect to understand tumor heterogeneity that each individual tumor can be regarded as a mixture of different populations with or without undergoing EMT. The heterogeneity of each individual tumor is summarized in Figure 1 and represented as an EMT Status (or EMT Score).

[0016] EMT can be triggered by different signal transduction pathways, including a large number of cell surface receptors like receptor tyrosine kinases, integrins, TGF- β receptors, as well as several intracellular kinases such as ILK and SRC. Most of the known inhibitors of these signaling pathways (e.g. Erlotinib, Dasatinib, Vatalanib, Sunitinib, etc.) were not originally identified based on their involvement on EMT regulation, but often as anti-proliferative agents. Anti-proliferation or growth inhibition has long been adopted as the standard endpoint for anti-cancer drug screen. Therefore, the current paradigm in cancer treatment still focuses on the discovery and development of cytotoxic therapeutic agents that alter the 5 hallmark mechanisms of cancer proposed by Hanahan and Weinberg (Hanahan and Weinberg, 2011, Cell, vol.144, no.5, pp.646).

[0017] Experimental systems, whether *in vitro* cancer cell lines or tumor xenografts, have been established to fulfill that purpose. The development of the US National Cancer Institute (NCI) 60 human tumour cell line (NCI60) which includes nine distinct tumour types: leukaemia, CNS, renal, melanoma, ovarian, breast and prostate, has served as a great asset for cancer researchers to provide an *in vitro* model for drug discovery by identifying compounds with growth-inhibitory effects.

[0018] However, experiences from treatment failure of cytotoxic drugs suggested that incorporating other biological mechanisms which regulate tumour invasiveness and dissemination as additional endpoints might help design novel therapeutics to overcome resistance. In fact, an increasing number of studies that have demonstrated failure of established drugs in arresting cancer progression at its invasive phase have indirectly highlighted the importance of EMT control. One study identified potential cytotoxic agents against breast cancer cells that have undergone EMT. To our knowledge, there has been no drug-screen platform reported to solely inhibit EMT and achieve phenotype reversion without altering cell proliferation.

[0019] An important aspect of the development of a scheme targeting EMT phenotype is to establish a framework of facilitating the use of experimental systems, whether *in vitro* cell lines or xenografts, to incorporate into the subtype identification of *in vivo* cancers to model the reality in

human. Cancer cell line collections such as breast cancer have been shown to retain their subtype characteristics corresponding to those of the *in vivo* counterparts and these cell lines have been demonstrated as powerful tools to model heterogeneity in cancer *in vitro*.

[0020] It has been shown that the gene expression profiles and genomic signatures of NCI60 have been further utilised to identify phenotype-specific drugs. The gene expression signature of NCI60 incorporated with the drug sensitivity results from over 40,000 compound screens have effectively identified targets not only with selectivity to the RAS and PI3K pathways but also with disease specificity to breast cancer subtypes (basal vs. luminal). This shows that oncogenomic data derived from a mixed assembly of cancer cell lines can be robust to provide valid therapeutic leads which are disease or phenotype specific, which further supports the possibility to establish a diagnostic-therapeutic framework incorporating both genome-scale data for cancer subtype identification and experimental models for therapeutic target discovery.

[0021] It is an object of the present invention to facilitate the development of better prognostic and therapeutic strategies which will benefit cancer patients with novel treatment options and to improve the overall survival.

SUMMARY OF THE INVENTION

[0022] In a first aspect the present invention is directed to a method of generating a scheme allowing classification of a cancer of an individual patient for estimating a clinical outcome for said patient, wherein the method comprises:

- a) identifying subtype clusters of a cancer type based on comparison of a set of gene expression data derived from clinical cancer samples of multiple test subjects suffering from said cancer type; wherein clinical samples are divided into subtype clusters of said cancer type based on the similarity of their gene expression data;
- b) correlating the subtype clusters identified under a) to a specific clinical outcome of cancer;
- c) determining an epithelial-mesenchymal transition (EMT) signature, comprising:
 - i) determining a quantitative expression of at least two markers characteristics for each subtype clusters identified under a), wherein each of these markers is either characteristic for a mesenchymal cell phenotype or for an epithelial cell phenotype,
 - ii) subjecting the results of the quantitative expression of the at least two markers to a regression analysis to thereby determine said epithelial-mesenchymal transition (EMT) signature;

iii) correlating the epithelial mesenchymal transition (EMT) signature to the specific clinical outcome of cancer identified in b);

d) estimating the outcome of a patient suffering from said cancer by :

1. assigning the set of gene expression data of said patient sample to any one of the subtype clusters according to a) and b), and

2. assigning the patients epithelial-mesenchymal transition (EMT) score by determining the quantitative expression of the at least two markers in said patient sample and comparing it with the epithelial-mesenchymal transition (EMT) signature under c) to assign an epithelial-mesenchymal transition (EMT) score for said patient sample to correlate the EMT score to the specific clinical outcome of cancer.

[0023] In a second aspect, the present invention refers to a method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (EOC) wherein the method comprises:

a) providing a set of expression data in a patient sample obtained from a patient suffering from epithelial ovarian cancer (EOC);

5 b) assigning the set of expression data derived from said patient sample to one of five subtype clusters for epithelial ovarian cancer (EOC),

wherein the first of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 – Epi A;

10 wherein the second of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - EpiB;

wherein the third of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - Mes;

wherein the fourth of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - StemA;

15 wherein the fifth of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - StemB;

c) determining an EMT score for the patient sample by;

20 i) computing an enrichment score by integration of the difference between the empirical cumulative distribution functions of genes from Gene List 3 and genes not in Gene List 3 for each set of expression data from the individual patient samples to determine the epithelial rank or mesenchymal rank of a sample;

ii) determining the EMT score by subtracting the value for the epithelial rank from the value for the mesenchymal rank

25 d) estimating the clinical outcome depending on any one of the five subtype clusters and the EMT score to which the patient sample is assigned.

[0024] In a third aspect, the present invention refers to a method of determining whether the epithelial mesenchymal score of a patient suffering from a cancer can be changed by administering an EMT reversal agent to increase patients susceptibility for an anti-cancer treatment, wherein the method comprises classifying a tumor sample of said patient using a method of the present invention
30 to determine the cancer subtype and EMT score; after determining the cancer subtype and EMT score determining whether a treatment with an EMT reversal agent is necessary to sensitize said patient to anti-cancer treatment.

[0025] In a fourth aspect the present invention refers to a cluster characterized in that it comprises at least one subtype cluster selected from the group consisting of subtype clusters shown in Gene List

2 - Epi A, subtype cluster shown in Gene List 2 Epi-B, subtype cluster shown in Gene List 2 – Mes, subtype cluster shown in Gene List 2 – Stem A and subtype cluster shown in Gene List 2 –Stem B.

[0026] In a fifth aspect, the present invention refers to a computer readable medium having stored therein a computer program comprising a set of executable instructions, when executed by a computer

5 processor, controls the processor to perform the method of the present invention.

[0027] In a sixth aspect, the present invention refers to a computer program comprising a set of executable instructions, when executed by a computer processor, controls the processor to perform the method of the present invention.

5

BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:

[0029] Fig. 1 shows that epithelial-mesenchymal expression (EMT) gradient contributes to tumor heterogeneity. The entire tumor can be regarded as a function (F_x) of the EMT process which encompasses different proportion of cancer cells that have not undergone EMT (No EMT), those have undergone partial EMT, and those have undergone full EMT. The EMT Status or EMT Score can thus represent different tumors (Tumor A, Tumor B, and Tumor C).

[0030] Fig. 2 shows a schematic of spot migration screening assay work flow.

[0031] Fig. 3 illustrates integrative analyses for tumors and cell lines to define a novel therapeutic strategy for ovarian carcinoma.

[0032] Fig. 4 shows sources of datasets and data processing scheme for investigating phenotypic complexity of EOC.

[0033] Fig. 5 (A) Gene expression heatmap for the five tumor clusters (dark = high; lighter = low expression). Consensus clustering of 1,538 samples identified five major subtypes, designated by the associated gene components. Note similarity between Epi-A/Stem-B subtype tumors and in the expression pattern of Epi-A/Stem genes and that between Epi-A/Epi-B subtypes for Epithelial genes. (B) Silhouette plot. Samples positive for the silhouette width (SW) in each subtype: Epi-A, 74.8% (101/135); Epi-B, 80.4% (315/392); Mes, 78.9% (325/412); Stem-A, 81.3% (256/315); and Stem-B, 76.7% (145/189). (C) Kaplan-Meier survival analysis based on the clusters. Among data for 1,538 patient samples, survival information for 845 samples was available (Duke: 143, GSE9891: 277, TCGA: 400 and Oslo: 25 samples) (Epi-A: 73, Epi-B: 233, Mes: 245, Stem-A: 190, Stem-B: 50 and others: 54 samples) and used for the Kaplan-Meier analysis. (D) Subtype-specific pathway enrichment. Heatmap shows subtype-specific ss-GSEA scores (false discovery rate (FDR) in significance analysis of microarrays (SAM) $q=0\%$, receiver operation curve (ROC) >0.85) for 1,538 ovarian cancer samples. Gene sets are aligned in descending value of ROC. Samples are aligned by the subtype classification and SW. Dark color = positive SW (core samples); pale color = the samples classified, but negative SW.

[0034] Fig. 6 (A) Relationship between expression subtypes with histological subtypes (upper panel) or the malignant potential (bottom panel) by histograms. Stem-B subtype had multiple histological characteristics. Most of low malignancy potential (LMP) tumors were classified as Epi-A.

subtype. (B) Kaplan-Meier survival analyses stratified by the clinical stage. Patients with stage I or II Stem-A ovarian carcinomas had significantly worse outcomes; Epi-A and Epi-B subtypes showed better prognoses; Stem-B cancers were no more benign at advanced stages. (C) Clinical features of subtypes in serous ovarian carcinomas without LMP tumors. Total 758 samples in this category were analyzed (Epi-A; 57, Epi-B; 227, Mes; 245, Stem-A; 188, and Stem-B; 41 samples). Upper panel. Kaplan-Meier analysis of serous ovarian carcinomas without LMP tumors. Lower panels. Relationship between expression subtypes with the clinical stages (left panel), and primary or metastatic tumors (right panel). Abbreviations: Epi-A; Epithelial-A, Epi-B; Epithelial-B, Mes; Mesenchymal, Stem-A; Stem-like-A, Stem-B; Stem-like-B, LMP; low malignant potential.

10 [0035] Fig. 7A illustrates the development of classification scheme.

[0036] Fig. 7B illustrates a scheme of diagnostic subtype prediction based on Binary Regression model. For each subtype, 50 samples with the highest silhouette values in Figure 5B were subdivided into training sets A and B, and predictive models were generated based on gene expression arrays of training set A. Multiple tests of predictions from training set A to training set B determined the best condition to perform Binary Regression analysis (BinReg). Defined condition was used to predict the status of the remaining samples. (B) shows diagnostic method to predict the ovarian cancer subtype based on Binary Regression model. Upper panels. Gene expression heatmap for subtype predictor. Expression of predictor genes: dark = high; lighter color = low. Bar = 25 samples used to generate the subtype signature. Lower panel. Heatmap for predicted probabilities of subtype status of remaining samples. Dark = high; lighter color = low. Samples were aligned according to the subtype classification by consensus clustering (CC) and the silhouette width (SW). Deep color = positive SW (core samples); pale color = samples classified, but negative SW. Concordance (comparing the subtype assignment by CC of 1,538 samples against the predicted subtype by BinReg) is also shown. Samples with probability > 0.5 for a subtype were deemed to be that subtype, whereas probability ≤ 0.5 was deemed as the other subtype. The number in parenthesis indicates the concordance of the prediction against core samples. Subtype prediction of samples in five independent datasets (GSE19829, GSE20565, Japan Kyoto Ovarian Cancer cohort; JPKO, GSE26712 and GSE27651; total n=418). Concordance analyses using the additional independent data were used to validate the ovarian subtype signatures. The subtyping derived from CC of those validation datasets with 1,413 core samples from the initially compiled 1,538 samples was performed. Concordance was calculated by comparing the CC classification with the BinReg prediction. The Mes and Stem A subtypes still show the same trend for overall worst survival. Abbreviations: Epi-A; Epithelial-A, Epi-B; Epithelial-B, Mes; Mesenchymal, Stem-A; Stem-like-A, Stem-B; Stem-like-B.

[0037] Fig. 8 shows diagnostic subtype prediction by SAM/ROC/ClaNC. (A) Gene expression heatmap of subtype-specific genes. Samples with positive silhouette values are aligned according to

their subtype. Gene expression pattern is shown by heatmap (dark = high, lighter color = low expression). The subtype-specific genes were identified using significance analysis of microarrays (SAM) (false discovery rate; FDR $q=0\%$) and receiver operating characteristic (ROC) (>0.78) (Tusher, 2001 #41). (B) Left panels. Scheme of 10-fold cross-validation. 10-fold cross-validation was

5 performed, in which the expression signatures from 90% samples were generated, the subtype status of the remaining 10% samples was predicted with the signatures by classification to nearest centroids (ClaNC), and these predictions were repeated 10 times. Data of 1,538 epithelial ovarian cancer (EOC) samples were randomly subdivided into 10 blocks of 154 or 153 sample data. Using data from 9 blocks (90% samples) (total 1,384 or 1,385 samples) as training data, subtype identification and
10 subsequent gene selection were performed with consensus clustering (CC), silhouette analysis (SA), SAM and ROC. The remaining block (10% samples) was used as a validation set and the subtype of each sample was predicted by classification to nearest centroids (ClaNC). This process was repeated 10 times, combined predictions and performed Kaplan-Meier survival analysis. Right panels: An example of cross validation (the experiment #2). Gene expression heatmaps (dark = high, lighter color
15 = low expression) and Kaplan-Meier survival analysis of the combined result at final stage are shown.

(C) Concordance of the ClaNC prediction with the subtype status derived from consensus clustering. Colored bar = subtype status prediction of a sample. Samples are aligned according to the subtype classification by CC and SW. Deep color = positive SW; pale color = samples classified to a subtype but negative SW. Concordance (%) of the prediction with the subtype status derived from CC is also
20 shown. The concordance was computed by comparing the subtype assignment by CC of 1,538 samples against the predicted subtype by ClaNC. The number in parenthesis indicates the accuracy of the prediction against core samples. This 10-fold cross validation showed an overall concordance of 72.4% for 1,538 samples. (D) Subtype prediction of samples in combined five independent datasets (GSE19829 [n=28], GSE20565 [n=95], Japan Kyoto Ovarian Cancer cohort; JPKO [n=67],
25 GSE26712 [n=185] and GSE27651 [n=43]; total n=418). The subtype expression signatures were generated using all of the core samples (Epi-A: 101, Epi-B: 315, Mes: 325, Stem-A: 256 and Stem-B: 145). The genes were selected by SAM/ROC so that a subtype was distinguishable from the remaining samples. Subsequently, ClaNC was employed to predict the sample status. The concordance was computed by comparing the subtype assignment by CC of the samples against the
30 predicted subtype. These independent cohorts showed a reasonable concordance of 80.1% (core samples: 89.6%) between the results derived from the prediction and the consensus clustering. Together, these results indicated the robustness of the classification scheme. Abbreviations: Epi-A; Epithelial-A, Epi-B; Epithelial-B, Mes; Mesenchymal, Stem-A; Stem-like-A, Stem-B; Stem-like-B.

[0038] Fig. 9 (A) shows a schematic presentation for subtype classification of cell lines by
35 consensus clustering. Data for total 142 of cell lines (Duke: 42, Kyoto: 37, National laboratory: 29

and Singapore: 34 cell lines with redundancy in cell line names) was analyzed together with 1,142 of core tumor samples in consensus clustering. Two-time consensus clustering coupled with re-selection of cell line classifiers finally identified five subtypes for the cell lines. Upper bars are to indicate the subtype status of clinical samples after the first consensus clustering. A lower bar underneath the upper bars indicates position of cell line sample with clinical tumor samples in the first clustering analysis. The cell line classes are shown by lower bars. Triangles are used to show the relation between the first and the second classifications. For example, all of 28 cell lines initially classified as Stem-B subtype were again classified in the same category, whilst a Stem-B cell line moved into Epithelial-A subclass. Likewise 10 cell lines of Group 1 (G1) and 17 of Group 5 (G5), appeared in the first clustering, fused to Epithelial-A subtype, while 10 of G1 and 8 of Epithelial-B moved to Stem-A subgroup. (B) Five subtypes in ovarian cancer cell line classification. Left panel; consensus clustering matrix (dark: high, white: low similarity), middle panel; gene expression heatmap (dark: high, lighter color: low expression), right panel; silhouette analysis for each subtype. (C) Prediction of clinical samples by cell line predictors using BinReg. Upper panels. Gene expression heatmaps for subtype predictors based on cell line expression data. The color map indicates high (dark color) or low (lighter color) expression of predictor genes. A bar indicates the cell line samples used for prediction to generate the subtype signature. The same labeling for cell lines in Figure 9C was used for BinReg analysis. Middle panels. Predicted probability of core clinical samples for cell-line subtype predictor by BinReg analyses. Concordance of the prediction by cell line predictors with silhouette positive core sample status was also shown beneath the dot plots. Each subtype signature detected the difference between the corresponding subtype from the remaining tumor samples with statistical significance (all pair-wise Mann-Whitney test; $p < 0.0001$). Lower panels. ROC analyses of subtype predictors. Overall accuracy of the prediction is shown by area under the ROC curve (AUC). Concordance of the subtype status derived from consensus clustering with the prediction based on the cell line subtype predictors was also shown in percentage. (D) Cell line names in the classification. Data sources of cell lines are Duke University (D), Kyoto University (K), Singapore (S) and National Laboratory (N). Many cell lines in Kyoto and Singapore collection are derived from Duke collection, while National Laboratory collection is totally independent of Kyoto, Duke or Singapore collection. Cell lines with negative silhouette width in Figure 9B are shown with gray font. Note that Kyoto data included duplicated arrays for HEY.

[0039] Fig. 10 shows (A) the EMT spectrum of the SOGCL A. Origin of the ovarian carcinoma cell lines and phenotypic characterization. (B) Immunostaining of one cell line representative of each subgroup. (C) Quantitative PCR of E-cadherin and Vimentin transcripts. (D) Expression values for E-cadherin, Pan-cytokeratin, N-cadherin and Vimentin for each subtype.

[0040] Fig. 11 illustrates characterization of the migratory, invasive, apoptotic and clonogenic properties of the SGOL42 cell lines. (A), (B) Migratory properties semi-quantitatively measured using the platypus technology. Intermediate mesenchymal are significantly more migratory. (C)-(D) Two intermediate E and two intermediate M invade the matrigel. (E) Intermediate E (left) invade as cell collective while intermediate M (right) invade as solitary cells. (F) A significant number of cells undergo anoikis, however cell lines with intermediate M and M are more resistant. (G) Intermediate M cells all formed spheroids except DOV13.

[0041] Fig. 12 illustrates the development of epithelial-mesenchymal transition signature based on cadherins expression of cultured cells. (A) Assignment of epithelial or mesenchymal phenotype by scoring cell lines with positivity of E- or N-cadherin on the cell surface. Upper panel. Cadherin score. A subtraction of N-cadherin from E-cadherin positivity was used as a score. Cell lines were sorted according to the score. Lower panel. Heatmap for E- or N-cadherin positivity. Cell line names are shown underneath. The color font indicates the cell line subclass (Green=Epi-A, light green=Epi-B, red=Mes, blue=Stem-A and purple=Stem-B). To generate the gene expression signature that can distinguish the cells with epithelial phenotype from those with mesenchymal phenotype, cell lines were selected with cadherin score above 2 (epithelial) or below 0 (mesenchymal). (B) A gene signature for epithelial-mesenchymal phenotype of ovarian cancer cells. Upper panel: the expression pattern of genes that distinguish epithelial from mesenchymal cells. The expression pattern of a 125-gene signature is shown as a heatmap (dark=high and lighter color=low expression). Lower panel: a leave-one-out cross-validation of probabilities for epithelial-mesenchymal phenotype (lighter color=epithelial, dark=mesenchymal cells). The accuracy of this signature was 100.0% using 0.5 as a cutoff probability. A bar indicates the mean value for each group. (C) Prediction of epithelial-mesenchymal phenotype of HMLER cells with different E-cadherin status by the gene signature derived from ovarian cancer cells. Predicted probabilities are shown as bar plots for epithelial and mesenchymal phenotype. Several manipulations of E-cadherin function are shown beneath the plots. Loss of E-cadherin expression or dominant-negative E-cadherin overexpression renders the HMLER cells more mesenchymal. The mesenchymal phenotype induced by loss of function of E-cadherin was recovered by simultaneously added beta-catenin knockdown. These phenotypic changes by the gene manipulations coincide with the alteration of mesenchymal predicted probability. (D) Prediction of epithelial-mesenchymal phenotype of the remaining ovarian cancer cell lines that were not used to generate the signature. Predicted probabilities were plotted according to the cell line subtype. A bar indicates the mean value for each group. (E) The epithelial-mesenchymal score and genes of clinical samples. ss-GSEA was used to estimate the status of a clinical tumor for epithelial and mesenchymal (EM) phenotype. A tumor was ranked according to the epithelial or mesenchymal phenotype. The rank for mesenchymal phenotype was subtracted from that for epithelial phenotype for each sample.

and designated it as an EMT score. The EMT score is shown in the heatmap (lighter color=epithelial, dark=mesenchymal phenotypes) with subtype information and the heatmap of the genes (lighter color=low, dark=high expression) used for SS-GSEA. (F) EMT score and the tumor subtype. EMT scores were plotted in the category of the tumor subtype. A dashed line is used to indicate the position of the median value of the EMT score. Epithelial and mesenchymal phenotypes were determined using this median as a cut-off value. Many of Epi-A, Epi-B and Stem-B tumors show epithelial phenotype (86.1%, 75.9% and 63.5%, respectively), while 83.2% of Stem-A and 66.2% of Mes ovarian cancers have mesenchymal phenotype.

[0042] Fig. 13 (A) The epithelial-mesenchymal score and genes of clinical samples. ss-GSEA was used to estimate the status of a clinical tumor for epithelial and mesenchymal (EM) phenotype. A tumor was ranked according to the epithelial or mesenchymal phenotype. The rank for mesenchymal phenotype was subtracted from that for epithelial phenotype for each sample and designated as an EMT score. The EMT score is shown in the heatmap (lighter color=epithelial, dark=mesenchymal phenotypes) with subtype information and the heatmap of the genes (lighter color=low, dark=high expression) used for SS-GSEA. (B) EMT score and the tumor subtype. EMT scores were plotted in the category of the tumor subtype. A dashed line is used to indicate the position of the median value of the EMT score. Epithelial and mesenchymal phenotypes were determined using this median as a cut-off value. Many of Epi-A, Epi-B and Stem-B tumors show epithelial phenotype (86.1%, 75.9% and 63.5%, respectively), while 83.2% of Stem-A and 66.2% of Mes ovarian cancers have mesenchymal phenotype. (C) Validation was made with an independent collection of ovarian carcinoma samples, termed JPKO, and another publically available ovarian cancer expression dataset, termed GSE2056. (D) Epi-A and Epi-B tumors were classified to have epithelial phenotype (100% and 87.5%, respectively), while 89.47% of Stem-A and 89.65% of Mes tumors were classified as the mesenchymal phenotype.

[0043] Fig. 14 (A) Relative expression level of the 4 genes (E-cadherin, DDR1, ERBB3 and ZEB1) across the four cell line subgroup. (B) 6 cell lines expressing high or low level of each of the 4 genes and the corresponding gene signatures to be used in the Venn diagram (C).

[0044] Fig. 15 Plot of Cell Dispersion ratio against sample number of all NegCtrl and PosCtrl conditions.

[0045] Fig. 16 Plot of Normalized Cell Dispersion ratio against sample number of all NegCtrl and PosCtrl conditions.

[0046] Fig. 17 Plot of Cell Dispersion ratio Z-factor statistics of NegCtrl vs. PosCtrl against plate number.

[0047] Fig. 18 Plot of Cell Dispersion ratio against Cell Count ratio of reference library compounds ("control" sample points encircled areas comprising control sample points as well as some "sample points").

[0048] Fig. 19 Plot of Normalized Cell Dispersion ratio against Cell Count ratio of reference library compounds ("Hit" sample points lower right quadrant; "control" sample points encircled areas comprising control sample points as well as some "sample points").

[0049] Fig. 20 (a) EMT screening assay image acquisition workflow. Robot-assisted plating of H2B-mcherry transfected NBT-II cells onto the well centers of 96-well plates. The initial plate image acquired at T1 serve as the baseline reference for calculation of Cell Count ratio and Cell Dispersion ratio for each well. The cells are then treated with test compounds overnight and further incubated for 24 h with a growth factor to induce EMT. (b) Final plate image acquired at T2, depicting dispersion response of cells 24 h after compounds and growth factor treatment. In the example shown, columns 2-11 are treated with 80 different test compounds at 6.67 μ M in 0.67% DMSO and 20 ng/mL EGF. Column 1 serve as negative control wells treated with 0.67% DMSO and 20 ng/mL EGF, while column 12 serve as positive controls wells treated with 6.67 μ M AG1478 in 0.67% DMSO and 20 ng/mL EGF. (c) Magnified images of selected wells from (b and c) acquired at T1 and T2. Wells C12, H03 and D02 are examples of cell colonies treated by compounds that can inhibit EGF initiated cell dispersion and do not severely inhibit cell growth. Well C01 is an example of a cell colony undergoing EGF induced EMT without any dispersion inhibition. Well E09 is an example of a cell colony treated by a growth inhibitory or toxic compound.

[0050] Fig. 21 Cell dispersion ratio vs. cell count ratio plots was plotted to illustrate the behavior of NBT-II treated with different test compounds and growth factors in this screening assay. Cell Dispersion Ratio (CDR) threshold is set at 50% CDR between Positive control CDR and negative control CDR. Cell Count Ratio threshold (CCR) is set as 1.5 growth rate. It was an interest to identify compounds that inhibit cell dispersion (i.e. less than CDR threshold) and do not severely inhibit cell growth (i.e. more than CCR threshold). To further refine the hits, the test compounds were run at a low and high concentration (1.67 microM and 6.67 microM respectively). Hit compounds (solid squares) were classified as test compounds that satisfy the CDR and CCR threshold criteria at both concentrations.

[0051] Fig. 22 Dose response profile of A83-01 against EMT induced by EGF, HGF or IGF-1.

[0052] Fig. 23 Dose response profile of PF-04217903 against EMT induced by EGF, HGF or IGF-1.

[0053] Fig. 24 Dose response profile of Gefitinib against EMT induced by EGF, HGF or IGF-1.

[0054] Fig. 25 shows morphology and Western blot analysis of SKOV3, HEY and OVCAR-2 after AZD0530 and BIBF-1120 treatment. (A) AZD0530 and BIBF-1120 restored epithelial

morphology in SKOV3, HEY and OVCAR-2 as compared to DMSO (vehicle). (B) Western blot analysis of E-cadherin and MMP13 protein levels from each of the cell lines treated with 2 compounds and a control (v). Raw intensities of the western blot bands are measured and plotted into graphs. V: vehicle; AZD: AZD0530; BIBF: BIBF-1120.

5 [0055] Fig. 26 shows the development of epithelial-mesenchymal transition signature. (A) Expression of E- or N-cadherin on the cell surface of cultured ovarian cancer cell lines detected by immunofluorescent staining. Photographs by inverted microscopy are shown with cell line names. Shown are the photographs of two cell lines that represent each of epithelial (E-cadherin positive / N-cadherin negative), mesenchymal (E-cadherin negative / N-cadherin positive) or intermediate state
10 (equal expression for both of E- and N-cadherins). The cell lines are aligned from the most epithelial, left, to the most mesenchymal, right. Upper and lower panels are to show E- and N-cadherin expression, respectively. (B) Assignment of epithelial or mesenchymal phenotype by scoring cell lines with positivity of E- and N-cadherins. Upper panel. Cadherin score. A subtraction of positivity for N-cadherin from that for E-cadherin was used as a cadherin score to reflect cellular epithelial-
15 mesenchymal status. Cell lines are sorted according to the score. Lower panels. Heatmaps for E- and N-cadherin positivity. The color code for the positivity is shown on the right. Cell line names are shown underneath. The color font indicates the cell line subtype (grey=Epi-A, light grey=Epi-B, dark=Mes, dark grey=Stem-A and black=Stem-B). The cell lines with cadherin score above 2 were arbitrarily assigned to represent cells with epithelial state, while cells with mesenchymal state were
20 defined by the cadherin score below 0. The asterisk indicates that OAW42 was not used for the signature generation, since it exhibits more mesenchymal phenotype in the transcriptome despite of the surface expression pattern of the cadherins (data not shown). (C) A gene signature to distinguish epithelial or mesenchymal state of cells, derived from cultured ovarian cancer cell lines with BinReg. Upper panel: The expression pattern of the EMT signature. The expression of a 50-gene signature is
25 shown as a heatmap (dark=high and grey=low expression). Lower panel: A leave-one-out cross-validation of probabilities for the EMT phenotype (grey=epithelial, black=mesenchymal cells). The accuracy of this signature was 100.0% using 0.5 as a cutoff probability. A black bar indicates the mean value for each group. D and E. Prediction of epithelial or mesenchymal status of experimental models of EMT by BinReg with the gene signature derived from ovarian cancer cells. HMLER cells with experimental perturbations of E-cadherin expression by combinations of shRNAs (D: GSE9691). HMLE cells overexpressing each of multiple EMT inducers (TGF, Twist, Goosecoid=Gsc, and Snail)
30 (E: GSE24202). Predicted probabilities are shown as bar plots with the experimental manipulations beneath the plots. Phenotypic changes by these gene manipulations coincide with altered predicted probability for the EMT signature.

35 [0056] Fig. 27 shows the epithelial-mesenchymal score in cultured cell lines.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

[0057] To be able to provide a method which allows assisting determination or classification of the possible outcome of cancer of a patient suffering or suspected to suffer from cancer, it is necessary at first to establish a general classification scheme established on the basis of data from patients who are confirmed to suffer from said cancer.

[0058] Therefore, in a first aspect the present invention is directed to a method of generating a scheme for classifying a cancer of an individual patient. The classification scheme allows estimating the clinical outcome for said patient suffering from cancer or suspected to suffer from cancer. In one example, the method comprises:

- a) identifying subtype clusters of a cancer type based on comparison of a set of gene expression data derived from clinical cancer samples (such as tissue samples or single cells) of multiple test subjects suffering from said cancer type; wherein clinical samples are divided into subtype clusters of said cancer type based on the similarity of their gene expression data;
- b) correlating the subtype clusters identified under a) to a specific clinical outcome of cancer by comparing the single samples assigned to any one of the subtype clusters with the clinical development of the test subject from which the respective set of gene expression data is obtained;
- c) determining an epithelial-mesenchymal transition (EMT) score, comprising:
 - i) determining the quantitative expression of at least two markers wherein each of these markers is either characteristic for a mesenchymal cell phenotype or for an epithelial cell phenotype, for determining said epithelial-mesenchymal transition (EMT) signature;
 - ii) determining the quantitative expression of the at least two markers in said patient sample and comparing it with the epithelial-mesenchymal transition (EMT) signature to assign an epithelial-mesenchymal transition (EMT) score for said patient sample;
- d) estimating an outcome of a patient suffering from said cancer by assigning the set of gene expression data of said patient sample to any one of the subtype clusters according to a) and b), and by determining the patient's epithelial-mesenchymal transition (EMT) score.

[0059] For identifying subtype clusters expression data sets of genes, such as microarray expression data sets, from patients suffering from the type of cancer for which the classification scheme is to be established are obtained. In one example the microarray technology used in these studies was for example from Affymetrix. However, any microarray technology known in the art can be used herein. Following hybridization with complementary cDNA of each tumor sample RNA a first data file is generated by scanning each microarray. The scanning results are provided as a table comprised of the fluorescence measurement and feature identity for each pixel of a scan. A

microarray feature is an area on the array occupied by a population of oligonucleotide probes with the same sequence. A feature is comprised of many pixels. The expression data in the first file can be processed to generate the values found in a second file comprising a single value for each feature. Each value in the second file is a statistical "summary" of the fluorescence from a single feature. The second file contains the information for viewing the images that result from scanning the hybridized arrays.

[0060] In a next step the data can be normalized and standardized to allow comparison of expression data in case they were obtained from different sources. Methods to normalize and standardize data from different sources are known in the art. For example robust multichip average (RMA) normalization can be performed on each different dataset from a different source. Such a method comprises adjusting background and/or quantile normalization and/or log transformation of probe values. RMA is an algorithm used to create an expression matrix from expression data, such as Affymetrix data. The raw intensity values are background corrected, log2 transformed and then quantile normalized. Next a linear model is fit to the normalized data to obtain an expression measure for each probe set on each array (Irizarry, R.A., 2003, Biostatistics, vol.4, no.2, pp.249).

[0061] For example, for quantile normalization it is assumed that the distribution of gene abundances is nearly the same in all samples. For convenience the pooled distribution of probes on all chips is taken. Then to normalize each chip, for each value, the quantile of that value in the distribution of probe intensities is computed; the original value is then transformed to that quantile's value on the reference chip. In a formula, the transform is $x_{norm} = F_2^{-1}(F_1(x))$, where F_1 is the distribution function of the actual chip, and F_2 is the distribution function of the reference chip.

[0062] As already mentioned normalization can be another step necessary when datasets come from different sources. Standardization is used to eliminate batch effects. The normalized data can be first visualized by principal component analysis (PCA) which reports the value of each patient gene expression reduced to 3 dimensions. In reality each patient should be represented by a 22000 dimension vector. Since such a vector is impossible to calculate the projected vector is only in 3 dimensions; a 3D representation offers more than 30 % of the total information contained in such a vector and allows visualizing the relative position of each patient in a cohort. For example, in an exemplary study described herein it was found that patients in different datasets were scattered and did not overlap (data not shown). In one example ComBat was used to remove batch effects.

[0063] ComBat is based on parametric and nonparametric empirical Bayes frameworks for adjusting data for batch effects that is robust to outliers in small sample sizes and performs comparable to existing methods for large samples (Johnson, W.E., Li, C., Biostatistics, 2007, vol.8, no.1, pp.118).

[0064] In one example identifying subtype clusters comprises:

a') selecting a subset of genes which are most variably expressed across all set of gene expression data;

b') subjecting the most variably expressed genes determined under a) to consensus clustering to identify said subtypes of said cancer type or in other words, pooling the genes that are most variably expressed into different clusters.

[0065] Step a' is also referred to as filtering. Filtering is carried out to select a subset of variably expressed gene across all samples. A gene is considered most variably expressed across all sets of gene expression data of all clinical samples referred to under a') if the standard deviation of the gene expression is higher across all sets of gene expression data in comparison to the standard deviation of any other gene. In one example the standard deviation is set to be 1.05. In another example, a gene is considered most variably expressed across all sets of gene expression data of all clinical samples referred to under a') if said gene has a higher variability in expression among all sets of expression data obtained from the clinical samples.

[0066] In general, cluster analysis permits the discovery of distinct and non-overlapping sub-populations within a larger population, the member items of each sub-population sharing some common features or properties. There are many methods to cluster which are known in the art; all of them are based on the computation of some type of geometrical distance between each sample in a collection which then be regrouped into clusters. The geometrical distance being a result for example of different variable expression.

[0067] In one example, the most 500 or 600 or 700 or 800 or 900 or 1000 variably expressed genes across all sets of gene expression data will be selected for clustering.

[0068] Issues to be addressed when clustering data include i) how to determine the number of clusters; and ii) how to assign confidence to the selected number of clusters, as well as to the induced cluster assignments. For example, consensus clustering provides a method to represent the consensus across multiple runs of a clustering algorithm, to determine the number of clusters in the data, and to assess the stability of the discovered clusters. The method can also be used to represent the consensus over multiple runs of a clustering algorithm with random restart (such as K-means, model-based Bayesian clustering, SOM, etc.), so as to account for its sensitivity to the initial conditions. Finally, it provides a visualization tool to inspect cluster number, membership, and boundaries.

[0069] In one example, the clustering algorithm for consensus clustering is hierarchical clustering with agglomerative linkage. More specifically, in one example, the clustering algorithm for consensus clustering is a hierarchical clustering with agglomerative linkage with Euclidian distance and with a sub-sampling ratio of between about 0.5 to 0.9, preferably 0.8 or at least 0.8, for 500, or 800 or 1000 or more than 500, or more than 800 or more than 1000 iterations. An example of consensus clustering that can be used herein has been described by Monti, S., et al. (2003, Kluwer Academic Publishers,

Printed in the Netherlands, Consensus Clustering – A re-sampling-based method for class discovery and visualization of gene expression microarray data).

[0070] Once different cancer subtype clusters have been identified the patient data in each cluster are compared with the phenotype of cancer which can be found in each cancer subtype cluster. For example, one group comprises patients having cancer at a more advanced stage and thus a poor prognosis compared to another subtype cluster with patients having a better prognosis. Whether the prognosis is death, survival, treatable with compound X or Y depends on the result of clustering of the initial data for a specific type of cancer. The result obtained can serve as guidance for a physician in making his decision on how to treat the patient.

10 [0071] In one example, assigning the set of gene expression data of the patient sample to a subtype cluster referred to under d) is carried out by:

- selecting a set of gene expression data from test subjects which correlate the best with the cancer phenotype assigned to each of the subtype clusters under b) for a given subtype cluster;

15 - subdividing said set of gene expression data of a clinical sample selected from all subtype clusters equally into at least two training groups;

- determining gene expression signatures within the at least two training groups which are characteristic for each of the subtype clusters previously determined; and

- comparing the set of gene expression data of a patient sample with the expression signatures for determining to which subtype cluster the patient sample is to be assigned.

20 [0072] In one example, an at least 50% or 60% or 70% or 75% match of the gene expression data of the patient sample with the expression signature of one of the subtype clusters assigns the patient sample to the respective subtype cluster. In other words, in case the gene expression data of the patient for whom the outcome of his or her disease is to be determined is most similar to the expression profile of one of the subtype clusters it will be assigned to this subtype cluster.

25 [0073] There are different statistical methods to assign the expression data of a patient to a specific subtype cluster. In one example, silhouette analysis is used to select sets of gene expression data from test subjects which correlate the best with the cancer phenotype assigned to each of the subtype clusters for a given subtype cluster.

30 [0074] Silhouette refers to a method of interpretation and validation of clusters of data. The technique provides a succinct graphical representation of how well each object lies within its cluster (Rousseeuw, P.J., 1987, Computational and Applied Mathematics, vol.20, p.53–65).

[0075] In one example, expression profiles having the highest silhouette values are selected from all subtype clusters to be subdivided into the at least two training groups.

35 [0076] Furthermore, a regression model, such as a linear or binary regression model can be used to determine gene expression signatures within one or both of the at least two training groups which

are characteristic for each of the subtype clusters previously determined. Regression models are generally used to predict the outcome of a categorical (a variable that can take on a limited number of categories) criterion variable based on one or more predictor variables.

[0077] A flowchart illustrating such a process is shown in Figure 7A.

5 [0078] In one example, for determining to which subtype cluster the patient sample is to be assigned a Bayesian probit regression model can be used. A probit model is a type of regression where the dependent variable can only take two values, for example belonging to group a or b.

[0079] Finally, the epithelial-mesenchymal transition (EMT) signature can be determined by subjecting the results of the quantitative expression of the at least two markers characteristic for each
10 subtype cluster identified under a) to a regression analysis, such as a logistic binary regression analysis.

[0080] The above method can be used for all types of cancer. In one example, the cancer includes, but is not limited to epithelial ovarian cancer (EOC), breast carcinoma, hepatocarcinoma, pancreatic carcinoma, glioblastoma multiforme (GBM), lung carcinoma, colorectal cancer and bladder
15 carcinoma. In one example the cancer is more generally referred to a solid tumor type of cancer. The patient can be a mammal, wherein the mammal includes, but is not limited to humans.

[0081] In the following an example is provided illustrating the above method on the basis of a classification scheme generated for patients suffering or suspected to suffer from epithelial ovarian cancer. In this example multiple expression datasets were obtained each including expression
20 microarray data of epithelial ovarian carcinoma derived from a given number of patients. The data were normalized and standardized as described above.

[0082] Before clustering is carried out a filtration of highly variably expressed genes across all samples is carried out. This filtering identified 1185 probesets corresponding to 941 genes which are listed in Gene List 1. This Gene List 1 can be used for clustering leading to the identification of the
25 subtype clusters (molecular subtypes).

[0083] The result of such a clustering is shown in Figure 5A. Clustering of 1538 samples using Gene List 1 results in five subtypes which are designated by the associated gene components. The five subtypes are the Epithelial-A (Epi-A) and Epithelial-B (Epi-B) tumor clusters exhibited expression of epithelial cell markers, such as CDH1 (E-cadherin), EPCAM, various keratin genes (KRTs) and
30 CD24. The Mesenchymal (Mes) tumor subtype predominantly expressed fibroblastic/mesenchymal genes, such as PDGFRA, VCAM1, ZEB1, TWIST1, and extracellular matrix genes, including collagen and FN1. The Stem-like-A (Stem-A) and Stem-like-B (Stem-B) tumor clusters did not share many gene markers, but expressed typical markers for epithelial stem cells: LGR5 and PROM1 (CD133), respectively. Stem-A tumors also expressed more MYCN, NCAM, CDH2 (N-cadherin) and
35 proliferation-related genes, suggesting neural characteristics. Epi-B and Mes tumors expressed

inflammatory genes, such as multiple interferon down-stream genes, MHC class II genes and immunoglobulin genes.

[0084] Therefore, in another aspect of the present invention, it is referred to at least one or at least two or at least three or at least four or all five group(s) selected from the group of genes belonging to one of the clusters including, but not limited to the group of genes shown in Gene List 2 - Epi A, Gene List 2 Epi-B, Gene List 2 - Mes, Gene List 2 - Stem A or Gene List 2 - Stem B.

[0085] After having clustered the samples into the five different groups it is now possible to determine to which of these groups any given sample of a patient belongs to. Once the sample has been assigned to one of the five groups it is possible to predict the outcome of the disease, such as epithelial ovarian cancer.

[0086] Therefore, in another aspect, the present invention refers to a method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (EOC) wherein the method comprises:

a) providing or determining a set of expression data in a patient sample obtained from a patient suffering from epithelial ovarian cancer (EOC);

b) assigning the set of expression data derived from said patient sample to one of five subtype clusters for epithelial ovarian cancer (EOC),

wherein the first of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - Epi A;

wherein the second of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - EpiB;

wherein the third of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - Mes;

wherein the fourth of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - StemA;

wherein the fifth of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - StemB;

c) determining an EMT score for the patient sample; and

d) estimating the clinical outcome depending on any one of the five subtype clusters and the EMT score to which the patient sample is assigned.

[0087] In general, the prognosis, outcome or clinical outcome referred to herein refers to the overall probability of survival. The following Table 2 shows significant impact on overall survival of Stem-A and Epi-B signatures being independent prognostic factors from multivariate analysis.

[0088] As illustrated in Table 2, the effect of molecular subtyping on prognosis or determination of outcome was significant in both univariate and multivariate Cox regression analyses (Table 2). The

results demonstrated robustness of the molecular classification scheme within the serous histotype and suggested that molecular subtyping is an independent prognostic factor for cancer patients, such as EOC patients.

5 Table 2. Univariate and multivariate Cox proportional hazards regression analysis for multiple clinical variables and tumor subtypes.

Clinical Variables	Sample size (Total n=537)	Univariate (HR, 95% CI)	p-value	Multivariate (HR, 95% CI)	p-value
Age (yr)					
< 55	176 (32.47%)	1		1	
≥ 55	364 (67.53%)	1.493 (1.071-1.839)	0.0741	1.285 (0.978-1.687)	0.07173
Stage					
I or II	47 (8.72%)	1		1	
III or IV	492 (91.28%)	3.907 (1.843-8.285)	0.00038	3.429 (1.591-7.389)	0.00165
Grade					
1	17 (3.15%)	1		1	
≥ 2	522 (96.85%)	2.58 (0.9578-6.949)	0.0608	1.365 (0.494-3.763)	0.54799
Metastasis					
Primary	500 (92.76%)	1		1	
Metastasis	39 (7.24%)	1.349 (0.8323-2.185)	0.224	1.391 (0.854-2.27)	0.1853
Subtype					
Non-Epi-A	483 (89.61%)	1		1	
Epi-A	56 (10.39%)	0.7103 (0.4496-1.122)	0.142	0.9449 (0.5834-1.53)	0.8176
Non-Epi-B	384 (71.24%)	1		1	
Epi-B	155 (28.76%)	0.69 (0.5206-0.9144)	0.0098	0.7347 (0.5532-0.976)	0.033
Non-Mes	361 (66.98%)	1		1	
Mes	178 (33.02%)	1.171 (0.907-1.513)	0.225	1.01 (0.777-1.324)	0.9164
Non-Stem-A	411 (76.25%)	1		1	
Stem-A	128 (23.75%)	1.417 (1.075-1.868)	0.0136	1.382 (1.045-1.83)	0.0234
Non-Stem-B	517 (95.92%)	1		1	
Stem-B	22 (4.08%)	1.204 (0.6383-2.271)	0.567	1.14 (0.6033-2.149)	0.6886

* Multivariate Cox regression analysis of clinical variables with Stem-A subtype.

** For multivariate Cox regression, each subtype was independently analyzed with the other clinical variables (age, stage, grade, and metastasis) from the remaining subtypes.

P-values below 0.05 are shown with red color.

Abbreviations: Epi-A; Epithelial-A, Epi-B; Epithelial-B, Mes; Mesenchymal, Stem-A; Stem-like-A,
5 Stem-B; Stem-like-B.

[0089] The five groups of genes provide a predictive framework that allows assigning data obtained from individual patients to one of the five groups and based on this assignment to make a prognosis regarding the clinical outcome of the cancer.

[0090] For example, as shown in the Kaplan-Meier analysis, Epi-A, Epi-B subtypes show better
10 prognosis while Mes subtype are linked with poorer prognosis (Figure 5C). Of the two groups with Stem-like marker gene expression, patients with Stem-B subtype showed intermediate prognosis, while patients with Stem-A subtype showed poorer prognosis similarly to Mes subtype (Figure 5C). Thus, the probability of survival decreases in the following order EpiA = EpiB > StemB > Mes = StemA.

[0091] Assigning the set of expression data derived from said patient sample to one of five
15 subtype clusters for epithelial ovarian cancer (EOC) can be carried out by methods known in the art. In one example assignment is carried out either a' by clustering, such as consensus clustering, the expression data derived from the patient sample together with the expression data which make up said five different subtype clusters of epithelial ovarian cancer (EOC) to determine to which group the
20 expression data of the patient sample belongs; or b' by subjecting the expression data obtained from the patient sample together with the expression data which make up said five different subtype clusters of epithelial ovarian cancer (EOC) to a regression analysis, such as a binary regression analysis. Examples for a binary regression analysis comprise a logistic binary regression analysis.

[0092] In addition to assigning the expression data of a patient to one of the five specific subtype
25 cluster the epithelial-mesenchymal score (EMT) score is determined. To determine an EMT score for a given type of cancer it is at first necessary to generate the basis for such a scoring system. Figure 26 illustrates one example how such a system can developend. It can then be used to assign an EMT scoring to a given patient sample.

[0093] An EM scoring methodology of the epithelial-mesenchymal (EM) score can be developed
30 to estimate the sample status for the epithelial or mesenchymal phenotype. A higher or lower EMT score indicates more of the mesenchymal or epithelial phenotype. The EMT score can be derived separately for clinical samples and cell lines. Using the cadherin score, a subtraction of N- from E-cadherin positivity on the cell surface detected by immunostaining, the cell lines can be assigned to the epithelial or mesenchymal phenotype and used to generate a gene expression signature using
35 regression, such as BinReg regression model, so as to distinguish the epithelial from mesenchymal

phenotype. The resultant EM signature comprises a certain number of genes. The EM status can then predicted of clinical samples and remaining cell lines. To re-train the models, the top 100 tumors or the top 20% or 25% or 30% cell lines with the highest probabilities for epithelial or mesenchymal phenotype can be chosen and identified the highly correlated genes using the expression data.

5 Afterwards each new sample can be assigned an individual epithelia-mesenchymal score by subtracting of the rank for mesenchymal from epithelial phenotype.

[0094] Figure 26 illustrates such a method in which two pathes for generating such an EMT scoring system are shown. One way uses cell lines while the other one uses the patient data which has been used to generate the subtype clusters.

10 [0095] As described above, for EMT scoring it was necessary to differentiate mesenchymal from epithelial cell types. Markes suitable for differentiating between mesenchymal and epithelial cells which are known in the art can be used. For example, markers for E-cadherin and N-cadherin can be used. The results of measuring the staining, such as immunostaining intensities for both markers are recorded (see e.g. Figure 12A) and a cadherine-score is established by subtraction of the E-cadherin
15 signal from the N-cadherin signal.

[0096] Using this scoring system an EMT scoring can be assigned to any given test sample from a patient. The EMT scoring is used together with the assignment to a specific subtype cluster to provide a prognosis regarding the clinical outcome of cancer.

[0097] Referring now to the example for epithelial ovarian cancer, the EMT score referred to
20 under c) can be determined by a') computing an enrichment score by integration of the difference between the empirical cumulative distribution functions of genes from Gene List 3 and genes not in Gene List 3 for each set of expression data from the individual patient samples to determine the epithelial rank or mesenchymal rank of a sample; and b') determining the EMT score by subtracting the value, such as the normalized value, for the epithelial rank from the value, such as the normalized
25 value, for the mesenchymal rank.

[0098] In another example, the EMT score referred to under c) for a patient cancer sample is determined by a') computing an enrichment score by integration of the difference between the empirical cumulative distribution functions of genes from Gene List 4 and genes not in Gene List 4 for each set of expression data from the individual patient cancer sample to determine the epithelial
30 rank or mesenchymal rank of a sample; and b') determining the EMT score by subtracting the value, such as the normalized value, for the epithelial rank from the value, such as the normalized value, for the mesenchymal rank.

[0099] It is also noted that integration of the difference between the empirical cumulative distribution functions of genes from Gene List 3 or Gene List 4 and genes not in Gene List 3 or Gene
35 List 4, respectively, for each set of expression data from the individual patient cancer sample to

determine the epithelial rank or mesenchymal rank of a sample can be carried out using single sample an enrichment analysis, such as gene set enrichment analysis (ss-GSEA).

[00100] Gene Set Enrichment Analysis (GSEA) (developed at the Broad Institute of MIT and Harvard) is a computational method that determines whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states (e.g. phenotypes).

[00101] As previously mentioned when handling data obtained from different sources, batch effects can be removed using methods known in the art, such as ComBat.

[00102] In another aspect, the present invention is directed to a method of selecting model cancer cell lines for studying the effect of drugs. The method can include, but is not limited to firstly determining model cancer cell lines having an expression profile which is close to the expression profile of a tumor specimen obtained from a patient suffering from said cancer; and secondly using said model cancer cell line to study the effect of pharmaceutical compositions which have or possibly show a therapeutic effect.

[00103] In another aspect, the present invention refers to a method of determining whether the epithelial mesenchymal score of a patient suffering from a cancer, such as epithelial ovarian cancer, can be changed by administering an EMT reversal agent to increase patients susceptibility for an anti-cancer treatment, wherein the method comprises classifying a tumor sample of said patient using a method of the present invention to determine the cancer subtype and EMT score; after determining the cancer subtype and EMT score *determining* whether a treatment with an EMT reversal agent is necessary to sensitize said patient to anti-cancer treatment.

[00104] The anti-cancer treatment referred to above can be any one of administering an anti-cancer drug, surgery, chemotherapy, or radiation therapy, or hormonal therapy, or a combination of these types of treatment.

[00105] For example, for ovarian cancer, such as epithelial ovarian cancer there are basically three forms of treatment. The primary one is surgery at which time the cancer is removed from the ovary and from as many other sites as is possible. Chemotherapy is the second important modality. This form of treatment uses drugs to kill the cancer cells. Taxane and/or platinum-based chemotherapy based anti-cancer drugs, such as carboplatin and paclitaxel are most often used for chemotherapy.

[00106] The other modality is radiation treatment, which is used in only certain instances. It utilizes high energy x-rays to kill cancer cells. Surgical treatment of ovarian cancer is best performed by a gynecologic oncologist who has been specially trained in the diagnosis and management of gynecologic malignancy. The treatment of ovarian cancer depends on the stage of the disease, the histologic cell type, and the patient's age and overall condition. The histologic cell type and the extent of disease based on the biopsies performed by the gynecologic oncologist during surgery (staging) are

determined by the pathologist who analyzes tissues with a microscope. Based on the results of the method described herein it is now possible to determine a better course of action.

[00107] In another aspect, the present invention refers to a computer readable medium having stored therein a computer program comprising a set of executable instructions, when executed by a computer processor, controls the processor to perform the method according to the present invention.

[00108] In still another aspect, the present invention refers to a computer program comprising a set of executable instructions, when executed by a computer processor, controls the processor to perform the method according to the present invention.

[00109] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[00110] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[00111] Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

EXPERIMENTAL SECTION

[00112] **Materials and Methods**

[00113] **Part A. Genome-scale gene expression meta-analyses**

[00114] Data preprocessing of Affymetrix expression data

[00115] Epithelial ovarian cancer datasets were obtained from multiple data repositories such as Gene Expression Omnibus (GEO), Array Express, Expression Project for Oncology (ExpO), and The

Cancel Genome Atlas (TCGA). Microarray data on Affymetrix U133A or U133 Plus 2 platform were utilized for analysis. Robust Multichip Average (RMA) normalization was performed separately on each dataset. The normalized data was compiled and subsequently standardized using ComBat {Johnson, 2007 #38} to remove batch effect. Removal of ovarian cancer cell lines, normal tissues and primary cultured normal cells from the standardized data yielded a dataset of 1,538 ovarian tumor samples. Eleven hundred and eighty-five probes corresponding to 941 genes were retained by applying threshold of standard deviation across all the samples greater than 1.05. The expression values of selected genes were normalized and centered with Cluster 3.0 and further processed to subtype identification.

10 [00116] Consensus clustering

[00117] Consensus clustering (Monti, Savage et al. 2005, Blood, vol.105, no.5, pp.1851) in Gene Pattern (Reich, Liefeld et al. 2006, Nat Genet, vol.38, no.5, pp.500) was used to identify robust clusters that correspond to the distinct subgroups in epithelial ovarian cancer. As the clustering algorithm hierarchical clustering was chosen with agglomerative average linkage, with Euclidean distance and with sub-sampling ratio of 0.8 for 1000 iterations. The condition of $K_{max}=18$ was employed since it gave a reasonable Gini index and purity with ~ 0.8 (data not shown).

15 [00118] Predictive modeling and validation by ClaNC

[00119] Silhouette analysis was performed using Matlab (ver. 7.8.0) to identify core samples that are defined as samples best representing their subtypes with positive silhouette width. Significance analysis of microarrays (SAM) and receiver-operative curve (ROC) were applied to determine the marker genes for each subtype and to assess the gene capability in distinguishing a subtype from the others [Tusher, Tibshirani et al., 2001, Proc Natl Acad Sci USA, vol.98, no.9, pp.5116]. False discovery rate of zero and AUC threshold of >0.78 (up-regulated in the subtype) or <0.22 (down-regulated in the subtype) were used to filter out non-significant genes for SAM and for ROC, respectively. Based on these marker genes, ClaNC was applied to generate signatures for each subtype, and subsequently subtype predictive model of clinical samples (Dabney, 2006, Bioinformatics, vol.22, no.1, pp.122). In order to validate the subtype prediction, ten-fold cross-validation was adopted to provide a sufficient estimation of the predictive model performance without the need of additional validation data. In ten-fold cross-validation, the 1,538 epithelial ovarian cancer samples were randomly partitioned into 10 sets each comprised 153-154 samples (Subramanian and Simon, 2011, Stat Med, vol.30, no.6, pp.642). One set was used as a validation set (to be predicted) whereas the other 9 sets (1384 or 1385 samples) were used to build the predictive model. This process was repeated 10 times such that each set was used as validation set exactly once. This method minimized the bias introduced by the sample order and distribution when assessing the predictive

model. Subtype predictions of all the validation sets were combined and compared against the subtype assignment by consensus clustering on all of the 1,538 samples.

[00120] Predictive modeling and validation by BinReg

[00121] Analysis of expression data based on a binary regression model using the BinReg ver. 2.0 was described previously (Mori, Rempel et al., 2008, Cancer Res, vol.68, no.20, pp.8525; Gatza, Lucas et al., 2010, Proc Natl Acad Sci USA, vol.107, no.15, pp.6994). Gene expression signatures were created by choosing the genes whose expression profiles across the training samples most highly correlated with the phenotype. Divide-and-conquer approach was adopted for generating signature for the different subtypes. In each subtype, a binary regression model was built that single out a subtype from the rest. The top 50 core samples were selected by their highest silhouette width of all the five subtypes, and subdivided them into two set of data, training set A and training set B. These training sets were utilized to determine appropriate condition/parameters for the binary regression model. Subsequently, the condition was used to predict the remaining samples by the training set A. To predict the status of the phenotype on a dataset, a Bayesian probit regression model was fitted that assigned the probability that a sample exhibited evidence of the phenotype, based on the concordance of its gene expression values with the signature (Gatza, Lucas et al., 2010, *supra*)

[00122] Single sample Gene Set Enrichment Analysis

[00123] Single sample Gene Set Enrichment Analysis (ss-GSEA) was originally described in a previous study (Verhaak, Hoadley et al., 2010, Cancer Cell, vol.17, no.1, pp.98). It is a statistic that computes, for each sample, the integration of the difference between the empirical cumulative distribution functions (ECDF) of genes in the signature and the genes not in the signature (Verhaak, Hoadley et al. 2010). Given a sample $S = \{x_1, x_2, \dots, x_i, \dots, x_N\}$, where x_i is the expression value of i^{th} gene, N is the total number of genes, and a geneset G with N_G number of genes, SS-GSEA computes the score by $ES(G, S)$, firstly, convert the gene expression to ranks, i.e. $S = \{\gamma_1, \gamma_2, \dots, \gamma_N\}$ based on their absolute expression, and rank ordered. Subsequently, SS-GSEA score $ES(G, S)$ is calculated as

$$ES(G, S) = \sum_i [P_G(G, S, i) - P_{NG}(G, S, i)]$$

Where $P_G(G, S, i)$ and $P_{NG}(G, S, i)$ are the ECDF of the genes in signature G and genes not in signature

G respectively. The ECDF is computed using the equations $P_G(G, S, i) = \sum_{r_j \in G, j \leq i} \frac{|\gamma_j|}{\sum_{\gamma_j \in G} |\gamma_j|}$

$$P_{NG}(G, S, i) = \sum_{r_j \in G, j \leq i} \frac{1}{(N - N_G)}$$

$||$ is the cardinality.

[00124] Statistical analysis for clinical parameters

[00125] GraphPad Prism was used to examine statistical significance of clinical stage, primary or metastatic tumors, histological subtypes, or the malignant potential of each subtype by Fisher's exact test. For Kaplan-Meier analysis, the statistical significance was calculated by log-rank test.

5 [00126] **Part B. *In vitro* EMT modeling in cancer cell lines**

[00127] Cell line subtype identification by consensus clustering

[00128] Four independent datasets for ovarian cancer cell lines from Duke University (42 cell lines), Kyoto University (37 cell lines), Singapore (34 cell lines) and National Laboratory (29 cell lines) were analyzed (Guan, Kuo et al., 2007, Clin Cancer Res, vol.13, no.19, pp.5745; Matsumura, Huang et al., 2011, Genome Res, vol.21, no.1, pp.74). The data for total of 142 cell lines were compiled and analyzed with the data of 1,142 core clinical samples in consensus clustering. Realizing that the identified subclass labeling for cell lines did not fully capture the pattern of clinical samples, this labeling was then used as tentative assignment for cell line subtypes for subsequent clustering analysis. After identification of the subtype-specific marker genes using the "cell-line only" expression data with SAM and ROC (Tusher, Tibshirani et al., 2001, Proc Natl Acad Sci USA, vol.98, no.9, pp.5116), a consensus clustering was performed once more relying on the selected gene sets. This analysis yielded a stable subtype classification for the cell lines with reasonable similarity to that for clinical samples. Finally to confirm the expression similarity between cell lines and clinical samples for each subtype, BinReg and ClaNC were adopted to validate the subtype assignment of the cell lines (Dabney, 2006, *supra*; Gatza, Lucas et al., 2010, *supra*).

[00129] Determination of EMT phenotype category in cancer cell lines

[00130] An ovarian cancer cell line library, termed SGOCL(42), consisting of 42 different ovarian cancer cell lines of serous, endometrioid, and undifferentiated histology was acquired via various sources and maintained in house. Detailed cell line names and growth conditions can be found in the following Table 3.

Table 3. Description of 42 ovarian cancer cell lines used in the study.

Name	Histology	Media	Original Repository	Catalogue Number	Source
A2008	Endometrioid	RPMI 1640 + 5% FBS			Kyoto U.
A2780	Undifferentiated	RPMI 1640 + 10% FBS	ECACC	93112519	ECACC
BG1	Poorly differentiated	DMEM + 10% FBS + Insulin (1mg.mL ⁻¹)			Kyoto U.
C13	Endometrioid	RPMI 1640 + 5% FBS (Iron-supplemented)			Kyoto U.

CAOV2	Adenocarcinoma	RPMI + 10% FBS			Kyoto U.
CAOV3	Serous	DMEM + 10% FBS	ATCC	HTB-75	ATCC
CHI	Papillary cystadenocarcinoma	DMEM + 10% FBS + Insulin (10mg.mL-1) + Hydrocortisone (0.5mg.mL-1)			Kyoto U.
COLO 720E	Adenocarcinoma	RPMI 1640 + 5-10% FBS	ECACC	93072111	ECACC
DOV13	Adenocarcinoma	DMEM + 10% FBS	M.D. Anderson Cancer Center		Kyoto U.
EFO21	Dedifferentiated serous cystadenocarcinoma	RPMI 1640 + 20% FBS + 1mM NaPy + 1x NEAA	DSMZ	ACC-235	DSMZ
FUOV1	Serous papillary adenocarcinoma	DMEM/Ham's F-12 (1:1) + 10% FBS	DSMZ	ACC-444	DSMZ
Hey	Serous	RPMI 1640 + 10% FBS			Kyoto U.
HeyA8	Serous	RPMI 1640 + 10% FBS			Kyoto U.
HeyC2	Serous	RPMI 1640 + 10% FBS			Kyoto U.
IGROV 1	Endometrioid	RPMI 1640 + 10% FBS	NCI- Frederick		Kyoto U.
JHOS2	Serous cystadenocarcinoma	DMEM/Ham's F-12 (1:1) + 10% FBS + 0.1mM NEAA	RIKEN	RCB1521	Kyoto U.
JHOS3	Serous cystadenocarcinoma	DMEM/Ham's F-12 (1:1) + 15% FBS + 0.1mM NEAA	RIKEN	RCB1546	Kyoto U.
JHOS4	Serous cystadenocarcinoma	DMEM/Ham's F-12 (1:1) + 10% FBS + 0.1mM NEAA	RIKEN	RCB1678	Kyoto U.
OVCAR 3	Serous	RPMI 1640 + 20% FBS + 10 mg.mL-1 Insulin	ATCC	HTB-161	ATCC
OAW 28	Cystadenocarcinoma	DMEM + 10% FBS + 20IU.L-1 Insulin + 1mM NaPy	ECACC	85101601	ECACC
OAW 42	Papillary serous cystadenocarcinoma	DMEM + 10% FBS + 20IU.L-1 Insulin + 1mM NaPy	ECACC	85073102	ECACC
OV17R	Adenocarcinoma	DMEM/ Ham's F-12 (1:1) + 5% FBS + 0.4mg.mL-1 Hydrocortisone + 10mg.mL-1 Insulin	ECACC	96020763	ECACC
OV2008	Serous cystadenocarcinoma	RPMI 1640 + 10% FBS (4mM L- Glutamine + 1mM NaPy + 1x NEAA)*			Kyoto U.

OV56	Poorly differentiated	DMEM/ Ham's F-12 (1:1) + 5% FBS + 0.5mg.mL-1 Hydrocortisone + 10mg.mL-1 Insulin	ECACC	96020759	ECACC
OV7	Poorly differentiated	DMEM/ Ham's F-12 (1:1) + 5% FBS + 0.5mg.mL-1 Hydrocortisone + 10mg.mL-1 Insulin	ECACC	96020764	ECACC
OV90	Serous	MCDB105 (1.5mg.mL-1 Na2CO3)/ M199 + 15% FBS (1:1)	ATCC	CRL- 11732	ATCC
ovary18 47 (A1847)	Serous	RPMI 1640 + 10% FBS + 10mg.mL-1 Insulin			Kyoto U.
OVCA4 20	Serous	DMEM + 10% FBS			Kyoto U.
OVCA4 29	Serous	DMEM + 10% FBS			Kyoto U.
OVCA4 32	Serous	DMEM + 10% FBS			Kyoto U.
OVCA4 33	Papillary serous cystadenocarcinoma	DMEM + 10% FBS			Kyoto U.
OVCAR 10	Poorly differentiated				Kyoto U.
OVCAR 2		RPMI 1640 + 10% FBS + Insulin (10mg.mL-1)			Kyoto U.
OVCAR 5	Adenocarcinoma	RPMI 1640 + 10% FBS + Insulin (10mg.mL-1)	NCI- Frederick		Kyoto U.
OVCAR 8	Undifferentiated	RPMI + 10% FBS + Insulin (10 mg.mL-1)	NCI- Frederick		Kyoto U.
OVK18	Endometrioid	MEM + 10% FBS	RIKEN	RCB1903	Kyoto U.
PEO1	Poorly differentiated serous adenocarcinoma	RPMI 1640 + 10% FBS + Insulin (2.5mg.mL-1) + 2mM NaPy	CRT	PE Ovarian Adenocarci noma Cell Line	CRT
PEO4	Poorly differentiated serous adenocarcinoma	DMEM (HG) + 15% FBS + Insulin (2.5mg.mL-1) + 1x NEAA	CRT	PE Ovarian Adenocarci noma Cell Line	CRT
SKOV3	Serous	DMEM (HG): DMEM (LG) (1:1) + 10% FBS	ATCC	HTB-77	ATCC
TOV112 D	Endometrioid	MCDB105 (1.5mg.mL-1 Na2CO3)/ M199 + 15% FBS (1:1)	ATCC	CRL- 11731	ATCC
TykNu	Undifferentiated	DMEM + 10% FCS	JCRB	JCRB0234.	Kyoto U.

UWB1.2 89	Papillary serous	RPMI 1640/ MEGM (Bullet Kit) (1:1) + 3% FBS	ATCC	0 CRL-2945	ATCC
--------------	------------------	---	------	---------------	------

Abbreviations:

ATCC: American Type Culture Collection

CRT: Cancer Research Technology (Cancer Research UK)

5 DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen

ECACC: European Collection of Cell Cultures

JCRB: Japanese Collection of Research Bioresources

Kyoto U.: Dr. Noriomi Matsumura Kyoto University (Matsumura, N., et al, Genome research, 2011,
vol.21, no.1, pp.74)

10 RIKEN: RIKEN BioResource Center

[00131] The EMT phenotypes of each ovarian cancer cell line were characterized by morphological examinations (phase contrast imaging) and immunofluorescence staining for prototypic EMT markers. Cells were grown on glass coverslips until 70-80% confluence before fixing in cold acetone at -20 °C for 10 min followed by rehydration with PBS and blocking with 3% of BSA in PBS for 60 min. After washing with PBS, incubations with primary antibodies against E-cadherin (BD), N-cadherin (Takara), pan-cytokeratin (AE1/AE3, Dako), and vimentin (Dako) were performed at 37 °C for 1 hr. After washing with PBS, incubation with secondary antibodies conjugated with Alexa-488 (Invitrogen) were performed at room temperature for 1 hr in the dark. After washing with PBS, coverslips were subsequently mounted onto the glass slides with anti-fading mounting media.

20 The staining results were read by three independent researchers (JPT, SWJ, and LYF). For E-cadherin and N-cadherin, only junctional stainings were regarded as positive. Cytoplasmic stainings of E-cadherin and N-cadherin were regarded as negative. A decision matrix was established to determine the EMT phenotype of each cell line into four categories: epithelial (E), intermediate epithelial (Int E), intermediate mesenchymal (Int M), and mesenchymal (M). In addition, the staining intensities were also documented as 0 (negative), 1 (weak positive), 2 (positive), and 3 (strong positive).

[00132] Quantification of EMT status in cancer cell lines

[00133] SGOCL(42) was grown in 10-cm tissue culture plates until 90% confluence before harvesting. Each cell line was duplicated. RNAs were extracted by using Qiazol (Qiagen) followed by clean-ups with miRNeasy columns (Qiagen). 500 ng of cell line RNAs were subjected for real-time PCR analysis for the expression levels of EMT genes. The expression levels of EMT markers were validated by using real-time quantitative PCR (qPCR) amplifications of 84 known molecules in EMT pathway (SABiosciences RT² Profiler EMT pathway, PAHS-090). The reactions were carried out

according to the manufacturer's protocol by using 7900HT Fast Real-Time PCR System (Applied Biosystems). In brief, total RNAs were converted to cDNA by the First Stand Synthesis Kit. cDNA templates were mixed with the RT² qPCR Master Mix. Equal volumes of mixtures were aliquot to the PCR plate (QIAGEN SA Biosciences RT2 Profile EMT PCR Array) with PCR primers of genes of interest, 5 housekeeping genes (Beta-2-microglobulin, Hypoxanthine Phosphoribosyltransferase 1, Ribosomal Protein L13a, Glyceraldehyde-3-phosphate Dehydrogenase, Actin, beta) and 5 assay quality controls (1 human genomic DNA contamination, 2 reverse transcription control, 2 positive PCR control). Delta-Ct (dCt) and delta delta-Ct (ddCt) was calculated. Delta-Ct values were obtained by subtracting the averaged Ct values for all 5 housekeeping genes (HKG: B2M, HPRT1, RPL13A, GAPDH, ACTB) from the Ct value of the gene of interest (GOI). It can be expressed by the following formula: $\text{delta-Ct (GOI)} = \text{Ct (GOI)} - \text{Average Ct (HKG)}$ whereby: delta-Ct (GOI): Differential threshold cycle (delta-Ct) of the gene of interest (GOI) against that of the average of all 5 housekeeping genes. Ct (GOI): Threshold cycle (Ct) for the gene of interest (GOI); Ct (HKG): Threshold cycle (Ct) for the housekeeping gene (HKG)

[00134] Example: $\text{Delta-Ct}_{\text{CTNNB1}} = \text{Ct}_{\text{CTNNB1}} - [(\text{Ct}_{\text{B2M}} + \text{Ct}_{\text{HPRT1}} + \text{Ct}_{\text{RPL13A}} + \text{Ct}_{\text{GAPDH}} + \text{Ct}_{\text{ACTB}}) + 5]$

[00135] Calculation of delta-delta-Ct: delta-delta-Ct values were obtained by subtracting the reference sample's delta-Ct value of the gene of interest from the sample's delta-Ct value of the same gene of interest.

[00136] Example: $\text{delta-delta-Ct}_{\text{CTNNB1}}$, the reference sample for this study used was PEO1 as it represents an epithelial ovarian carcinoma with positive immunofluorescence staining against epithelial markers (E-Cadherin and pan-cytokeratin) while negative against mesenchymal markers (N-Cadherin and vimentin). $\text{Delta-delta-Ct}_{\text{CTNNB1}} (\text{SKOV-3}) = \text{delta-Ct}_{\text{CTNNB1}} (\text{SKOV-3}) - \text{delta-Ct}_{\text{CTNNB1}} (\text{PEO1})$.

[00137] EMT-related cell-based functional studies

[00138] Pipelines of EMT-related cell-based functional studies including migration assays, anoikis assays, spheroid formation assays, invasion and colony formation assays were established.

[00139] Migration assays were performed in a specially designed 96 well-format by seeding approximately 50,000 cells into the wells that have been pre-inserted with stoppers to occlude the center of the wells (Platypus Technology Oris Cell Migration Assays). In migration wells, stoppers were removed after reaching the desired incubation time to allow cell migration over night. In control wells, stoppers were not removed until reaching the migration endpoint. Quantitative readouts of migrations were accessed with two methods. For half of the plates, cells were stained with calcein-AM for 30 mins before subjecting to quantitative fluorescence reading by using a microplate reader (Tecan). For the other half of the plates, cells were fixed with 4% paraformaldehyde followed by

permeabilization with 0.1% Triton X-100 and stained with phalloidin conjugated with FITC (Sigma-Aldrich). Images were then captured by using (microscope) at 4x followed by image analysis using metamorph software.

[00140] Anoikis resistance assays were performed by seeding 10^5 cells into 6-well plates of either normal tissue culture plates (TCP; NUNC) or ultra-low attachment plates (ULA; Corning). Cells were incubated for 48 and 96 hrs before subjected for live-cell staining by using calcein AM /EthD-1 (CytoSelect) or subjected for MTT assays (CytoSelect). Fluorescence readouts for calceinAM and EthD-1 and absorbance readout for MTT were obtained by using a microplate reader (Tecan).

[00141] Epithelial-mesenchymal score

[00142] A scoring methodology of the epithelial-mesenchymal (EM) score was developed to estimate the sample status for the epithelial or mesenchymal phenotype. A higher or lower EMT score indicates more of the mesenchymal or epithelial phenotype. The EMT score was derived separately for clinical samples and cell lines as below. Using the cadherin score, a subtraction of N- from E-cadherin positivity on the cell surface detected by immunostaining, the cell lines were assigned to the

epithelial or mesenchymal phenotype and used to generate a gene expression signature using BinReg so as to distinguish the epithelial from mesenchymal phenotype. The resultant EM signature comprised 125 genes (data not shown). The EM status was then predicted of clinical samples and remaining cell lines by BinReg. To re-train the models, the top 100 tumors or the top 25% cell lines with the highest probabilities for epithelial or mesenchymal phenotype were chosen and identified the highly correlated genes using the expression data through SAM with q -value of 0 and ROC of 0.8. These procedures gave the gene lists of 693 probes for clinical samples (epithelial: 475 probes and mesenchymal: 218 probes; Gene List 4) and 989 probes for cell lines (epithelial: 550 probes and mesenchymal: 439 probes; Gene List 4). Importantly in both of clinical tumors and cell lines epithelial and mesenchymal genes included *CDH1* and *CDH2*, respectively. Moreover, the strong correlations between the EMT score and the *CDH1* or *CDH2* expression value was observed (Cell-line Spearman p -value, *CDH1*: $5.96E-37$, *CDH2*: 0.00000112, Tumor Spearman p -value, *CDH1*: 0, *CDH2*: 0). The ss-GSEA was then employed to compute the enrichment score of a clinical sample or a cell line based on the expression of epithelial- or mesenchymal signature genes. After ranking each sample according to the epithelial or mesenchymal enrichment score, the subtraction of the rank for mesenchymal from epithelial phenotype was defined as the epithelial-mesenchymal (EM) score.

[00143] **Part C. Cell-based small molecule EMT screening assay**

[00144] Maintenance of mcherry fluorescence-labeled NBT-II cells

[00145] Stably transfected mcherry fluorescence-labeled NBT-II cells are maintained in DMEM supplemented with 10% fetal bovine serum (FBS, Thermo Scientific), 1 μ g/mL puromycin (Sigma),

100 units/mL penicillin - 100 units/mL streptomycin (1× pen-strep, Invitrogen) and 2 mM L-glutamine (Invitrogen).

[00146] Preparation of compound stock plates

[00147] Test compounds were purchased from various vendors (Selleck Chemicals, Sigma Aldrich, SYNthesis Med Chem, and Tocris Bioscience). For screening studies, test compounds at both 0.25 mM and 1.0 mM concentrations in DMSO are prepared, each occupying a single well in columns 2 to 11 of 96-well V-bottom plates (Greiner). For dose response studies, selected test compounds were prepared in duplicate wells and serially diluted in DMSO, starting at a 1.0 mM concentration. Compound stock plates were stored at -20°C and thawed at room temperature before use.

[00148] Spot migration assay

[00149] A schematic for the spot migration assay is illustrated in Figure 2. Cells were grown up to 80% confluency in tissue culture flasks prior to cell plating. Cells were first trypsinized, concentrated and re-suspended to a density of 5×10^6 cell/mL in CO₂ independent medium (Invitrogen) supplemented with 10% FBS. The cell suspension was then evenly aliquoted into the wells of 2 columns of a 96-well V-bottom plate. Using a robotic liquid handling station (Bravo, Agilent Technologies), 0.5 µL of cell suspension was transferred from the 2 columns of the cell suspension-loaded plate and deposited into the center of the wells of 2 columns of a 96-well clear bottom, black assay plate (Corning). This process was repeated six times so that all 96 wells of the assay plate were deposited with a cell suspension spot. The plate was then sealed to minimize evaporation of the cell suspension spots and transferred to a 37°C, 5% CO₂ incubator to allow for cells to attach to the culture surface. After one hour, the plate was gently washed with medium once to remove unattached cells, refreshed with 100 µL assay medium (DMEM supplemented with 10% FBS, 1× pen-strep and 2 mM L-glutamine), and then further incubated to allow for cell-cell contacts to establish in the cell colonies.

[00150] After 4 hours of incubation, the cell colonies for each well were imaged using a confocal microplate imager (MetaXpress Ultra, Molecular Devices) with 10× Plan Fluor objective, 561 nm laser excitation and 593/40 nm emission filter configuration. Four tiled, non-overlapping images were acquired around the center of each well, which were then stitched together during image analysis to generate a montage covering an area of 3.2 mm × 3.2 mm. These images (T1) represent the initial state of the cell colonies before EMT induction.

[00151] After the T1 images are acquired, 1 µL of test compounds were transferred from compound stock plates and added to the assay plates. Appropriate negative controls (1 µL DMSO) and positive controls (1 µL 1.0 mM compound in DMSO) were also added into columns 1 and 12 of each assay plate respectively. The assay was adjusted to use AG1478, JNJ38877605 and BMS-536924

as reference positive control compounds for EGF, HGF and IGF-1 induced EMT respectively. The cultures were then further incubated overnight.

[00152] The next day, 50 μ L of growth factor containing medium was added each well of the assay plates. For each of the EGF, HGF or IGF-1 induced EMT spot migration assays, the final growth factor concentrations was adjusted in each well to be 20 ng/mL EGF (Sigma), 4 ng/mL HGF (Calbiochem) or 150 ng/mL IGF-1 (R&D Systems), respectively. The cultures were then incubated for another 24 hours, to allow for EMT and sufficient cell motility / dispersion to occur in the cell colonies.

[00153] Finally, the cell colonies were imaged again using the confocal microplate imager as described above. These images (T2) represent the final state of the cell colonies after compound treatment and EMT induction. The acquired T1 and T2 image sets for each assay plate were then subjected to image analysis.

[00154] Image analysis routine

[00155] Acquired image sets were loaded into image analysis routine developed using Metamorph software. Briefly, a complete image of the entire cell colony in a well was first obtained by stitching the four tiled, non-overlapping images together. Image analysis consists of counting the cell number and measuring the area occupied by the cells. The positive nuclei were segmented using a wavelet decomposition scheme to remove the photonic noise and the inhomogeneous background. A watershed procedure was used to refine the result by separating the confluent nuclei. Also, segmented objects showing sizes smaller than that of a given threshold value was filtered off. Then, the nuclei segmentation was utilized to estimate the area of cell colonies. A morphological filter named close (combination of dilation and erosion) accurately perform the filling of the nuclei area. If some cells break out the colony, the close filter leads to different area containing cells. The biggest area was considered as the colony and other areas represent the outside cell islets. Each well was described by the cell number, the colony area and the cell islets area. The results were then exported.

[00156] **Part D. EMT reversal assays**

[00157] Maintenance of ovarian cell lines

[00158] SKOV3, HEY and OVCA2 cells were maintained in RPMI (Invitrogen) supplemented with 10% fetal bovine serum (FBS, Thermo Scientific), 1 μ g/mL puromycin (Sigma), 100 units/mL penicillin - 100 units/mL streptomycin (1 $\times$ pen-strep, Invitrogen) and 2 mM L-glutamine (Invitrogen).

[00159] Preparation of compounds

[00160] AZD0530 and BIBF-1120 were purchased from Selleck Chemicals and SYNthesis Med Chem respectively. DMSO was used as a vehicle to dissolve both compounds. A stock concentration of 10mM was prepared for both compounds and stored at -20°C and aliquots were thawed at room temperature before use.

[00161] EMT reversal assay

[00162] Cells were grown up to 80% confluency in tissue culture flasks prior to cell plating. Cells were first trypsinized, concentrated and re-suspended to a density of 1×10^6 cell/mL in RPMI supplemented with 10% FBS. For each cell lines, 1×10^5 cells were plated onto 100mm cell culture treated dishes (Nunc) for each condition. The cells were then allowed to attach to the culture dish surface and grow overnight in 37°C, 5% CO₂ incubator. In drug conditions, the cells were then incubated with each of the compounds at a final concentration of 2 μ M for 3 days to allow cell-cell contacts to establish in the dispersed culture. The medium was aspirated from the culture dishes and the cells were washed with PBS Ca²⁺, Mg²⁺ before they were snap-frozen with liquid nitrogen.

10 [00163] Western Blot and semi quantitative analysis

[00164] Cells were lysed with RIPA buffer (Sigma) supplemented with protease inhibitor cocktail (Calbiochem) and phosphatase inhibitor cocktail (Roche). Protein concentration was measured using BCA (Pierce) protocol provided by the manufacturer. 8% polyacrylamide gels were used for the separation of proteins and transferred to PDVF membranes (Millipore). Membranes were blocked in 15 5% non-fat milk (Bio-rad) and incubated at 4 degree Celsius overnight with primary antibodies. E-cadherin antibody was purchased from BD laboratories, MMP13 antibody was purchased from Millipore and Tubulin was purchased from Sigma. The membranes were then incubated with HRP (Amersham) and developed with ECL (Millipore). The membranes were imaged using Gel documentation system with XTcooled Camera (Syngene). The raw intensity of the protein bands were 20 quantified using GeneTools software (Syngene).

[00165] **Results**

[00166] **Part A. Genome-scale gene expression meta-analyses**

[00167] Assessing the molecular heterogeneity of EOC and identifying clinically relevant subtypes

[00168] Genome-scale gene expression meta-analysis was applied on gene expression profiles of 25 epithelial ovarian cancer (EOC) obtained from publically available databases. The strategy was to firstly identify clinically relevant oncogenomic subtypes based on meta-analysis of expression data. These identified subtypes were further correlated with clinico-pathological factors, transcriptional characters and copy number aberrations. Subsequently, predictive models with supervised approaches were generated to develop gene expression based diagnostics. Representative cell lines for each 30 subtype were identified, the cell line subtypes with *in vitro* phenotypes were correlated and those cell lines were used as a model to explore possible therapeutic options (Figure 3).

[00169] To investigate the phenotypic complexity of EOC, a large collection of gene expression data was utilized (n=1,538; serous: 1,244, mucinous: 25, clear cell: 25, endometrioid: 92 and others: 56 samples) derived from 17 independent studies (Figure 4) (Hogdall, Christensen et al., 2003,

35 Cancer, vol.98, no.1, pp.66; Hendrix, Wu et al., 2006; Cancer Res, vol.66, no.3, pp.1354; Hsu,

Balakumaran et al., 2007, J Clin Oncol, vol.25, no.28, pp.4350; Jochumsen, Tan et al., 2007, Int J Gynecol Cancer, vol.17, no.5, pp.979; Anglesio, Arnold et al., 2008, Mol Cancer Res, vol.6, no.11, pp.1678; Tone, Begley et al., 2008, Clin Cancer Res, vol.14, no.13, pp.4067; Tothill, Tinker et al., 2008, Clin Cancer Res, vol.14, no.16, pp.5198; Bowen, Walker et al., 2009, BMC Med Genomics, vol.2, pp.71; Denkert, Budczies et al., 2009, J Pathol, vol.218, no.2, pp.273; Mok, Bonome et al., 2009, Cancer Cell, vol.16, no.6, pp.521; Pejovic, Pande et al., 2009, Transl Oncol, vol.2, no.4, pp.341; Tung, Mok et al., 2009, Mod Pathol, vol.22, no.9, pp.1243; Iorio, Ricci et al., 2010, Cancer Res, vol.70, no.5, pp.2126).

[00170] By performing consensus clustering of the assembled dataset, five predominant clusters characterized by distinct gene expression patterns were revealed (Figure 5). Epithelial-A (Epi-A) and Epithelial-B (Epi-B) tumor clusters were characterized by epithelial cell marker expressions such as *CDH1* (*E-cadherin*), *EPCAM*, various keratin genes (*KRTs*) and *CD24*. Mesenchymal tumor (Mes) subtype predominantly expresses fibroblastic/ mesenchymal genes such as *PDGFRA*, *VCAM1*, *ZEB1*, *TWIST1* and various extracellular matrices genes like collagen genes and *FNI*. Stem-like-A (Stem-A) and Stem-like-B (Stem-B) tumor clusters shared expresses *LGR5* and *PROM1* (*CD133*), typical markers for epithelial stem cells, respectively [Fodde, 2009 #30]. In addition, Stem-A tumors expressed proliferation-related genes as well as genes such as *MYCN*, *NCAM*, *CDH2* (*N-cadherin*), implying their neural characters. Inflammatory genes, which were composed mainly by multiple interferon down-stream genes, MHC class II genes and immunoglobulin genes, were obviously detected in Epi-B and Mes tumors but rarely detected in the other subtypes (Figure 5A). The silhouette plot confirmed the similarity of each tumor sample within a subtype, indicating robustness of the classification (Figure 5B).

[00171] Our study exhibits robustness, it describes the molecular subtypes in details and provides clues for therapeutics intervention based on this novel stratification.

[00172] These identified subtypes were correlated with various clinico-pathological characters that are known to be important in ovarian cancer. Firstly, significance of the subtypes was investigated while correlated with patient outcomes. As shown in the Kaplan-Meier analysis, Epi-A, Epi-B subtypes show better prognosis while Mes subtype are linked with poorer prognosis (Figure 5C). Of the two groups with Stem-like marker gene expression, patients with Stem-B subtype showed intermediate prognosis, while patients with Stem-A subtype showed poorer prognosis similarly to Mes subtype (Figure 5C). It was confirmed that the tumors with the subtype were indeed characterized by epithelial, mesenchymal or stem-cell markers based on the Single Sample Gene Set Enrichment Analysis (ss-GSEA) (Verhaak, Hoadley et al., 2010, *supra*) with the literature-curated gene signatures for epithelial, mesenchymal and stem cells (Figure 5D).

[00173] It was noted that serous adenocarcinoma histotype was identified in every subtype suggesting the molecular heterogeneity. Stem-B subtype consisted of multiple histologies and most of tumors with low malignancy potential are classified as Epi-A (Figure 6A). It was found that Mes tumors were almost exclusively at more advanced stages (Stage III or IV) which could explain the worst prognosis on survival (Figure 6C). The Epi-A and Epi-B subtypes generally had better prognosis in both early staged (I & II) and advanced staged (III & IV) diseases. Interestingly, the Stem-A subtype showed consistent poorer prognosis in both early staged (I & II) and advanced staged (III & IV) diseases, which indicated an aggressive phenotype associated with the stem cell-like property (Figure 6B and 6C). These results illustrated that the expression-based subtyping method could dissect the heterogeneity of ovarian adenocarcinoma and could also identify clinically relevant subtypes. Consistent with the notion that women of an advanced age have a higher risk among all ovarian cancer patient, the highest mean age was found in patients with Stem-A tumors (not Shown)

[00174] Development of a predictive framework for ovarian cancer subtype classification

[00175] In order to obtain an effective classification strategy for future application, a classification scheme was subsequently developed representing a predictive framework whereby tumor samples can be quantitatively assigned to subgroups based on the patterns of gene expression (Figure 7A). To overcome insufficient resolution in subtype status prediction of any independent cohort, it was set to develop a statistically sophisticated predictive model for subtype classification. From each subtype, 50 samples were selected with the highest silhouette values that were computed in Figure 5B, subdivided into two training datasets A and B, and generated predictive models based on gene expression arrays of training set A. Multiple trials of Binary Regression analysis (BinReg) were performed by changing relevant parameters such as the number for metagenes and for genes in a metagene (Bild, Potti et al., 2006, Nat Rev Cancer, vol.6, no.9, pp.735; Mori, Rempel et al., 2008, Cancer Res, vol.68, no.20, pp.8525). The best condition to predict the status of the samples in the training set B was obtained, this defined condition was used to predict the status of all the remaining samples including the training dataset B (Figure 7B). Figure 7B(B) shows the heatmap for predicted probabilities for subtype status of the remaining samples. Comparison of the subtype predicted by BinReg with that classified by the consensus clustering (Figure 5A) revealed overall 89.1% concordance for all the subtypes (89.4% for core samples), clearly indicating the powerful predictive capability of the method. To evaluate the extent to which such classifications are indeed robust, subtype prediction of samples in five independent datasets (GSE19829, GSE20565, Japan Kyoto Ovarian Cancer cohort; JPKO, GSE26712 and GSE27651; total n=418) which were not included in the meta-analysis, were investigated to evaluate the predictive capability as a more rigorous evaluation. In a separate analysis, the data of GSE20565 and JPKO were compiled with that of 1,142 core samples derived from the initial dataset of 1,538 samples and performed the consensus

clustering. Afterwards concordance of those two different analytical methods was calculated. The high percentage of overall concordance (90.5% for GSE20565 and 83.6% for JPKO) for all the subtypes (Figure 8D) clearly demonstrated robustness of this classification scheme as well as sound predictive capability of this predictive model.

[00176] Robustness of the classification was further confirmed by an additional examination employing another statistical approach (Figure 8). The gene signature to distinguish a subtype from the remaining subtypes was developed by supervised gene selection with SAM and ROC using all of 1,142 core samples (Epi-A: 101, Epi-B: 315, Mes: 325, Stem-A: 256 and Stem-B: 145) (Figure 8A) (Tusher, Tibshirani et al. 2001). Three-dimensional visualization of the principal components of these selected genes for the all core samples revealed clearly distinguishable patterns for each subtype (data not shown). In order to know whether these genes have predictive capabilities, 10-fold cross validations were performed, in which the expression signatures from 90% samples in the same manner were generated, the subtype status of the remaining 10% samples with the signatures by ClaNC was predicted and the predictions were repeated 10 times (Figure 8B) (Dabney, 2006, Bioinformatics, vol.22, no.1, pp.122; Subramanian and Simon, 2011, Stat Med, vol.3, no.6, pp.642). After compilation of 10 repeated results, the overall concordance for 1,538 samples was obtained as 72.4% (Figure 8C). Furthermore, five independent datasets (GSE19829 [n=28], GSE20565 [n=95], Japan Kyoto Ovarian Cancer cohort; JPKO [n=67], GSE26712 [n=185] and GSE27651 [n=43]; total n=418) showed a reasonable concordance of 80.1% (core samples: 89.6%) between the results derived from the prediction and the consensus clustering using the gene signatures that were developed in Figure 7B(B). Although the method relying on SAM/ ROC/ ClaNC showed slightly poorer predictive capability than that relying on BinReg (Figure 7A), the observed concordance still demonstrates strong robustness of the classification scheme.

[00177] **Part B. *In vitro* modeling of carcinoma subtypes and EMT phenotypes by using an ovarian cancer cell line library**

[00178] Identification of cell lines as representatives of *in vivo* tumors in multiple subtypes

[00179] An important aspect of the development of a classification scheme is to establish a framework for facilitating the use of experimental systems, whether *in vitro* cell lines or xenografts, as models for the study of the *in vivo* cancers, so that cell line does truly reflect the underlying biology of the tumor. Expression studies of cultured breast cancer cell lines have indeed shown that these *in vitro* cells retain their subtype characteristics corresponding to those of the *in vivo* counterparts, therefore, the matched breast cell lines can be used for further study as representatives of *in vivo* tumors. In order to identify the cell-line counterparts of ovarian tumors, a co-clustering analysis was performed of a collection of total 142 cultured cell lines (Duke: GSE25429; 42, Kyoto: 37, National Laboratory: E-TABM-254; 29 and Singapore: 34 cell lines with redundancy in cell line names) with 1,142 of core

tumor samples using the same clustering profiling method with the same tumor classifiers used in Figure 5. This co-clustering resulted that all the cell lines were subdivided into 7 clusters (G1: 21, G5: 23, Epi-A: 1, Epi-B: 12, Mes: 33, Stem-A: 24 and Stem-B: 28 cell lines), among which at this time two clusters (G1 and G5) were excluded from the majority of tumor clusters and composed by predominantly cell lines. It was assumed that the expression signature for *in vitro* cultured ovarian cell-line subtype might to some extent differ from that of clinical tumors, one more round of consensus clustering was performed purely relying on the re-selected cell-line classifiers based on the first clustering result. Genes were selected that can distinguish each subtype from the remaining subtypes by SAM/ ROC (data not shown). This double consensus clustering yielded five subtypes for the cell lines (Epi-A: 29, Epi-B: 10, Mes: 34, Stem-A: 42 and Stem-B: 27 cell lines) (Figure 9A). The similarity matrices and the silhouette values further supported the proper assignment of the cell line samples to corresponding subtypes (Figure 9B). As shown in Figure 9C, the cell-line subtype predictors were then developed based on the cell-line classification and applied to clinical data to estimate the similarity between *in vivo* tumors and *in vitro* cell lines in the gene expression pattern of the subtype predictors. The levels of accuracy of prediction between a cell-line classifier and a tumor subclass were tested with the area under curve (0.744 to 0.918) and concordance (75.8 to 87.9%), indicating similarity of cell lines and *in vivo* tumors in the expression (Figure 9C). Finally, consistency of the classification in the cell-line names was confirmed across the different collections among Duke, Kyoto and Singapore cell lines (Figure 9D). The analyses demonstrated that *in vitro* cancer cell lines may serve as a good experimental model system representing *in vivo* tumors classified as a given subtype.

[00180] Correlation of *in vitro* cell line phenotypes with the cell line subtypes

[00181] The subtype classifying signatures that were identified involved differential expression of genes that are regarded as epithelial-mesenchymal (EM) markers and EMT drivers. It was set to utilize an assemble of ovarian cancer cell line library, termed SGOCL(42), to model the entire spectrum of EMT. (Figure 10A) In order to accurately model the heterogeneity, quantitative positioning of different EMT status/score is required. Established *in vitro* cancer cell lines can be regarded as snapshots of given phenotypic or molecular statuses representing different populations of *in vivo* tumors. Then examined the expressions of these markers was examined by using immunofluorescent stainings in cell lines (Figure 10B). Based on the immunofluorescence staining pattern of E-cadherin, N-cadherin, pan-cytokeratin, and vimentin, a decision matrix was established to determine the EMT phenotype of each cell line. E-cadherin immunoreactivity was utilized to allocate the general epithelial (E-Cad positive) or mesenchymal (E-Cad negative) category. Subsequently, pan-cytokeratin and vimentin were utilized to determine the differentiation subcategory. Cells allocated into the epithelial category with negative vimentin immunoreactivity were designated as true

epithelial (E). Cells allocated into the mesenchymal category with negative pan-cytokeratin immunoreactivity were designated as true mesenchymal (M). Those that co-express pan-cytokeratin and vimentin were designated as intermediates. Thus, SGOCL(42) was phenotypically characterized as four EMT categories: epithelial (E), intermediate epithelial (intermediate E), intermediate mesenchymal (intermediate M), mesenchymal (M).

[00182] In addition, the staining intensities were also documented as 0 (negative), 1 (weak positive), 2 (positive), and 3 (strong positive). The SGOCL(42) was subsequently ranked according to the quantitative PCR expression ratio of E-cadherin (CDH1) versus vimentin (VIM) within each EMT phenotype category. This categorization method created a quantitative EMT spectrum (Figure 10C). This spectrum took into the considerations of both phenotypic and quantitative characterization which indicated that the expression patterns of epithelial-mesenchymal markers as well as major EMT drivers followed the EMT gradient.

[00183] Next the staining patterns were correlated with the subtypes identified. Epi-A, Epi-B and Stem-B cell lines were found to have positive stainings of E-cadherin, a epithelial marker; whereas the cell lines classified as Mes or Stem-A were characterized by immunopositivity for N-cadherin, a mesenchymal marker (Figure 10D). The head-to-head matching between the oncogenomic subtypes and EMT phenotypes of SGOCL(42) also showed that most of the Mes and Stem-A lines were categorized as Intermediate M or M phenotype.

[00184] Cell lines of Intermediate M or M category displayed more aggressive *in vitro* phenotypes

[00185] Next the EMT-related functional differences were compared among the four EMT phenotypic categories in cell-based assays including migration, invasion, anoikis, and spheroid forming assays on a selected panel of cell lines from SGOCL(42). Firstly, the migratory abilities among EMT phenotypes were examined by using migration assays which detect the cell coverage of central migration zones created by silicon stoppers. After overnight migration, the Intermediate M phenotype covered most of the area of the migration zones (Figure 11A and B) compared to other phenotypes. In addition, invasiveness was also examined among these cell lines by measuring the number of cells penetrating into 3-D central invasion zones created by silicon stoppers subsequently filled with basement membrane extracts (BME). After 48 hr of incubation, two cell lines with Intermediate E and all four cell lines with Intermediate M phenotype showed significant invasion detected by fluorescence (Figure 11C and D). At the invasive front, we noticed that Intermediate E and Intermediate M displayed different invasive properties. Intermediate E displayed a collective movement while Intermediate M showed single cell movement forming radial spike (Figure 11E). Furthermore, the ability of different EMT phenotypes to survive under anchorage independent conditions overtime were compared. In anoikis resistance assays, the viability between cells was measured which were grown on normal tissue culture treated surfaces (TCP) and low attachment

suspension (ULAS) conditions using MTT assays. Generally, all four EMT phenotypes survived well in TCP conditions evident by the increase in the absorbance readings from 48 to 96 hrs (viability index greater than 1.0). In ULAS conditions, the viability dropped significantly in majority of the cell lines, indicating that the suspension conditions were not favorable for cell growth. However, the average viability index of Intermediate M and M phenotypes in ULAS conditions were still higher than those in E and Intermediate E (Figure 11F), indicating that Intermediate M and M might be more resistant to anoikis. Interestingly, morphology differences were observed in ULAS conditions after 96 hr of incubation among EMT phenotypes. Majority of the tested cell lines formed 'grape-like' aggregates in ULAS conditions. Cell lines with Intermediate M phenotype all formed spheroids except DOV13 (Figure 11G).

[00186] From these *in vitro* functional studies, it was concluded that cells harboring the Intermediate M phenotype was more prone to be migratory, invasive, anoikis resistant, and was more colony forming and spheroidogenic. These results indicated that the Intermediate M phenotype might represent an aggressive category *in vitro*.

[00187] From these *in vitro* functional studies, it was concluded that cells harboring the Intermediate M phenotype was more prone to be migratory, invasive, anoikis resistant, and was more colony forming and spheroidogenic. These results indicated that the Intermediate M phenotype represents a more aggressive category.

[00188] An expression profiling-based epithelial-mesenchymal scoring system developed in ovarian cancer cell lines (EMT score)

[00189] Since multiple EMT markers were detected as the subtype classifiers in the clinical tumor as well as cultured cell-lines, it was hypothesized that EMT has a significant impact on *in vitro* and *in vivo* behaviors and can be defined by a gene expression signature. Firstly, a scoring system was developed to quantify EMT status by using *in vitro* cell lines. 23 cell lines from SGOCL(42) were incorporated that included the 17 cell lines with epithelial phenotype (5 Epi-A, 1 Epi-B, 1 Stem-A and 8 Stem-B cell lines) and 8 cell lines with mesenchymal phenotype (4 Mes and 4 Stem-A cell lines) based on the cadherin score, that is the subtraction between E-cadherin and N-cadherin immunostaining intensities (Figure 12A and 12B). The EM expression signature derived contained *CDH1* (*E-cadherin*) and *CDH2* (*N-cadherin*) in the gene list and showed robustness in distinguishing epithelial from mesenchymal phenotype with a strong *p*-value ($p=0.0001$) in a leave-one-out cross validation study (Figure 12B). The EM signature obtained from cultured ovarian cancer cell lines also accurately predicted the EM status in a model of EMT of cancer cells by silencing E-cadherin or introducing dominant negative E-cadherin, suggesting the EM expression signature could precisely reflect the cellular EM status (Figure 12C). To validate the EM status prediction independently, the gene expression profilings of the remaining cell lines obtained from the meta-analysis that were not

included in the signature generation were further utilized. The subtypes in cell lines could be perfectly categorized by this EM phenotype and EM expression signature (Figure 12D). Epi-A, Epi-B, and Stem-B groups were predicted as epithelial status; Mes and Stem-A groups were predicted as mesenchymal status (Figure 12D). It was thus possible to develop a scoring system to quantify the EM status, to create an **EMT spectrum** using the expression profiling of a panel of ovarian cancer cell lines, and to correlate with clinically relevant subtypes (Figure 12E and 12F).

[00190] Figure 27 shows EMT score and genes of cell lines. The EMT score was computed with the same method used for that of clinical samples and is shown in the heatmap (green=epithelial, red=mesenchymal phenotypes) with subtype information and the heatmap of the genes (green=low, red=high expression) used for ss-GSEA. F. Relation of EMT score and cell line subtype. The EMT score of the cell lines were plotted according to their subtype. Epithelial and mesenchymal phenotypes were assigned to each cell lines based on the median EMT score, indicated by the dashed line. All of the Epi-A cell lines exhibit epithelial phenotypes. 80.0% of Epi-B and 84.0% of Stem-B cell lines exhibit epithelial phenotypes. On the other hand, majority of Mes and Stem-A cell lines show mesenchymal phenotypes (82.4% and 91.2%, respectively).

[00191] **Epithelial-mesenchymal transition (EMT) scoring**

[00192] Using N-cadherin and E-cadherin positivity on the cell surface detected by immunostaining, the cell lines were assigned to the epithelial or mesenchymal phenotype and used to generate a gene expression signature by BinReg so as to distinguish the epithelial from mesenchymal phenotype of a sample. The resultant EMT signature comprised 50 genes significantly up- or down-regulated in the epithelial and mesenchymal phenotypes. The EMT status of clinical samples and remaining cell lines by BinReg was then predicted. The top 100 among 1,538 tumors or the 25% (35 or 36 among 142) cell lines with the highest probabilities for epithelial or mesenchymal phenotype were used to obtain the clinical samples- or cell line-specific EMT signature (i.e. significant up- or down-regulated genes in epithelial or mesenchymal phenotype) through SAM with q -value of 0 and ROC of 0.85. Based on the EMT signature, ss-GSEA was then employed to compute the enrichment score of a clinical sample or a cell line based on the expression of epithelial or mesenchymal signature genes. After ranking each sample according to the epithelial or mesenchymal enrichment score, the normalized subtraction of the rank for mesenchymal from epithelial phenotype was defined as the EMT score.

[00193] Application of epithelial-mesenchymal scoring system in ovarian carcinoma samples

[00194] To prove that this EM scoring system could be apply in clinical sample categorization, the cell line EM signature was applied in the meta-analysis data consisting of 1,538 ovarian cancer samples (Figure 13A and 13B). Using the median of the EMT score as a cut-off value, many of Epi-A, Epi-B and Stem-B tumors were classified to have epithelial phenotype (86.1%, 75.9% and 63.5%,

respectively), while 83.2% of Stem-A and 66.2% of Mes ovarian cancers showed the mesenchymal phenotype. Importantly, since these clinical samples of Mes or Stem-A subtypes were found to have poorer survival outcomes, this indicated a correlation between a poor clinical outcome and the phenotypic mesenchymal character (Figure 5). To further generate a robust prediction gene list, from the 1,538 meta-analysis samples, top 100 samples were selected from both epithelial and mesenchymal phenotypes designated by the cell line EM signature to re-train the dataset. An **EMT Scoring Gene Signature** was generated and subsequently validated the EM status prediction utilizing an independent collection of ovarian carcinoma samples, termed JPKO, and another publically available ovarian cancer expression dataset, termed GSE2056. As shown in Figure 13D, Epi-A and Epi-B tumors were classified to have epithelial phenotype (100% and 87.5%, respectively), while 89.47% of Stem-A and 89.65% of Mes tumors were classified as the mesenchymal phenotype (Figure 13C and 13D). The Stem-B subtype was not significantly correlated with EM status. These results not only demonstrated that the EMT Scoring Gene Signature could robustly be applied for the prediction of epithelial or mesenchymal phenotype of independent tumor collections, but also supported the tight relationship between the ovarian cancer intrinsic subtype and the EM phenotype.

[00195] Key EMT components identified from CDH1, DDR1, ERBB3, and ZEB1 signatures might be potential novel markers for sub-classification of EOC.

[00196] Epithelial-mesenchymal transition (EMT), a crucial mechanism in development, has been known to promote carcinoma progression. Four genes, CDH1, DDR1, ERBB3 and ZEB 1 were utilized to generate EMT signatures. CDH1 codes for E-cadherin, the prototypical classical cadherin from the cadherin superfamily. E-cadherin is a calcium dependent cell-cell adhesion glycoprotein, which is the hallmark of EMT by the loss of its expression via mutation, promoter hypermethylation, or activation of its transcriptional suppressors. DDR1 codes for discoidin domain receptor 1, a receptor tyrosine kinase family member. Its autophosphorylation is achieved by collagens (type I to type VI). The expression of DDR1 is restricted to epithelial cells. DDR1 is significantly over-expressed in several human tumors from breast, ovarian, esophageal, and pediatric brain. ERBB3 codes for a member of the epidermal growth factor receptor (EGFR) family. It has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. ZEB1 codes for Zinc finger E-box-binding homeobox 1, is a zinc finger transcription factor. ZEB1 represses E-cadherin promoter and induces EMT by recruiting

SMARCA4/BRG1. Therefore, these four markers, in combination, should be able to provide the sketch of the silhouette of EMT.

[00197] Quantitative real-time PCR (qPCR) was utilized to examine the expression patterns of CDH1, DDR1, ERBB3, and EMP3 in the panel of 42 ovarian cancer cell lines. The comparison of relative expression levels of these four genes among 42 cell lines were done via calculating ddCt. The expression levels of *CDH1*, *DDR1*, *ERBB3* were found to be highest in ovarian cancer cell lines which harbor epithelial phenotypes. This confirms that *CDH1*, *DDR1*, *ERBB3* expressions are linked to the EMT gradient (Figure 14A). 6 cell lines were chosen with highest and 6 with lowest expressions of CDH1, DDR1, ERBB3, and ZEB1 respectively to generate signatures by using expression microarrays (Figure 14B). Subsequently these four signatures were intersected by comparing the gene IDs using Venn diagram to search for commonly encountered genes, which it is believed are able to represent the key components in EMT (Figure 14C). Among them, 14 genes (*CDH1*, *CDH3*, *DDR1*, *EPCAM*, *ESRP1*, *ITGA5*, *JUP*, *MAL2*, *PKP1*, *PRSS8*, *SPINT1*, *ST14*, *VIM*, *ZEB1*) have been shown to be involved in EMT; 19 genes (*AP1M2*, *ARHGEF5*, *C19orf21*, *CD99L2*, *CTAGE6P*, *EMP3*, *GRHL1*, *GRHL2*, *HOOK1*, *LLGL2*, *LSR*, *MAP7*, *MYO5B*, *RAB25*, *S100A14*, *SLC44A2*, *SYDE1*, *TC2N*, *ZNF165*) have not been reported to be involved in EMT by Pubmed search. Therefore, the method is robust enough to identify key EMT components that are well-known as well as novel ones.

[00198] **Part C. Cell-based small molecule EMT screening assay**

[00199] Image Analysis Parameters

[00200] As described above the images obtained from T1 and T2 were then sent for image analysis. Two parameters, "Cell Count" and "Cell Dispersion", are measured through the image segmentation routines. Briefly, the cell nuclei are segmented using a wavelet decomposition scheme, followed by a watershed procedure and size filtering as described previously. The final segmented objects or cell nuclei are then summed up to give the "Cell Count" of the analyzed well.

[00201] In addition, the X and Y coordinates of all cell nuclei are recorded and the average coordinates, which corresponds to the centre of the cell colony, is calculated. Finally, "Cell Dispersion" which is the standard deviation of the positions of all the cell nuclei in the analyzed well, is then calculated with respect to the centre of the cell colony.

[00202] By combining time-course imaging of T1 and T2, it was possible to obtain the derived measurements "Cell Count Ratio" and "Cell Dispersion Ratio", which correspond to the cell growth status and the cell migration / scattering status of each cell colony respectively (Figure 18). The results generated from these two ratio parameters are used to assess the EMT inhibitory properties of the test compounds.

[00203] Assay Robustness Analysis

[00204] An example of 6 experiment sets done on different days is illustrated in Figures 15, 16 and 17. The Cell Dispersion ratio parameter is analyzed here to show the robustness of the assay in determining whether it can differentiate an EMT inhibited condition (i.e. PosCtrl condition) from an EMT uninhibited condition (i.e. NegCtrl condition):

- 5 [00205] For NegCtrl condition, [AG 1478] = 0 microM and [EGF] = 20 ng/mL
- [00206] For PosCtrl condition, [AG1478] = 6.67 microM and [EGF] = 20 ng/mL
- [00207] Cell Dispersion ratio for NegCtrl condition is observed to be at 2.50 ± 0.12 (Figure 15)
- [00208] Cell Dispersion ratio for PosCtrl condition is observed to be at 1.48 ± 0.05 (Figure 15)
- [00209] Normalizing all plates to PosCtrl = 0% and NegCtrl = 100%
- 10 [00210] S.D. (normalized Cell Dispersion ratio for NegCtrl condition) = 7.3% (Figure 16)
- [00211] S.D. (normalized Cell Dispersion ratio for PosCtrl condition) = 2.3% (Figure 17)
- [00212] Lastly, the Cell Dispersion ratio Z-factor statistics of NegCtrl vs. PosCtrl conditions is found to be ≥ 0.5 , demonstrating robustness of this assay (Figure 17)
- [00213] Hits Criteria Analysis
- 15 [00214] The Tocris library set (Tocriscreentm) kinase inhibitor toolbox, Tocris Bioscience, Bristol, UK) was used as the reference to set the Threshold values for determining EMT inhibition in this assay. The Cell Dispersion ratio parameter in combination with the Cell Count ratio parameter were used in the analysis to select possible inhibitors of EMT. The Cell Count ratio was used to eliminate compounds that are cytotoxic to cells, or severely inhibit cell growth. By plotting Cell
- 20 Dispersion ratio against Cell Count ratio together, it was possible to cluster sample points into the following observations (Figure 18 and 19):
- [00215] Compound conditions that are cytotoxic to cells, and are severely inhibiting cell growth.
- [00216] Compound conditions that inhibit cell dispersion, and do not severely inhibit cell growth.
- [00217] Compound conditions that do not inhibit cell dispersion and cell growth.
- 25 [00218] Normalizing all plates to Cell Dispersion ratio [PosCtrl = 0% and NegCtrl = 100%] and Cell Count ratio [PosCtrl = 100%], it was possible to further resolve the clustering of the data points and apply the Threshold values to separate these clusters. In conclusion, the optimized hit selection criteria used to select for possible EMT inhibitors against EGF, HGF or IGF-1 induction are as follows:
- 30 Against EGF induction:
 - Sample Cell Count ratio ≥ 1.5 (or $\geq 60\%$ of PosCtrl Cell Count ratio), AND
 - Sample Cell Dispersion ratio $\leq 50\%$ of NegCtrl / PosCtrl Cell Dispersion ratios range
- Against HGF induction:
 - Sample Cell Count ratio ≥ 1.5 (or $\geq 60\%$ of PosCtrl Cell Count ratio), AND

- Sample Cell Dispersion ratio $\leq 50\%$ of NegCtrl / PosCtrl Cell Dispersion ratios range

And lastly, against IGF-1 induction:

- Sample Cell Count ratio ≥ 1.5 (or $\geq 85\%$ of PosCtrl Cell Count ratio), AND

- Sample Cell Dispersion ratio $\leq 50\%$ of NegCtrl / PosCtrl Cell Dispersion ratios range

5 [00219] Compound library screening

[00220] Test compounds were consolidated, formatted into compound library plates and tested in this spot migration assay to identify for possible EMT inhibitors. An example of the assay process of a typical spot migration assay is illustrated in Figure 20. In this example, it was observed that the combined effect of the test compounds and EMT inducer (EGF in this example) on cell motility and proliferation can be grouped into the three classifications mentioned earlier, i.e.: (1) Compound conditions that are cytotoxic to cells, and are severely inhibiting cell growth; (2) Compound conditions that inhibit cell dispersion, and do not severely inhibit cell growth; and (3) Compound conditions that do not inhibit cell dispersion and cell growth (Figure 21(b) and Figure 21(c)).

10 [00221] A collection of 269 compounds were eventually tested under EMT-activated conditions via induction with EGF, HGF or IGF-1. These compounds primarily consist of known inhibitors of various signaling pathways. The screening process is further refined to facilitate removal of weak motility inhibitors, and this can be done by screening the compounds at two concentrations of 1.67 μM and 6.67 μM (Figure 21). The hit selection criteria defined previously for each growth factor condition is then applied. In general, compounds with weak motility inhibition effect will only show satisfactory cell dispersion inhibition at 6.67 μM but not at 1.67 μM . Conversely, some weak cytotoxic compounds may also exhibit satisfactory cell dispersion inhibition at 1.67 μM without severely inhibiting cell growth, but at higher 6.67 μM concentration, cellular toxicity is significant (Cell Count ratio ≤ 1.5). We are therefore interested in selecting compounds that meet the hit selection criteria at both testing concentrations, which indicate that the compounds may exhibited good EMT inhibitory properties across a broad concentration range.

20 [00222] A total of 26 compounds satisfy the screening hit selection criteria and were subjected to further testing to generate dose response profile plots.

[00223] Dose response profile generation for initial screening hit compounds

30 [00224] For dose response studies, compound plates containing serial diluted screening hit compounds were prepared as described previously. Complete spot migration assays were then performed with these compound plates. The Cell Dispersion ratio for every diluting concentration was then plotted in Prism software to generate the EMT dose response profile of the hit compounds against EGF, HGF or IGF-1 induction.

[00225] In general, the EMT spot migration assay has enabled us to identify compounds that compounds that are effective against all three growth factor signaling (Figure 22 and Table 1) or compounds that can only inhibit specific growth factor signaling (Figure 23, 24 and Table 1).

[00226] Table 1: Summary of inhibitor dose response against EMT induced by EGF, HGF or IGF-

5 1.

Name	ETC-ID	Cell Dispersion IC ₅₀ (nM)		
		EGF	HGF	IGF-1
A83-01	ETC-1677013	69	130	120
AG 1478	ETC-1676935	350	-	-
AP1-2	ETC-1676962	1300	970	-
AZD 0530	ETC-1692993	565	650	240
AZD 6244	ETC-1677316	840	471	534
BMS-536924	ETC-1681224	6600	2300	170
CI-1040	ETC-1677317	1000	820	1200
D 4476	ETC-1677010	1100	1400	1900
Erlotinib	ETC-1677295	950	-	-
GDC-0941	ETC-1677322	740	380	490
Gefitinib	ETC-1677294	880	-	-
JNJ-38877605	ETC-1677320	-	43	-
Lapatinib	ETC-1677296	620	-	-
LY 364947	ETC-1677009	140	180	240
MP-470	ETC-1677344	510	970	580
PD-0325901	ETC-1677318	31	20	8.9
PD 153035	ETC-1676982	550	-	-
PD 158780	ETC-1676943	1200	-	-
PF-04217903	ETC-1677319	-	55	-
PI-103	ETC-1677327	680	380	400
PIK-90	ETC-1677325	950	400	620
PP 1	ETC-1676944	1725	2000	1200
SB 431542	ETC-1676933	1600	940	820
SD-208	ETC-1677008	85	110	150
WHI-P 154	ETC-1681221	590	-	-
ZSTK 474	ETC-1677331	850	410	660

[00227] Part D. EMT reversal assays

[00228] Based on their oncogenic subtypes and EMT categories, three cell lines were selected for EMT reversal assays. The three cell lines namely SKOV3, HEY and OVCAR-2 sub grouped into Mesenchymal, Intermediate M; Stem A, Intermediate M; and Stem B, Intermediate E; respectively were evaluated for their morphology and EMT markers after reversal. Two promising EMT inhibitors were identified, AZD0530 (potent inhibitor of Src kinase) from AstraZeneca and BIBF-1120 from Boehringer Ingelheim (potent inhibitor of VEGFR, PDGFR and FGFR) and went ahead with testing the three ovarian lines. These two inhibitors are currently used in phase 2 clinical trials.

[00229] HEY and SKOV3 cells displayed a spindle-like dispersed phenotype while OVCAR-2 cells conferred a more epithelial-like morphology. Although the starting morphology was different for

the three cell lines, compaction was markedly increased after treatment with small molecules AZD0530 and BIBF-1120 (Figure 25A). HEY and SKOV3 cells restored the epithelioid-like morphology while OVCAR-2 cells formed tighter cobblestone-like cell colonies upon drug treatment. Along with the observed increased compaction, the three cell lines showed MET-like changes in protein expression. The addition of AZD 0530 and BIBF-1120 increased E-cadherin (epithelial marker) and reduced MMP13 (matrix metalloproteinase) protein levels (Figure 25B). Semi-quantification of E-cadherin and MMP13 protein bands enabled comparison of the relative reversal profile of the two drugs on the three cell lines.

[00230] AZD0530 and BIBF-1120 increased E-cadherin levels to a different extent in the three cell lines. Treatment with BIBF-1120 resulted in marked increase of E-cadherin protein levels in all 3 cells lines while AZD0530 treatment showed a greater increase in E-cadherin protein levels in SKOV3 and HEY relative to OVCAR-2. Similar fashion was observed for reduction in MMP13 protein levels where AZD0530 treatment resulted in greater reduction of MMP13 protein levels in SKOV3 and HEY as compared to OVCAR-2. In conclusion, AZD0530 and BIBF-1120 showed similar reversal profile in SKOV3 and HEY cells while BIBF-1120 showed a relatively better reversal profile than AZD0530 in OVCAR-2 cells.

[00231] In this embodiment, the present study provides a technology to stratify individual ovarian carcinoma patients in one of 5 distinct subtypes and to assess an EMT score. These 2 parameters provide new surrogate markers to follow patients during the course of targeted therapy. A high content, high throughput cell-based screen has been designed to identify drugs interfering with the EMT status. This screening method permits to identify drugs in combination which can effectively reverse the EMT status. It is also used to define pathway interactions which overcome the therapeutic effect of single agent. Thus, it allows choosing the best combinations to circumvent the potential bypass mechanisms promoting activation of additional pathway not interfered with the prescribed drugs. Phosphoproteomic profiling of 42 ovarian carcinoma cell lines and of tumors will further help selecting appropriate drugs to reverse the EMT status. The reversal of the EMT status should alleviate resistance to conventional therapeutics. A therapeutic protocol can be designed to render ovarian cancer patient more sensitive to conventional therapeutics following administration of targeted EMT reversal therapeutics.

Gene List 1. Gene components used for the clustering.

Affymetrix Probe ID	Gene Symbol	Gene Cluster
201739_at	SGK1	Not Assigned
202499_s_at	SLC2A3	Not Assigned
202627_s_at	SERPINE1	Not Assigned
202628_s_at	SERPINE1	Not Assigned
202388_at	RGS2	Not Assigned
204472_at	GEM	Not Assigned
201466_s_at	JUN	Not Assigned
202672_s_at	ATF3	Not Assigned
201693_s_at	EGR1	Not Assigned
201694_s_at	EGR1	Not Assigned
202768_at	FOSB	Not Assigned
201041_s_at	DUSP1	Not Assigned
209189_at	FOS	Not Assigned
206115_at	EGR3	Not Assigned
201289_at	CYR61	Not Assigned
210764_s_at	CYR61	Not Assigned
209101_at	CTGF	Not Assigned
221841_s_at	KLF4	Not Assigned
204621_s_at	NR4A2	Not Assigned
204622_x_at	NR4A2	Not Assigned
216248_s_at	NR4A2	Not Assigned
204018_x_at	HBA1 /// HBA2	Not Assigned
211699_x_at	HBA1 /// HBA2	Not Assigned
209458_x_at	HBA1 /// HBA2	Not Assigned
211745_x_at	HBA1 /// HBA2	Not Assigned
217414_x_at	HBA1 /// HBA2	Not Assigned
214414_x_at	HBA1 /// HBA2	Not Assigned
209116_x_at	HBB	Not Assigned
211696_x_at	HBB	Not Assigned
217232_x_at	HBB	Not Assigned
205239_at	AREG	Not Assigned
201631_s_at	IER3	Not Assigned
209457_at	DUSP5	Not Assigned
36711_at	MAFF	Not Assigned
218541_s_at	C8orf4	Not Assigned
201645_at	TNC	Mesenchymal
205206_at	KAL1	Mesenchymal
201430_s_at	DPYSL3	Mesenchymal
201431_s_at	DPYSL3	Mesenchymal
201860_s_at	PLAT	Mesenchymal
204457_s_at	GAS1	Mesenchymal
202157_s_at	CUGBP2	Mesenchymal
202391_at	BASP1	Mesenchymal
203066_at	GALNAC4S-6ST	Mesenchymal
212012_at	PXDN	Mesenchymal

212013_at	PXDN	Mesenchymal
202435_s_at	CYP1B1	Mesenchymal
202436_s_at	CYP1B1	Mesenchymal
202437_s_at	CYP1B1	Mesenchymal
203180_at	ALDH1A3	Mesenchymal
205433_at	BCHE	Mesenchymal
203548_s_at	LPL	Mesenchymal
203549_s_at	LPL	Mesenchymal
203980_at	FABP4	Mesenchymal
209612_s_at	ADH1B	Mesenchymal
209613_s_at	ADH1B	Mesenchymal
206488_s_at	CD36	Mesenchymal
209555_s_at	CD36	Mesenchymal
213524_s_at	G0S2	Mesenchymal
211726_s_at	FMO2	Mesenchymal
201787_at	FBLN1 /// LOC100133843	Mesenchymal
202994_s_at	FBLN1	Mesenchymal
202995_s_at	FBLN1	Mesenchymal
201286_at	SDC1	Mesenchymal
201287_s_at	SDC1	Mesenchymal
202363_at	SPOCK1	Mesenchymal
218002_s_at	CXCL14	Mesenchymal
205559_s_at	PCSK5	Mesenchymal
202274_at	ACTG2	Mesenchymal
202555_s_at	MYLK	Mesenchymal
201058_s_at	MYL9	Mesenchymal
204083_s_at	TPM2	Mesenchymal
201667_at	GJA1	Mesenchymal
206227_at	CILP	Mesenchymal
205226_at	PDGFRL	Mesenchymal
201215_at	PLS3	Mesenchymal
203058_s_at	PAPSS2	Mesenchymal
203060_s_at	PAPSS2	Mesenchymal
203903_s_at	HEPH	Mesenchymal
203477_at	COL15A1	Mesenchymal
202202_s_at	LAMA4	Mesenchymal
202007_at	NID1	Mesenchymal
204114_at	NID2	Mesenchymal
201505_at	LAMB1	Mesenchymal
211651_s_at	LAMB1	Mesenchymal
213429_at	---	Mesenchymal
204955_at	SRPX	Mesenchymal
208782_at	FSTL1	Mesenchymal
210762_s_at	DLC1	Mesenchymal
212298_at	NRP1	Mesenchymal
201506_at	TGFBI	Mesenchymal
203868_s_at	VCAM1	Mesenchymal

209732_at	CLEC2B	Mesenchymal
201616_s_at	CALD1	Mesenchymal
201617_x_at	CALD1	Mesenchymal
201108_s_at	THBS1	Mesenchymal
201109_s_at	THBS1	Mesenchymal
201110_s_at	THBS1	Mesenchymal
200974_at	ACTA2	Mesenchymal
205547_s_at	TAGLN	Mesenchymal
209621_s_at	PDLIM3	Mesenchymal
204051_s_at	SFRP4	Mesenchymal
204052_s_at	SFRP4	Mesenchymal
204135_at	FILIP1L	Mesenchymal
203131_at	PDGFRA	Mesenchymal
207172_s_at	CDH11	Mesenchymal
207173_x_at	CDH11	Mesenchymal
202283_at	SERPINF1	Mesenchymal
201893_x_at	DCN	Mesenchymal
211813_x_at	DCN	Mesenchymal
211896_s_at	DCN	Mesenchymal
209335_at	DCN	Mesenchymal
206101_at	ECM2	Mesenchymal
212764_at	ZEB1	Mesenchymal
218656_s_at	LHFP	Mesenchymal
210139_s_at	PMP22	Mesenchymal
204337_at	RGS4	Mesenchymal
208131_s_at	PTGIS	Mesenchymal
203570_at	LOXL1	Mesenchymal
204463_s_at	EDNRA	Mesenchymal
204464_s_at	EDNRA	Mesenchymal
201149_s_at	TIMP3	Mesenchymal
201147_s_at	TIMP3	Mesenchymal
201150_s_at	TIMP3	Mesenchymal
206439_at	EPYC	Mesenchymal
205422_s_at	ITGBL1	Mesenchymal
205941_s_at	COL10A1	Mesenchymal
217428_s_at	COL10A1	Mesenchymal
203876_s_at	MMP11	Mesenchymal
203878_s_at	MMP11	Mesenchymal
213909_at	LRRC15	Mesenchymal
213338_at	TMEM158	Mesenchymal
205479_s_at	PLAU	Mesenchymal
211668_s_at	PLAU	Mesenchymal
218468_s_at	GREM1	Mesenchymal
218469_at	GREM1	Mesenchymal
204589_at	NUAK1	Mesenchymal
202765_s_at	FBN1	Mesenchymal
202766_s_at	FBN1	Mesenchymal

213139_at	SNAIL2	Mesenchymal
201069_at	MMP2	Mesenchymal
201792_at	AEBP1	Mesenchymal
201438_at	COL6A3	Mesenchymal
200665_s_at	SPARC	Mesenchymal
212667_at	SPARC	Mesenchymal
202403_s_at	COL1A2	Mesenchymal
202404_s_at	COL1A2	Mesenchymal
202310_s_at	COL1A1	Mesenchymal
202311_s_at	COL1A1	Mesenchymal
201852_x_at	COL3A1	Mesenchymal
215076_s_at	COL3A1	Mesenchymal
211161_s_at	COL3A1	Mesenchymal
203325_s_at	COL5A1	Mesenchymal
212488_at	COL5A1	Mesenchymal
212489_at	COL5A1	Mesenchymal
221729_at	COL5A2	Mesenchymal
221730_at	COL5A2	Mesenchymal
201744_s_at	LUM	Mesenchymal
202450_s_at	CTSK	Mesenchymal
203083_at	THBS2	Mesenchymal
211719_x_at	FN1	Mesenchymal
212464_s_at	FN1	Mesenchymal
210495_x_at	FN1	Mesenchymal
216442_x_at	FN1	Mesenchymal
209955_s_at	FAP	Mesenchymal
210511_s_at	INHBA	Mesenchymal
204320_at	COL11A1	Mesenchymal
37892_at	COL11A1	Mesenchymal
210809_s_at	POSTN	Mesenchymal
204619_s_at	VCAN	Mesenchymal
204620_s_at	VCAN	Mesenchymal
221731_x_at	VCAN	Mesenchymal
211571_s_at	VCAN	Mesenchymal
215646_s_at	VCAN	Mesenchymal
213790_at	ADAM12	Mesenchymal
219087_at	ASPN	Mesenchymal
221541_at	CRISPLD2	Mesenchymal
217430_x_at	COL1A1	Mesenchymal
221019_s_at	COLEC12	Mesenchymal
204298_s_at	LOX	Mesenchymal
215446_s_at	LOX	Mesenchymal
202465_at	PCOLCE	Mesenchymal
209156_s_at	COL6A2	Mesenchymal
213428_s_at	COL6A1	Mesenchymal
209651_at	TGFB1I1	Mesenchymal
213905_x_at	BGN	Mesenchymal

209687_at	CXCL12	Mesenchymal
218162_at	OLFML3	Mesenchymal
205943_at	TDO2	Mesenchymal
206025_s_at	TNFAIP6	Mesenchymal
206026_s_at	TNFAIP6	Mesenchymal
202998_s_at	LOXL2	Mesenchymal
211980_at	COL4A1	Mesenchymal
211981_at	COL4A1	Mesenchymal
213943_at	TWIST1	Mesenchymal
221911_at	ETV1	Mesenchymal
212473_s_at	MICAL2	Mesenchymal
202237_at	NNMT	Mesenchymal
202238_s_at	NNMT	Mesenchymal
212344_at	SULF1	Mesenchymal
212353_at	SULF1	Mesenchymal
212354_at	SULF1	Mesenchymal
208747_s_at	C1S	Mesenchymal
212067_s_at	C1R	Mesenchymal
205713_s_at	COMP	Mesenchymal
221900_at	COL8A2	Mesenchymal
209758_s_at	MFAP5	Mesenchymal
213764_s_at	MFAP5	Mesenchymal
213765_at	MFAP5	Mesenchymal
209496_at	RARRES2	Mesenchymal
208850_s_at	THY1	Mesenchymal
213869_x_at	THY1	Mesenchymal
209540_at	IGF1	Mesenchymal
209541_at	IGF1	Mesenchymal
209542_x_at	IGF1	Mesenchymal
222288_at	---	Mesenchymal
219304_s_at	PDGFD	Mesenchymal
219935_at	ADAMTS5	Mesenchymal
218723_s_at	C13orf15	Mesenchymal
202458_at	PRSS23	Not Assigned
219773_at	NOX4	Not Assigned
203817_at	GUCY1B3	Not Assigned
221942_s_at	GUCY1A3	Not Assigned
212942_s_at	KIAA1199	Not Assigned
209596_at	MXRA5	Not Assigned
219454_at	EGFL6	Not Assigned
202619_s_at	PLOD2	Not Assigned
202620_s_at	PLOD2	Not Assigned
201313_at	ENO2	Not Assigned
201849_at	BNIP3	Not Assigned
202887_s_at	DDIT4	Not Assigned
202912_at	ADM	Not Assigned
204595_s_at	STC1	Not Assigned

204597_x_at	STC1	Not Assigned
210095_s_at	IGFBP3	Not Assigned
212143_s_at	IGFBP3	Not Assigned
204475_at	MMP1	Not Assigned
209301_at	CA2	Not Assigned
209267_s_at	SLC39A8	Not Assigned
219869_s_at	SLC39A8	Not Assigned
205542_at	STEAP1	Not Assigned
204259_at	MMP7	Not Assigned
209875_s_at	SPP1	Not Assigned
204285_s_at	PMAIP1	Not Assigned
205590_at	RASGRP1	Not Assigned
209277_at	TFPI2	Not Assigned
209278_s_at	TFPI2	Not Assigned
205534_at	PCDH7	Not Assigned
204932_at	TNFRSF11B	Not Assigned
204933_s_at	TNFRSF11B	Not Assigned
217143_s_at	TRA@ /// TRD@	Not Assigned
202888_s_at	ANPEP	Not Assigned
204198_s_at	RUNX3	Not Assigned
202018_s_at	LTF	Not Assigned
202376_at	SERPINA3	Not Assigned
209443_at	SERPINA5	Not Assigned
202917_s_at	S100A8	Not Assigned
203535_at	S100A9	Not Assigned
205916_at	S100A7	Not Assigned
203691_at	PI3	Not Assigned
41469_at	PI3	Not Assigned
206157_at	PTX3	Not Assigned
206336_at	CXCL6	Not Assigned
202859_x_at	IL8	Not Assigned
211506_s_at	IL8	Not Assigned
204470_at	CXCL1	Not Assigned
209774_x_at	CXCL2	Not Assigned
214974_x_at	CXCL5	Not Assigned
204099_at	SMARCD3	Not Assigned
206859_s_at	PAEP	Not Assigned
206697_s_at	HP /// HPR	Not Assigned
208470_s_at	HP /// HPR	Not Assigned
208451_s_at	C4A /// C4B	Not Assigned
214428_x_at	C4A /// C4B	Not Assigned
205844_at	VNN1	Not Assigned
212531_at	LCN2	Not Assigned
219630_at	PDZK1IP1	Not Assigned
214456_x_at	SAA1 /// SAA2	Not Assigned
217966_s_at	FAM129A	Not Assigned
217967_s_at	FAM129A	Not Assigned

200633_at	UBB	Not Assigned
200799_at	HSPA1A	Not Assigned
201348_at	GPX3	Not Assigned
214091_s_at	GPX3	Not Assigned
209283_at	CRYAB	Not Assigned
208396_s_at	PDE1A	Not Assigned
204971_at	CSTA	Not Assigned
206391_at	RARRES1	Not Assigned
206392_s_at	RARRES1	Not Assigned
221872_at	RARRES1	Not Assigned
218729_at	LXN	Not Assigned
201641_at	BST2	IFN Inducible
201601_x_at	IFITM1	IFN Inducible
214022_s_at	IFITM1	IFN Inducible
204698_at	ISG20	IFN Inducible
202307_s_at	TAP1	IFN Inducible
204279_at	PSMB9	IFN Inducible
206082_at	HCP5	IFN Inducible
202269_x_at	GBP1	IFN Inducible
202270_at	GBP1	IFN Inducible
204533_at	CXCL10	IFN Inducible
210163_at	CXCL11	IFN Inducible
211122_s_at	CXCL11	IFN Inducible
209969_s_at	STAT1	IFN Inducible
214038_at	CCL8	IFN Inducible
204994_at	MX2	IFN Inducible
202411_at	IFI27	IFN Inducible
205569_at	LAMP3	IFN Inducible
202869_at	OAS1	IFN Inducible
205552_s_at	OAS1	IFN Inducible
204972_at	OAS2	IFN Inducible
204415_at	IFI6	IFN Inducible
205483_s_at	ISG15	IFN Inducible
202086_at	MX1	IFN Inducible
204439_at	IFI44L	IFN Inducible
214453_s_at	IFI44	IFN Inducible
203153_at	IFIT1	IFN Inducible
213797_at	RSAD2	IFN Inducible
218943_s_at	DDX58	IFN Inducible
219209_at	IFIH1	IFN Inducible
219863_at	HERC5	IFN Inducible
214059_at	IFI44	IFN Inducible
210029_at	IDO1	IFN Inducible
205992_s_at	IL15	IFN Inducible
202687_s_at	TNFSF10	IFN Inducible
202688_at	TNFSF10	IFN Inducible
214329_x_at	TNFSF10	IFN Inducible

202357_s_at	C2 /// CFB	IFN Inducible
217767_at	C3	IFN Inducible
206332_s_at	IFI16	IFN Inducible
208966_x_at	IFI16	IFN Inducible
208965_s_at	IFI16	IFN Inducible
204070_at	RARRES3	IFN Inducible
219684_at	RTP4	IFN Inducible
219403_s_at	HPSE	Not Assigned
204745_x_at	MT1G	Not Assigned
206461_x_at	MT1H	Not Assigned
208581_x_at	MT1X	Not Assigned
213629_x_at	MT1F	Not Assigned
217165_x_at	MT1F	Not Assigned
212859_x_at	MT1E	Not Assigned
217546_at	MT1M	Not Assigned
204897_at	PTGER4	Not Assigned
201963_at	ACSL1	Not Assigned
201141_at	GPNMB	Not Assigned
218559_s_at	MAFB	Not Assigned
204446_s_at	ALOX5	MHC Class II
203381_s_at	APOE	MHC Class II
203382_s_at	APOE	MHC Class II
204416_x_at	APOC1	MHC Class II
202957_at	HCLS1	MHC Class II
204174_at	ALOX5AP	MHC Class II
204006_s_at	FCGR3A /// FCGR3B	MHC Class II
202803_s_at	ITGB2	MHC Class II
206584_at	LY96	MHC Class II
201858_s_at	SRGN	MHC Class II
201859_at	SRGN	MHC Class II
201743_at	CD14	MHC Class II
201721_s_at	LAPTM5	MHC Class II
204122_at	TYROBP	MHC Class II
202953_at	C1QB	MHC Class II
218232_at	C1QA	MHC Class II
203645_s_at	CD163	MHC Class II
215049_x_at	CD163	MHC Class II
219607_s_at	MS4A4A	MHC Class II
212587_s_at	PTPRC	MHC Class II
211742_s_at	EVI2B	MHC Class II
212588_at	PTPRC	MHC Class II
220330_s_at	SAMSN1	MHC Class II
210889_s_at	FCGR2B	MHC Class II
202902_s_at	CTSS	MHC Class II
213975_s_at	LYZ	MHC Class II
205890_s_at	GABBR1 /// UBD	MHC Class II
205242_at	CXCL13	MHC Class II

203915_at	CXCL9	MHC Class II
1405_i_at	CCL5	MHC Class II
204655_at	CCL5	MHC Class II
210915_x_at	TRBC1	MHC Class II
211796_s_at	TRBC1 /// TRBC2	MHC Class II
34210_at	CD52	MHC Class II
202748_at	GBP2	MHC Class II
204646_at	DPYD	MHC Class II
211368_s_at	CASP1	MHC Class II
213293_s_at	TRIM22	MHC Class II
217995_at	SQRDL	MHC Class II
201137_s_at	HLA-DPB1	MHC Class II
209619_at	CD74	MHC Class II
204670_x_at	HLA-DRB1 /// HLA-DRB4	MHC Class II
208306_x_at	---	MHC Class II
209312_x_at	HLA-DRB1 /// HLA-DRB4 /// HLA-DRB5	MHC Class II
215193_x_at	HLA-DRB1 /// HLA-DRB3 /// HLA-DRB4	MHC Class II
208894_at	HLA-DRA	MHC Class II
210982_s_at	HLA-DRA	MHC Class II
217478_s_at	HLA-DMA	MHC Class II
211990_at	HLA-DPA1	MHC Class II
211991_s_at	HLA-DPA1	MHC Class II
209823_x_at	HLA-DQB1	MHC Class II
211656_x_at	HLA-DQB1	MHC Class II
212671_s_at	HLA-DQA1 /// HLA-DQA2	MHC Class II
213537_at	HLA-DPA1	MHC Class II
211654_x_at	HLA-DQB1	MHC Class II
212998_x_at	HLA-DQB1	MHC Class II
202988_s_at	RGS1	MHC Class II
216834_at	RGS1	MHC Class II
209795_at	CD69	MHC Class II
204580_at	MMP12	Not Assigned
203936_s_at	MMP9	Not Assigned
206134_at	ADAMDEC1	Not Assigned
202638_s_at	ICAM1	Not Assigned
203828_s_at	IL32	Not Assigned
216598_s_at	CCL2	Not Assigned
205476_at	CCL20	Not Assigned
210538_s_at	BIRC3	Not Assigned
215223_s_at	SOD2	Not Assigned
216841_s_at	SOD2	Not Assigned
217388_s_at	KYNU	Not Assigned
205267_at	POU2AF1	Immunoglobulin
211634_x_at	IGHM /// LOC100133862	Immunoglobulin
	IGH@ /// IGHA1 /// IGHA2 /// IGHG1 ///	
	IGHG3 /// IGHM /// IGHV1OR15-5 ///	
211635_x_at	IGHV4-31 /// IGHV7-81 /// LOC642131	Immunoglobulin
209374_s_at	IGHM	Immunoglobulin

	IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG2 /// IGHG3 /// IGHM /// IGHV3-23 /// IGHV4-31 ///	
214916_x_at	LOC100126583	Immunoglobulin
211798_x_at	IGLJ3	Immunoglobulin
211881_x_at	IGLJ3	Immunoglobulin
216853_x_at	IGLV3-19	Immunoglobulin
	IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG3 /// IGHG4 /// IGHM /// IGHV3-23 /// IGHV4-31 ///	
	LOC100126583 /// LOC642131 ///	
211637_x_at	LOC652128 /// VSIG6	Immunoglobulin
216491_x_at	IGHM	Immunoglobulin
	IGHA1 /// IGHD /// IGHG1 /// IGHG3 /// IGHM /// IGHV3-23 /// IGHV4-31 ///	
211650_x_at	LOC100126583	Immunoglobulin
	IGHA1 /// IGHD /// IGHG1 /// IGHM /// IGHV3-23 /// IGHV4-31	
216510_x_at	IGH@ /// IGHA1 /// IGHG1 /// IGHG3 /// IGHM /// IGHV3-23 /// IGHV4-31	Immunoglobulin
216557_x_at	IGH@ /// IGHA1 /// IGHA2 /// IGHG1 /// IGHG2 /// IGHG3 /// IGHM /// IGHV4-31 /// LOC100126583 /// LOC652494	Immunoglobulin
217281_x_at	IGK@ /// IGKV3-20 /// IGKV3D-11 ///	Immunoglobulin
211643_x_at	IGKV3D-15 /// LOC440871	Immunoglobulin
211644_x_at	IGK@ /// IGKC /// IGKV3-20 /// IGKV3D- 11 /// IGKV3D-15 /// LOC440871	Immunoglobulin
211645_x_at	---	Immunoglobulin
216401_x_at	LOC652493	Immunoglobulin
217378_x_at	LOC100130100	Immunoglobulin
	IGKC /// IGKV1-5 /// LOC100130100 /// LOC647506 /// LOC650405 /// LOC652493 /// LOC652694	Immunoglobulin
216207_x_at	IGKV1OR15-118	Immunoglobulin
217480_x_at	IGKC /// IGKV1-5 /// LOC647506 ///	
216576_x_at	LOC652694	Immunoglobulin
215176_x_at	LOC100130100	Immunoglobulin
	IGK@ /// IGKC /// LOC647506 ///	
217157_x_at	LOC650405 /// LOC652493	Immunoglobulin
216984_x_at	IGLV2-11 /// IGLV2-18 /// IGLV2-23	Immunoglobulin
217148_x_at	IGL@	Immunoglobulin
	IGL@ /// IGLC1 /// IGLV2-11 /// IGLV2- 18 /// IGLV2-23	
217235_x_at	IGHD	Immunoglobulin
214973_x_at	---	Immunoglobulin
217179_x_at	IGL@	Immunoglobulin
217227_x_at	IGL@	Immunoglobulin
217258_x_at	FAM20B	Immunoglobulin
214768_x_at	IGKV4-1	Immunoglobulin
214777_at		

212592_at	IGJ	Immunoglobulin
209138_x_at	IGL@	Immunoglobulin
215121_x_at	IGL@	Immunoglobulin
214677_x_at	IGL@	Immunoglobulin
215379_x_at	IGL@	Immunoglobulin
214669_x_at	IGKC	Immunoglobulin
214836_x_at	IGKC	Immunoglobulin
	IGH@ /// IGHG1 /// IGHG2 /// IGHM ///	
211430_s_at	IGHV4-31	Immunoglobulin
221651_x_at	IGK@ /// IGKC	Immunoglobulin
221671_x_at	IGK@ /// IGKC	Immunoglobulin
215946_x_at	IGLL3	Immunoglobulin
	IGH@ /// IGHA1 /// IGHA2 ///	
217022_s_at	LOC100126583	Immunoglobulin
215214_at	IGL@	Immunoglobulin
216560_x_at	IGL@	Immunoglobulin
203290_at	HLA-DQA1	Not Assigned
	HLA-DRB1 /// HLA-DRB3 /// HLA-DRB4 /// HLA-DRB5 /// LOC100133484 ///	
221491_x_at	LOC100133661 /// LOC731718	Not Assigned
209480_at	HLA-DQB1	Not Assigned
213831_at	HLA-DQA1	Not Assigned
212999_x_at	HLA-DQB1	Not Assigned
219759_at	ERAP2	Not Assigned
209728_at	HLA-DRB4	Not Assigned
204836_at	GLDC	Not Assigned
210785_s_at	C1orf38	Not Assigned
211663_x_at	PTGDS	Not Assigned
211748_x_at	PTGDS	Not Assigned
212187_x_at	PTGDS	Not Assigned
201008_s_at	TXNIP	Stem-A/B
201983_s_at	EGFR	Stem-A/B
208146_s_at	CPVL	Stem-A/B
213385_at	CHN2	Stem-A/B
201842_s_at	EFEMP1	Stem-A/B
201843_s_at	EFEMP1	Stem-A/B
202291_s_at	MGP	Stem-A/B
202746_at	ITM2A	Stem-A/B
213258_at	TFPI	Stem-A/B
211597_s_at	HOPX	Stem-A/B
201280_s_at	DAB2	Stem-A/B
203305_at	F13A1	Stem-A/B
204438_at	MRC1 /// MRC1L1	Stem-A/B
204112_s_at	HNMT	Stem-A/B
212063_at	CD44	Stem-A/B
211675_s_at	MDFIC	Stem-A/B
221760_at	MAN1A1	Stem-A/B
209392_at	ENPP2	Stem-A/B

204235_s_at	GULP1	Stem-A/B
204237_at	GULP1	Stem-A/B
203323_at	CAV2	Stem-A/B
203324_s_at	CAV2	Stem-A/B
203065_s_at	CAV1	Stem-A/B
212097_at	CAV1	Stem-A/B
203476_at	TPBG	Stem-A/B
203939_at	NT5E	Stem-A/B
213800_at	CFH	Stem-A/B
215388_s_at	CFH /// CFHR1	Stem-A/B
201579_at	FAT1	Stem-A/B
209487_at	RBPMS	Stem-A/B
209488_s_at	RBPMS	Stem-A/B
219049_at	CSGALNACTI	Stem-A/B
206858_s_at	HOXC6	Stem-A/B
201565_s_at	ID2	Stem-A/B
207826_s_at	ID3	Stem-A/B
208937_s_at	ID1	Stem-A/B
201162_at	IGFBP7	Stem-A/B
201426_s_at	VIM	Stem-A/B
201508_at	IGFBP4	Stem-A/B
201185_at	HTRA1	Stem-A/B
207191_s_at	ISLR	Stem-A/B
202975_s_at	RHOBTB3	Stem-A/B
202976_s_at	RHOBTB3	Stem-A/B
204749_at	NAP1L3	Stem-A/B
214247_s_at	DKK3	Stem-A/B
219463_at	C20orf103	Stem-A/B
209505_at	NR2F1	Stem-A/B
202149_at	NEDD9	Stem-A/B
212154_at	SDC2	Stem-A/B
212158_at	SDC2	Stem-A/B
221933_at	NLGN4X	Stem-A/B
205381_at	LRRRC17	Stem-A/B
203789_s_at	SEMA3C	Stem-A/B
212915_at	PDZRN3	Stem-A/B
202036_s_at	SFRP1	Stem-A/B
202037_s_at	SFRP1	Stem-A/B
202609_at	EPS8	Stem-A/B
203881_s_at	DMD	Stem-A/B
213397_x_at	RNASE4	Stem-A/B
203680_at	PRKAR2B	Stem-A/B
202920_at	ANK2	Stem-A/B
202992_at	C7	Stem-A/B
204719_at	ABCA8	Stem-A/B
204359_at	FLRT2	Stem-A/B
212865_s_at	COL14A1	Stem-A/B

218730_s_at	OGN	Stem-A/B
209469_at	GPM6A	Stem-A/B
203304_at	BAMBI	Stem-A/B
204041_at	MAOB	Stem-A/B
203824_at	TSPAN8	Stem-A/B
204931_at	TCF21	Stem-A/B
209242_at	PEG3	Stem-A/B
209243_s_at	PEG3 /// ZIM2	Stem-A/B
204548_at	STAR	Stem-A/B
220102_at	FOXL2	Stem-A/B
209560_s_at	DLK1	Stem-A/B
219873_at	COLEC11	Stem-A/B
216733_s_at	GATM	Stem-A/B
214079_at	DHRS2	Stem-A/B
215506_s_at	DIRAS3	Stem-A/B
218974_at	SOBP	Stem-A/B
212224_at	ALDH1A1	Stem-A/B
205990_s_at	WNT5A	Stem-A/B
213425_at	WNT5A	Stem-A/B
209822_s_at	VLDLR	Stem-A/B
212190_at	SERPINE2	Stem-A/B
209894_at	LEPR	Stem-A/B
207002_s_at	PLAGL1	Stem-A/B
209318_x_at	PLAGL1	Stem-A/B
215016_x_at	DST	Stem-A/B
202948_at	IL1R1	Epi-A/Stem-B
203854_at	CFI	Epi-A/Stem-B
204201_s_at	PTPN13	Epi-A/Stem-B
204872_at	TLE4	Epi-A/Stem-B
212188_at	KCTD12	Epi-A/Stem-B
212192_at	KCTD12	Epi-A/Stem-B
213093_at	PRKCA	Epi-A/Stem-B
214218_s_at	XIST	Epi-A/Stem-B
221728_x_at	XIST	Epi-A/Stem-B
207480_s_at	MEIS2	Epi-A/Stem-B
210002_at	GATA6	Epi-A/Stem-B
214945_at	FAM153A /// FAM153B /// FAM153C	Epi-A/Stem-B
213094_at	GPR126	Epi-A/Stem-B
218326_s_at	LGR4	Epi-A/Stem-B
202342_s_at	TRIM2	Not Assigned
205442_at	MFAP3L	Not Assigned
205453_at	HOXB2	Not Assigned
205366_s_at	HOXB6	Not Assigned
204779_s_at	HOXB7	Not Assigned
216973_s_at	HOXB7	Not Assigned
211538_s_at	HSPA2	Not Assigned
203924_at	GSTA1	Not Assigned

204151_x_at	AKR1C1	Not Assigned
209699_x_at	AKR1C2	Not Assigned
211653_x_at	AKR1C2	Not Assigned
209160_at	AKR1C3	Not Assigned
202554_s_at	GSTM3	Not Assigned
205799_s_at	SLC3A1	Not Assigned
206268_at	LEFTY1	Not Assigned
206561_s_at	AKR1B10	Not Assigned
205403_at	IL1R2	Not Assigned
219564_at	KCNJ16	Not Assigned
203961_at	NEBL	Not Assigned
203962_s_at	NEBL	Not Assigned
212328_at	LIMCH1	Not Assigned
204364_s_at	REEP1	Not Assigned
221523_s_at	RRAGD	Not Assigned
219789_at	NPR3	Not Assigned
201340_s_at	ENC1	Not Assigned
201939_at	PLK2	Not Assigned
208711_s_at	CCND1	Not Assigned
208712_at	CCND1	Not Assigned
205680_at	MMP10	Not Assigned
206228_at	PAX2	Not Assigned
205997_at	ADAM28	Not Assigned
202478_at	TRIB2	Not Assigned
204011_at	SPRY2	Not Assigned
212558_at	SPRY1	Not Assigned
208891_at	DUSP6	Not Assigned
208892_s_at	DUSP6	Not Assigned
208893_s_at	DUSP6	Not Assigned
204014_at	DUSP4	Not Assigned
213462_at	NPAS2	Not Assigned
39549_at	NPAS2	Not Assigned
219230_at	TMEM100	Not Assigned
217996_at	PHLDA1	Not Assigned
217997_at	PHLDA1	Not Assigned
209030_s_at	CADM1	Not Assigned
209031_at	CADM1	Not Assigned
213479_at	NPTX2	Not Assigned
213131_at	OLFM1	Not Assigned
202068_s_at	LDLR	Not Assigned
201925_s_at	CD55	Not Assigned
201926_s_at	CD55	Not Assigned
218960_at	TMPRSS4	Not Assigned
205328_at	CLDN10	Not Assigned
209803_s_at	PHLDA2	Not Assigned
205174_s_at	QPCT	Not Assigned
202833_s_at	SERPINA1	Not Assigned

211429_s_at	SERPINA1	Not Assigned
205016_at	TGFA	Not Assigned
211026_s_at	MGLL	Not Assigned
209529_at	PPAP2C	Not Assigned
218963_s_at	KRT23	Not Assigned
213432_at	MUC5B	Not Assigned
219857_at	C10orf81	Not Assigned
201468_s_at	NQO1	Not Assigned
210519_s_at	NQO1	Not Assigned
202489_s_at	FXVD3	Not Assigned
209498_at	CEACAM1	Not Assigned
202712_s_at	CKMT1A /// CKMT1B	Not Assigned
33322_i_at	SFN	Not Assigned
33323_r_at	SFN	Not Assigned
203963_at	CA12	Not Assigned
214164_x_at	CA12	Not Assigned
215867_x_at	CA12	Not Assigned
203510_at	MET	Epi-A/Stem-B
204304_s_at	PROM1	Epi-A/Stem-B
213664_at	SLC1A1	Epi-A/Stem-B
204363_at	F3	Not Assigned
209373_at	MALL	Not Assigned
203108_at	GPRC5A	Not Assigned
212444_at	---	Not Assigned
218309_at	CAMK2N1	Not Assigned
204351_at	S100P	Not Assigned
201884_at	CEACAM5	Not Assigned
203757_s_at	CEACAM6	Not Assigned
211657_at	CEACAM6	Not Assigned
205009_at	TFF1	Not Assigned
206239_s_at	SPINK1	Not Assigned
212768_s_at	OLFM4	Not Assigned
203908_at	SLC4A4	Not Assigned
204623_at	TFF3	Not Assigned
209173_at	AGR2	Not Assigned
215108_x_at	TOX3	Not Assigned
214774_x_at	TOX3	Not Assigned
216623_x_at	TOX3	Not Assigned
209114_at	TSPAN1	Not Assigned
219508_at	GCNT3	Not Assigned
221577_x_at	GDF15	Not Assigned
205765_at	CYP3A5	Not Assigned
214234_s_at	CYP3A5	Not Assigned
214235_at	CYP3A5	Not Assigned
205597_at	SLC44A4	Not Assigned
219580_s_at	TMC5	Not Assigned
204855_at	SERPINB5	Not Assigned

218796_at	FERMT1	Not Assigned
218976_at	DNAJC12	Not Assigned
213506_at	F2RL1	Not Assigned
203717_at	DPP4	Not Assigned
211478_s_at	DPP4	Not Assigned
222108_at	AMIGO2	Not Assigned
205044_at	GABRP	Not Assigned
204664_at	ALPP	Not Assigned
217109_at	MUC4	Not Assigned
217110_s_at	MUC4	Not Assigned
39248_at	AQP3	Not Assigned
203240_at	FCGBP /// LOC100133944	Not Assigned
205898_at	CX3CR1	Not Assigned
205668_at	LY75	Not Assigned
218322_s_at	ACSL5	Not Assigned
212543_at	AIM1	Not Assigned
219014_at	PLAC8	Not Assigned
206100_at	CPM	Not Assigned
205043_at	CFTR	Not Assigned
218435_at	DNAJC15	Not Assigned
203559_s_at	ABPI	Not Assigned
220532_s_at	TMEM176B	Not Assigned
203913_s_at	HPGD	Not Assigned
203914_x_at	HPGD	Not Assigned
211548_s_at	HPGD	Not Assigned
201116_s_at	CPE	Not Assigned
201117_s_at	CPE	Not Assigned
201540_at	FHL1	Not Assigned
210299_s_at	FHL1	Not Assigned
209763_at	CHRD1	Not Assigned
210517_s_at	AKAP12	Not Assigned
204223_at	PRELP	Not Assigned
219778_at	ZFPM2	Not Assigned
207808_s_at	PROS1	Not Assigned
218901_at	PLSCR4	Not Assigned
204948_s_at	FST	Not Assigned
213265_at	PGA3 /// PGA4 /// PGA5	Not Assigned
217889_s_at	CYBRD1	Not Assigned
212816_s_at	CBS	Not Assigned
222242_s_at	KLK5	Not Assigned
201746_at	TP53	Stem-A
201123_s_at	EIF5A	Stem-A
205048_s_at	PSPH	Stem-A
208719_s_at	DDX17	Stem-A
207016_s_at	ALDH1A2	Stem-A
200951_s_at	CCND2	Stem-A
200953_s_at	CCND2	Stem-A

203408_s_at	SATB1	Stem-A
205110_s_at	FGF13	Stem-A
209598_at	PNMA2	Stem-A
212233_at	MAP1B	Stem-A
204529_s_at	TOX	Stem-A
206172_at	IL13RA2	Stem-A
203705_s_at	FZD7	Stem-A
203706_s_at	FZD7	Stem-A
204983_s_at	GPC4	Stem-A
204984_at	GPC4	Stem-A
203895_at	PLCB4	Stem-A
207030_s_at	CSRP2	Stem-A
205932_s_at	MSX1	Stem-A
202965_s_at	CAPN6	Stem-A
213110_s_at	COL4A5	Stem-A
203184_at	FBN2	Stem-A
204400_at	EFS	Stem-A
202016_at	MEST	Stem-A
201310_s_at	C5orf13	Stem-A
203417_at	MFAP2	Stem-A
210220_at	FZD2	Stem-A
211071_s_at	MLLT11	Stem-A
204913_s_at	SOX11	Stem-A
204914_s_at	SOX11	Stem-A
204915_s_at	SOX11	Stem-A
205122_at	TMEFF1	Stem-A
205347_s_at	TMSB15A	Stem-A
214023_x_at	TUBB2B	Stem-A
204724_s_at	COL9A3	Stem-A
205471_s_at	DACH1	Stem-A
205472_s_at	DACH1	Stem-A
212850_s_at	LRP4	Stem-A
214761_at	ZNF423	Stem-A
209757_s_at	MYCN	Stem-A
211276_at	TCEAL2	Stem-A
218332_at	BEX1	Stem-A
206857_s_at	FKBP1B	Stem-A
203256_at	CDH3	Stem-A
221958_s_at	GPR177	Stem-A
219250_s_at	FLRT3	Stem-A
213348_at	CDKN1C	Stem-A
204141_at	TUBB2A	Stem-A
211959_at	IGFBP5	Stem-A
212977_at	CXCR7	Stem-A
219410_at	TMEM45A	Stem-A
221024_s_at	SLC2A10	Stem-A
209355_s_at	PPAP2B	Stem-A

209220_at	GPC3	Stem-A
44783_s_at	HEY1	Stem-A
203697_at	FRZB	Stem-A
203698_s_at	FRZB	Stem-A
209656_s_at	TMEM47	Stem-A
209897_s_at	SLIT2	Stem-A
213568_at	OSR2	Stem-A
204073_s_at	C11orf9	Stem-A
204379_s_at	FGFR3	Stem-A
202409_at	IGF2 /// INS-IGF2	Stem-A
202410_x_at	IGF2 /// INS-IGF2	Stem-A
210881_s_at	IGF2 /// INS-IGF2	Stem-A
202242_at	TSPAN7	Stem-A
203627_at	IGF1R	Stem-A
203628_at	IGF1R	Stem-A
208025_s_at	HMGA2	Stem-A
218847_at	IGF2BP2	Stem-A
221004_s_at	ITM2C	Stem-A
221245_s_at	FZD5	Stem-A
209035_at	MDK	Stem-A
214390_s_at	BCAT1	Stem-A
214452_at	BCAT1	Stem-A
205619_s_at	MEOX1	Stem-A
202668_at	EFNB2	Stem-A
202669_s_at	EFNB2	Stem-A
206953_s_at	LPHN2	Stem-A
213325_at	PVRL3	Stem-A
205901_at	PNOC	Stem-A
205402_x_at	PRSS2	Stem-A
202718_at	IGFBP2	Stem-A
204450_x_at	APOA1	Stem-A
217073_x_at	APOA1	Stem-A
204105_s_at	NRCAM	Stem-A
205549_at	PCP4	Stem-A
209590_at	BMP7	Stem-A
209591_s_at	BMP7	Stem-A
212843_at	NCAM1	Stem-A
218824_at	PNMAL1	Stem-A
206987_x_at	FGF18	Stem-A
211029_x_at	FGF18	Stem-A
209552_at	PAX8	Stem-A
213917_at	PAX8	Stem-A
214528_s_at	PAX8	Stem-A
221950_at	EMX2	Stem-A
203849_s_at	KIF1A	Stem-A
213622_at	COL9A2	Stem-A
206772_at	PTH2R	Stem-A

220167_s_at	LOC729355 /// TP53TG3	Stem-A
214373_at	---	Stem-A
214157_at	GNAS	Stem-A
204784_s_at	MLF1	Stem-A
213122_at	TSPYL5	Stem-A
212092_at	PEG10	Stem-A
212094_at	PEG10	Stem-A
219743_at	HEY2	Stem-A
203638_s_at	FGFR2	Stem-A
208228_s_at	FGFR2	Stem-A
214053_at	ERBB4	Stem-A
219132_at	PELI2	Stem-A
205358_at	GRIA2	Stem-A
210393_at	LGR5	Stem-A
213880_at	LGR5	Stem-A
205413_at	MPPED2	Stem-A
215692_s_at	MPPED2	Stem-A
204069_at	MEIS1	Stem-A
211596_s_at	LRIG1	Stem-A
219993_at	SOX17	Stem-A
221884_at	EVII	Stem-A
204602_at	DKK1	Stem-A
204712_at	WIF1	Stem-A
205278_at	GAD1	Stem-A
206224_at	CST1	Stem-A
204748_at	PTGS2	Stem-A
210145_at	PLA2G4A	Stem-A
213222_at	PLCB1	Stem-A
201522_x_at	SNRPN /// SNURF	Stem-A
206042_x_at	SNRPN /// SNURF	Stem-A
221974_at	IPW	Stem-A
209550_at	NDN	Stem-A
205541_s_at	GSPT2	Stem-A
209228_x_at	TUSC3	Stem-A
213423_x_at	TUSC3	Stem-A
215440_s_at	BEX4	Stem-A
203130_s_at	KIF5C	Stem-A
203423_at	RBP1	Stem-A
203889_at	SCG5	Stem-A
207717_s_at	PKP2	Stem-A
209569_x_at	D4S234E	Stem-A
209570_s_at	D4S234E	Stem-A
209459_s_at	ABAT	Stem-A
200962_at	RPL31	Stem-A
202431_s_at	MYC	Stem-A
209291_at	ID4	Stem-A
209292_at	ID4	Stem-A

209293_x_at	ID4	Stem-A
209582_s_at	CD200	Stem-A
209583_s_at	CD200	Stem-A
201578_at	PODXL	Stem-A
219764_at	FZD10	Stem-A
203440_at	CDH2	Stem-A
206002_at	GPR64	Stem-A
222325_at	---	Stem-A
221558_s_at	LEF1	Stem-A
213456_at	SOSTDC1	Stem-A
209504_s_at	PLEKHB1	Stem-A
58916_at	KCTD14	Stem-A
209921_at	SLC7A11	Stem-A
217678_at	SLC7A11	Stem-A
213849_s_at	PPP2R2B	Stem-A
205186_at	DNALI1	Stem-A
206197_at	NME5	Stem-A
218876_at	TPPP3	Stem-A
220269_at	ZBBX	Stem-A
220168_at	CASC1	Stem-A
222271_at	---	Stem-A
221185_s_at	IQCG	Stem-A
205625_s_at	CALB1	Stem-A
205626_s_at	CALB1	Stem-A
204614_at	SERPINB2	Stem-A
206404_at	FGF9	Stem-A
209904_at	TNNC1	Stem-A
219529_at	CLIC3	Stem-A
214321_at	NOV	Stem-A
201242_s_at	ATP1B1	Stem-A
206291_at	NTS	Stem-A
205342_s_at	SULT1C2	Stem-A
211470_s_at	SULT1C2	Stem-A
201387_s_at	UCHL1	Stem-A
209406_at	BAG2	Stem-A
205229_s_at	COCH	Stem-A
218888_s_at	NETO2	Stem-A
204159_at	CDKN2C	Stem-A
206632_s_at	APOBEC3B	Stem-A
203560_at	GGH	Stem-A
206023_at	NMU	Stem-A
201890_at	RRM2	Stem-A
209773_s_at	RRM2	Stem-A
201291_s_at	TOP2A	Stem-A
201292_at	TOP2A	Stem-A
203764_at	DLGAP5	Stem-A
209714_s_at	CDKN3	Stem-A

202870_s_at	CDC20	Stem-A
204822_at	TTK	Stem-A
204962_s_at	CENPA	Stem-A
210052_s_at	TPX2	Stem-A
209642_at	BUB1	Stem-A
219918_s_at	ASPM	Stem-A
210559_s_at	CDC2	Stem-A
218009_s_at	PRC1	Stem-A
218542_at	CEP55	Stem-A
219148_at	PBK	Stem-A
207039_at	CDKN2A	Stem-A
209644_x_at	CDKN2A	Stem-A
213523_at	CCNE1	Stem-A
213872_at	C6orf62	Stem-A
220892_s_at	PSAT1	Stem-A
209122_at	ADFP	Stem-A
218454_at	PLBD1	Stem-A
202350_s_at	MATN2	Stem-A
206698_at	XK	Stem-A
207469_s_at	PIR	Stem-A
220994_s_at	STXBP6	Stem-A
203819_s_at	IGF2BP3	Stem-A
203820_s_at	IGF2BP3	Stem-A
33767_at	NEFH	Stem-A
	GAGE12C /// GAGE12D /// GAGE12E ///	
	GAGE12F /// GAGE12G /// GAGE12H ///	
	GAGE12I /// GAGE2A /// GAGE2C ///	
206640_x_at	GAGE4 /// GAGE5 /// GAGE6 /// GAGE7	Stem-A
	GAGE12F /// GAGE12G /// GAGE12I ///	
208235_x_at	GAGE7	Stem-A
	GAGE1 /// GAGE12C /// GAGE12D ///	
	GAGE12E /// GAGE12F /// GAGE12G ///	
	GAGE12H /// GAGE12I /// GAGE12J ///	
	GAGE2A /// GAGE2C /// GAGE2D ///	
	GAGE2E /// GAGE4 /// GAGE5 /// GAGE6	
207086_x_at	/// GAGE7 /// GAGE8	Stem-A
	GAGE1 /// GAGE12F /// GAGE12G ///	
	GAGE12I /// GAGE12J /// GAGE4 ///	
208155_x_at	GAGE5 /// GAGE6 /// GAGE7	Stem-A
207663_x_at	GAGE3	Stem-A
	GAGE1 /// GAGE12F /// GAGE12G ///	
	GAGE12I /// GAGE12J /// GAGE2A ///	
	GAGE2B /// GAGE2C /// GAGE2D ///	
	GAGE2E /// GAGE3 /// GAGE4 /// GAGE5	
207739_s_at	/// GAGE6 /// GAGE7 /// GAGE8	Stem-A
210503_at	MAGEA11	Stem-A
214254_at	MAGEA4	Stem-A
209942_x_at	MAGEA3	Stem-A

214612_x_at	MAGEA6	Stem-A
210546_x_at	CTAG1A /// CTAG1B	Stem-A
211674_x_at	CTAG1A /// CTAG1B	Stem-A
210394_x_at	SSX4 /// SSX4B	Stem-A
214183_s_at	TKTL1	Stem-A
210445_at	FABP6	Stem-A
204424_s_at	LMO3	Stem-A
206018_at	FOXG1	Stem-A
206373_at	ZIC1	Stem-A
213844_at	HOXA5	Stem-A
213150_at	HOXA10	Stem-A
214651_s_at	HOXA9	Stem-A
218625_at	NRN1	Stem-A
221690_s_at	NLRP2	Stem-A
219288_at	C3orf14	Stem-A
200832_s_at	SCD	Stem-A
219215_s_at	SLC39A4	Stem-A
209398_at	HIST1H1C	Stem-A
202708_s_at	HIST2H2BE	Stem-A
214290_s_at	HIST2H2AA3 /// HIST2H2AA4	Stem-A
218280_x_at	HIST2H2AA3 /// HIST2H2AA4	Stem-A
209911_x_at	HIST1H2BD	Stem-A
208579_x_at	H2BFS	Stem-A
215071_s_at	HIST1H2AC	Stem-A
206110_at	---	Stem-A
210387_at	HIST1H2BG	Stem-A
214469_at	HIST1H2AE	Stem-A
203815_at	GSTT1	Not Assigned
201042_at	TGM2	Epithelial
202856_s_at	SLC16A3	Epithelial
211564_s_at	PDLIM4	Epithelial
203074_at	ANXA8 /// ANXA8L1 /// ANXA8L2	Epithelial
206595_at	CST6	Epithelial
215704_at	FLG	Epithelial
204584_at	L1CAM	Epithelial
205258_at	INHBB	Epithelial
201820_at	KRT5	Epithelial
209125_at	KRT6A	Epithelial
205157_s_at	KRT17	Epithelial
212236_x_at	KRT17	Epithelial
209351_at	KRT14	Epithelial
205081_at	CRIP1	Epithelial
203726_s_at	LAMA3	Epithelial
202267_at	LAMC2	Epithelial
209270_at	LAMB3	Epithelial
203407_at	PPL	Epithelial
202504_at	TRIM29	Epithelial

212992_at	AHNAK2	Epithelial
205780_at	BIK	Epithelial
206884_s_at	SCEL	Epithelial
210064_s_at	UPK1B	Epithelial
210065_s_at	UPK1B	Epithelial
203186_s_at	S100A4	Epithelial
204268_at	S100A2	Epithelial
217728_at	S100A6	Epithelial
203571_s_at	C10orf116	Epithelial
218677_at	S100A14	Epithelial
202286_s_at	TACSTD2	Epithelial
209016_s_at	KRT7	Epithelial
201650_at	KRT19	Epithelial
217744_s_at	PERP	Epithelial
218186_at	RAB25	Epithelial
215729_s_at	VGLL1	Epithelial
213240_s_at	KRT4	Epithelial
219476_at	C1orf116	Epithelial
201012_at	ANXA1	Epithelial
209386_at	TM4SF1	Epithelial
209387_s_at	TM4SF1	Epithelial
215034_s_at	TM4SF1	Epithelial
209369_at	ANXA3	Epithelial
201324_at	EMP1	Epithelial
201325_s_at	EMP1	Epithelial
202206_at	ARL4C	Epithelial
202207_at	ARL4C	Epithelial
203910_at	ARHGAP29	Epithelial
218182_s_at	CLDN1	Epithelial
220332_at	CLDN16	Epithelial
204777_s_at	MAL	Epithelial
204751_x_at	DSC2	Epithelial
205532_s_at	CDH6	Epithelial
210602_s_at	CDH6	Epithelial
214803_at	---	Epithelial
219274_at	TSPAN12	Epithelial
206658_at	UPK3B	Epithelial
202524_s_at	SPOCK2	Epithelial
219836_at	ZBED2	Epithelial
213317_at	CLIC5	Epithelial
219866_at	CLIC5	Epithelial
206825_at	OXTR	Epithelial
220979_s_at	ST6GALNAC5	Epithelial
219064_at	ITIH5	Epithelial
222162_s_at	ADAMTS1	Epithelial
201951_at	ALCAM	Not Assigned
201952_at	ALCAM	Not Assigned

209781_s_at	KHDRBS3	Not Assigned
202233_s_at	UQCRH	Not Assigned
209167_at	GPM6B	Not Assigned
209170_s_at	GPM6B	Not Assigned
219497_s_at	BCL11A	Not Assigned
209465_x_at	PTN	Not Assigned
209466_x_at	PTN	Not Assigned
211737_x_at	PTN	Not Assigned
218502_s_at	TRPS1	Epithelial
201131_s_at	CDH1	Epithelial
201839_s_at	EPCAM	Epithelial
203397_s_at	GALNT3	Epithelial
203453_at	SCNN1A	Epithelial
202525_at	PRSS8	Epithelial
202454_s_at	ERBB3	Epithelial
219121_s_at	ESRP1	Epithelial
208650_s_at	CD24	Epithelial
209772_s_at	CD24	Epithelial
208651_x_at	CD24	Epithelial
209771_x_at	CD24	Epithelial
216379_x_at	CD24	Epithelial
266_s_at	CD24	Epithelial
204653_at	TFAP2A	Epithelial
218806_s_at	VAV3	Epithelial
218807_at	VAV3	Epithelial
219768_at	VTCN1	Epithelial
202935_s_at	SOX9	Not Assigned
202936_s_at	SOX9	Not Assigned
204542_at	ST6GALNAC2	Not Assigned
204990_s_at	ITGB4	Not Assigned
207547_s_at	FAM107A	Not Assigned
209074_s_at	FAM107A	Not Assigned
208791_at	CLU	Not Assigned
208792_s_at	CLU	Not Assigned
222043_at	CLU	Not Assigned
203021_at	SLPI	Not Assigned
203892_at	WFDC2	Not Assigned
203953_s_at	CLDN3	Not Assigned
202510_s_at	TNFAIP2	Not Assigned
207847_s_at	MUC1	Not Assigned
213693_s_at	MUC1	Not Assigned
204846_at	CP	Not Assigned
214282_at	---	Not Assigned
209395_at	CHI3L1	Not Assigned
209396_s_at	CHI3L1	Not Assigned
210096_at	CYP4B1	Not Assigned
204733_at	KLK6	Not Assigned

205778_at	KLK7	Not Assigned
206125_s_at	KLK8	Not Assigned
205470_s_at	KLK11	Not Assigned
209792_s_at	KLK10	Not Assigned
204124_at	SLC34A2	Not Assigned
220196_at	MUC16	Not Assigned
205334_at	S100A1	Not Assigned
32625_at	NPR1	Not Assigned
205363_at	BBOX1	Not Assigned
214844_s_at	DOK5	Not Assigned
203661_s_at	TMOD1	Not Assigned
203662_s_at	TMOD1	Not Assigned
221530_s_at	BHLHE41	Not Assigned
209437_s_at	SPON1	Not Assigned
209436_at	SPON1	Not Assigned
213994_s_at	SPON1	Not Assigned
213993_at	SPON1	Not Assigned
204437_s_at	FOLR1	Not Assigned
204885_s_at	MSLN	Not Assigned
205473_at	ATP6V1B1	Not Assigned
220177_s_at	TMPRSS3	Not Assigned
219440_at	RAI2	Not Assigned
	AMY1A /// AMY1B /// AMY1C ///	
208498_s_at	AMY2A /// AMY2B	Not Assigned
222139_at	KIAA1466	Not Assigned
222281_s_at	---	Not Assigned
222334_at	---	Not Assigned
204537_s_at	GABRE	Not Assigned
209493_at	PDZD2	Not Assigned
204942_s_at	ALDH3B2	Not Assigned
205286_at	TFAP2C	Not Assigned
210397_at	DEFB1	Not Assigned
216615_s_at	HTR3A	Not Assigned
217002_s_at	HTR3A	Not Assigned
214657_s_at	NCRNA00084	Not Assigned
219153_s_at	THSD4	Not Assigned
205097_at	SLC26A2	Not Assigned
206022_at	NDP	Not Assigned
211685_s_at	NCALD	Not Assigned
204591_at	CHL1	Not Assigned
219932_at	SLC27A6	Not Assigned
207802_at	CRISP3	Not Assigned
203780_at	MPZL2	Not Assigned
213285_at	TMEM30B	Not Assigned
212560_at	SORL1	Not Assigned
205316_at	SLC15A2	Not Assigned
205225_at	ESR1	Not Assigned

209692_at	EYA2	Not Assigned
219850_s_at	EHF	Not Assigned
207910_at	SCGB1D1	Not Assigned
206378_at	SCGB2A2	Not Assigned
205979_at	SCGB2A1	Not Assigned
206799_at	SCGB1D2	Not Assigned
218857_s_at	ASRGL1	Not Assigned
218858_at	DEPDC6	Not Assigned
205432_at	OVGP1	Not Assigned
205862_at	GREB1	Not Assigned
218211_s_at	MLPH	Not Assigned
218692_at	GOLSYN	Not Assigned
218804_at	ANO1	Not Assigned
212805_at	PRUNE2	Not Assigned
218736_s_at	PALMD	Not Assigned
219359_at	ATHL1	Not Assigned
205830_at	CLGN	Not Assigned
205899_at	CCNA1	Not Assigned
205833_s_at	PART1	Not Assigned
212909_at	LYPD1	Not Assigned
213273_at	ODZ4	Not Assigned
205969_at	AADAC	Not Assigned
210861_s_at	WISP3	Not Assigned
202575_at	CRABP2	Not Assigned
205350_at	CRABP1	Not Assigned
203786_s_at	TPD52L1	Not Assigned
210372_s_at	TPD52L1	Not Assigned
207076_s_at	ASS1	Not Assigned
203632_s_at	GPRC5B	Not Assigned
206067_s_at	WT1	Not Assigned
216953_s_at	WT1	Not Assigned
205127_at	PTGS1	Not Assigned
205128_x_at	PTGS1	Not Assigned
215813_s_at	PTGS1	Not Assigned
205975_s_at	HOXD1	Not Assigned
205522_at	HOXD4	Not Assigned
206601_s_at	HOXD3	Not Assigned
219867_at	CHODL	Not Assigned
220816_at	LPAR3	Not Assigned
209201_x_at	CXCR4	Not Assigned
211919_s_at	CXCR4	Not Assigned
217028_at	CXCR4	Not Assigned
204086_at	PRAME	Not Assigned
220051_at	PRSS21	Not Assigned
220179_at	DPEP3	Not Assigned
213201_s_at	TNNT1	Not Assigned
208383_s_at	PCK1	Not Assigned

213921_at
211343_s_at

SST
COL13A1

Not Assigned
Not Assigned

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
1	211430_s_at	IGH@ /// IGHG1 /// IGHG2 /// IGHM /// IGHV4-31	EpiA_Dn
2	214677_x_at	IGL@	EpiA_Dn
3	209138_x_at	IGL@	EpiA_Dn
4	221651_x_at	IGK@ /// IGKC	EpiA_Dn
5	221671_x_at	IGK@ /// IGKC	EpiA_Dn
6	217022_s_at	IGH@ /// IGHA1 /// IGHA2 /// LOC100126583	EpiA_Dn
7	215121_x_at	IGL@	EpiA_Dn
8	215176_x_at	LOC100130100	EpiA_Dn
9	214669_x_at	IGKC	EpiA_Dn
10	209687_at	CXCL12	EpiA_Dn
11	203417_at	MFAP2	EpiA_Dn
12	214836_x_at	IGKC	EpiA_Dn
13	209541_at	IGF1	EpiA_Dn
14	203381_s_at	APOE	EpiA_Dn
15	201147_s_at	TIMP3	EpiA_Dn
16	209122_at	ADFP	EpiA_Dn
17	201150_s_at	TIMP3	EpiA_Dn
18	203382_s_at	APOE	EpiA_Dn
19	204320_at	COL11A1	EpiA_Dn
20	215446_s_at	LOX	EpiA_Dn
21	203560_at	GGH	EpiA_Dn
22	209540_at	IGF1	EpiA_Dn
23	221541_at	CRISPLD2	EpiA_Dn
24	201149_s_at	TIMP3	EpiA_Dn
25	219410_at	TMEM45A	EpiA_Dn
26	205347_s_at	TMSB15A	EpiA_Dn
27	209542_x_at	IGF1	EpiA_Dn
28	204298_s_at	LOX	EpiA_Dn
29	218454_at	PLBD1	EpiA_Dn
30	218559_s_at	MAFB	EpiA_Dn
31	213187_x_at	FTL	EpiA_Dn
32	201148_s_at	TIMP3	EpiA_Dn
33	218888_s_at	NETO2	EpiA_Dn
34	212365_at	MYO1B	EpiA_Dn
35	211577_s_at	IGF1	EpiA_Dn
36	209708_at	MOXD1	EpiA_Dn
37	203666_at	CXCL12	EpiA_Dn
38	221766_s_at	FAM46A	EpiA_Dn
39	209209_s_at	FERMT2	EpiA_Dn

Gene
List 2 -
EpiA

Index	Probe	Gène	Category
40	216044_x_at	FAM69A	EpiA_Dn
41	201050_at	PLD3	EpiA_Dn
42	212884_x_at	APOE	EpiA_Dn
43	213125_at	OLFML2B	EpiA_Dn
44	218223_s_at	PLEKHO1	EpiA_Dn
45	206028_s_at	MERTK	EpiA_Dn
46	202619_s_at	PLOD2	EpiA_Dn
47	210052_s_at	TPX2	EpiA_Dn
48	209210_s_at	FERMT2	EpiA_Dn
49	205304_s_at	KCNJ8	EpiA_Dn
50	214845_s_at	CALU	EpiA_Dn
51	203300_x_at	AP1S2	EpiA_Dn
52	200783_s_at	STMN1	EpiA_Dn
53	209198_s_at	SYT11	EpiA_Dn
54	219479_at	KDELC1	EpiA_Dn
55	202273_at	PDGFRB	EpiA_Dn
56	221210_s_at	NPL	EpiA_Dn
57	207426_s_at	TNFSF4	EpiA_Dn
58	218193_s_at	GOLT1B	EpiA_Dn
59	201559_s_at	CLIC4	EpiA_Dn
60	212788_x_at	FTL	EpiA_Dn
61	212279_at	TMEM97	EpiA_Dn
62	200866_s_at	PSAP	EpiA_Dn
63	201212_at	LGMN	EpiA_Dn
64	209365_s_at	ECM1	EpiA_Dn
65	204415_at	IFI6	EpiA_Dn
66	208962_s_at	FADS1	EpiA_Dn
67	204203_at	CEBPG	EpiA_Dn
68	209882_at	RIT1	EpiA_Dn
69	212396_s_at	KIAA0090	EpiA_Dn
70	207390_s_at	SMTN	EpiA_Dn
71	209325_s_at	RGS16	EpiA_Dn
72	202558_s_at	HSPA13	EpiA_Dn
73	210568_s_at	RECQL	EpiA_Dn
74	200744_s_at	GNB1	EpiA_Dn
75	200756_x_at	CALU	EpiA_Dn
76	221269_s_at	SH3BGRL3	EpiA_Dn
77	202747_s_at	ITM2A	EpiA_Dn
78	204233_s_at	CHKA	EpiA_Dn
79	201560_at	CLIC4	EpiA_Dn
80	201801_s_at	SLC29A1	EpiA_Dn

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
81	211913_s_at	MERTK	EpiA_Dn
82	221881_s_at	CLIC4	EpiA_Dn
83	202779_s_at	LOC731049 /// UBE2S	EpiA_Dn
84	200755_s_at	CALU	EpiA_Dn
85	217946_s_at	SAE1	EpiA_Dn
86	208510_s_at	PPARG	EpiA_Dn
87	209773_s_at	RRM2	EpiA_Dn
88	205700_at	HSD17B6	EpiA_Dn
89	220651_s_at	MCM10	EpiA_Dn
90	210087_s_at	MPZL1	EpiA_Dn
91	202647_s_at	NRAS	EpiA_Dn
92	212282_at	TMEM97	EpiA_Dn
93	211714_x_at	TUBB	EpiA_Dn
94	218516_s_at	IMPAD1	EpiA_Dn
95	204146_at	RAD51AP1	EpiA_Dn
96	204962_s_at	CENPA	EpiA_Dn
97	204430_s_at	SLC2A5	EpiA_Dn
98	209026_x_at	TUBB	EpiA_Dn
99	212281_s_at	TMEM97	EpiA_Dn
100	201291_s_at	TOP2A	EpiA_Dn
101	209363_s_at	MED21	EpiA_Dn
102	203046_s_at	TIMELESS	EpiA_Dn
103	219257_s_at	SPHK1	EpiA_Dn
104	202580_x_at	FOXMI	EpiA_Dn
105	202954_at	UBE2C	EpiA_Dn
106	221591_s_at	FAM64A	EpiA_Dn
107	221436_s_at	CDCA3	EpiA_Dn
108	210133_at	CCL11	EpiA_Dn
109	206102_at	GINS1	EpiA_Dn
110	219403_s_at	HPSE	EpiA_Dn
111	219025_at	CD248	EpiA_Dn
112	218045_x_at	PTMS	EpiA_Dn
113	214212_x_at	FERMT2	EpiA_Dn
114	217785_s_at	YKT6	EpiA_Dn
115	204318_s_at	GTSE1	EpiA_Dn
116	221194_s_at	RNFT1	EpiA_Dn
117	209642_at	BUB1	EpiA_Dn
118	221676_s_at	CORO1C	EpiA_Dn
119	218374_s_at	C12orf4	EpiA_Dn
120	202108_at	PEPD	EpiA_Dn
121	200727_s_at	ACTR2	EpiA_Dn

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
122	203418_at	CCNA2	EpiA_Dn
123	201710_at	MYBL2	EpiA_Dn
124	204730_at	RIMS3	EpiA_Dn
125	209408_at	KIF2C	EpiA_Dn
126	207828_s_at	CENPF	EpiA_Dn
127	219061_s_at	LAGE3	EpiA_Dn
128	213523_at	CCNE1	EpiA_Dn
129	218282_at	EDEM2	EpiA_Dn
130	209464_at	AURKB	EpiA_Dn
131	218252_at	CKAP2	EpiA_Dn
132	218574_s_at	LMCD1	EpiA_Dn
133	218350_s_at	GMNN	EpiA_Dn
134	200720_s_at	ACTR1A	EpiA_Dn
135	201950_x_at	CAPZB	EpiA_Dn
136	208074_s_at	AP2S1	EpiA_Dn
137	208627_s_at	YBX1	EpiA_Dn
138	208918_s_at	NADK	EpiA_Dn
139	209427_at	SMTN	EpiA_Dn
140	208079_s_at	AURKA	EpiA_Dn
141	209891_at	SPC25	EpiA_Dn
142	209653_at	KPNA4	EpiA_Dn
143	211047_x_at	AP2S1	EpiA_Dn
144	219555_s_at	CENPN	EpiA_Dn
145	208689_s_at	RPN2	EpiA_Dn
146	203588_s_at	TFDP2	EpiA_Dn
147	221677_s_at	DONSON	EpiA_Dn
148	201252_at	PSMC4	EpiA_Dn
149	202064_s_at	SEL1L	EpiA_Dn
150	203968_s_at	CDC6	EpiA_Dn
151	209707_at	PIGK	EpiA_Dn
152	209714_s_at	CDKN3	EpiA_Dn
153	201802_at	SLC29A1	EpiA_Dn
154	218257_s_at	UGCGL1	EpiA_Dn
155	217094_s_at	ITCH	EpiA_Dn
156	217770_at	PIGT	EpiA_Dn
157	213696_s_at	MED8	EpiA_Dn
158	218781_at	SMC6	EpiA_Dn
159	205393_s_at	CHEK1	EpiA_Dn
160	202095_s_at	BIRC5	EpiA_Dn
161	211519_s_at	KIF2C	EpiA_Dn
162	219551_at	EAF2	EpiA_Dn

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
163	218542_at	CEP55	EpiA_Dn
164	218088_s_at	RRAGC	EpiA_Dn
165	210594_x_at	MPZL1	EpiA_Dn
166	200815_s_at	PAFAH1B1	EpiA_Dn
167	202613_at	CTPS	EpiA_Dn
168	201663_s_at	SMC4	EpiA_Dn
169	214487_s_at	RAP2A /// RAP2B	EpiA_Dn
170	202871_at	TRAF4	EpiA_Dn
171	220011_at	C1orf135	EpiA_Dn
172	208836_at	ATP1B3	EpiA_Dn
173	219544_at	C13orf34	EpiA_Dn
174	204092_s_at	AURKA	EpiA_Dn
175	219918_s_at	ASPM	EpiA_Dn
176	221522_at	ANKRD27	EpiA_Dn
177	215509_s_at	BUB1	EpiA_Dn
178	202487_s_at	H2AFV	EpiA_Dn
179	202120_x_at	AP2S1	EpiA_Dn
180	203764_at	DLGAP5	EpiA_Dn
181	208628_s_at	YBX1	EpiA_Dn
182	222039_at	KIF18B	EpiA_Dn
183	201475_x_at	MARS	EpiA_Dn
184	219978_s_at	NUSAP1	EpiA_Dn
185	203516_at	SNTA1	EpiA_Dn
186	212020_s_at	MKI67	EpiA_Dn
187	205046_at	CENPE	EpiA_Dn
188	212949_at	NCAPH	EpiA_Dn
189	218497_s_at	RNASEH1	EpiA_Dn
190	204822_at	TTK	EpiA_Dn
191	203109_at	UBE2M	EpiA_Dn
192	217714_x_at	STMN1	EpiA_Dn
193	204026_s_at	ZWINT	EpiA_Dn
194	201930_at	MCM6	EpiA_Dn
195	201897_s_at	CKS1B	EpiA_Dn
196	211762_s_at	KPNA2	EpiA_Dn
197	213088_s_at	DNAJC9	EpiA_Dn
198	204460_s_at	RAD1	EpiA_Dn
199	220160_s_at	KPTN	EpiA_Dn
200	201112_s_at	CSE1L	EpiA_Dn
201	205704_s_at	ATP6V0A2	EpiA_Dn
202	206686_at	PDK1	EpiA_Dn
203	222158_s_at	PPPDE1	EpiA_Dn

**Gene
List 2 -
EpiA**

Index	Probe	Gene	Category
204	218782_s_at	ATAD2	EpiA_Dn
205	221021_s_at	CTNBL1	EpiA_Dn
206	218799_at	GPN2	EpiA_Dn
207	200868_s_at	RNF114	EpiA_Dn
208	203145_at	SPAG5	EpiA_Dn
209	218755_at	KIF20A	EpiA_Dn
210	200975_at	PPT1	EpiA_Dn
211	209680_s_at	KIFC1	EpiA_Dn
212	220642_x_at	GPR89A /// GPR89B /// GPR89C	EpiA_Dn
213	206296_x_at	MAP4K1	EpiA_Dn
214	211251_x_at	NFYC	EpiA_Dn
215	210559_s_at	CDC2	EpiA_Dn
216	204240_s_at	SMC2	EpiA_Dn
217	219507_at	RSRC1	EpiA_Dn
218	202407_s_at	PRPF31	EpiA_Dn
219	207183_at	GPR19	EpiA_Dn
220	203422_at	POLD1	EpiA_Dn
221	204315_s_at	GTSE1	EpiA_Dn
222	213996_at	YPEL1	EpiA_Dn
223	204331_s_at	MRPS12	EpiA_Dn
224	214474_at	PRKAB2	EpiA_Dn
225	214442_s_at	PIAS2	EpiA_Dn
226	202820_at	AHR	EpiA_Dn
227	214649_s_at	MTMR2	EpiA_Dn
228	220840_s_at	Clorf112	EpiA_Dn
229	213607_x_at	NADK	EpiA_Dn
230	205240_at	GPSM2	EpiA_Dn
231	219512_at	DSN1	EpiA_Dn
232	202216_x_at	NFYC	EpiA_Dn
233	201543_s_at	SAR1A	EpiA_Dn
234	221528_s_at	ELMO2	EpiA_Dn
235	205930_at	GTF2E1	EpiA_Dn
236	212219_at	PSME4	EpiA_Dn
237	210334_x_at	BIRC5	EpiA_Dn
238	204825_at	MELK	EpiA_Dn
239	221520_s_at	CDCA8	EpiA_Dn
240	202094_at	BIRC5	EpiA_Dn
241	38158_at	ESPL1	EpiA_Dn
242	201090_x_at	TUBA1B	EpiA_Dn
243	212694_s_at	PCCB	EpiA_Dn
244	210766_s_at	CSE1L	EpiA_Dn

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
245	214880_x_at	CALDI	EpiA_Dn
246	218726_at	HJURP	EpiA_Dn
247	204243_at	RLF	EpiA_Dn
248	210178_x_at	FUSIP1	EpiA_Dn
249	218295_s_at	NUP50	EpiA_Dn
250	201777_s_at	KIAA0494	EpiA_Dn
251	201504_s_at	TSN	EpiA_Dn
252	211058_x_at	TUBA1B	EpiA_Dn
253	204126_s_at	CDC45L	EpiA_Dn
254	203214_x_at	CDC2	EpiA_Dn
255	214173_x_at	C19orf2	EpiA_Dn
256	204128_s_at	RFC3	EpiA_Dn
257	210216_x_at	RAD1	EpiA_Dn
258	213646_x_at	TUBA1B	EpiA_Dn
259	201177_s_at	UBA2	EpiA_Dn
260	220060_s_at	C12orf48	EpiA_Dn
261	219306_at	KIF15	EpiA_Dn
262	203755_at	BUB1B	EpiA_Dn
263	212639_x_at	TUBA1B	EpiA_Dn
264	209727_at	GM2A	EpiA_Dn
265	210008_s_at	MRPS12	EpiA_Dn
266	203013_at	ECD	EpiA_Dn
267	219219_at	TMEM160	EpiA_Dn
268	204558_at	RAD54L	EpiA_Dn
269	222077_s_at	RACGAP1	EpiA_Dn
270	211072_x_at	TUBA1B	EpiA_Dn
271	208973_at	ERI3	EpiA_Dn
272	211750_x_at	TUBA1C	EpiA_Dn
273	221046_s_at	GTPBP8	EpiA_Dn
274	220295_x_at	DEPDC1	EpiA_Dn
275	214006_s_at	GGCX	EpiA_Dn
276	209825_s_at	UCK2	EpiA_Dn
277	213827_at	SNX26	EpiA_Dn
278	209251_x_at	TUBA1C	EpiA_Dn
279	202058_s_at	KPNA1	EpiA_Dn
280	211814_s_at	CCNE2	EpiA_Dn
281	219650_at	ERCC6L	EpiA_Dn
282	204603_at	EXO1	EpiA_Dn
283	205909_at	POLE2	EpiA_Dn
284	210681_s_at	USP15	EpiA_Dn
285	214431_at	GMPS	EpiA_Dn

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
286	218299_at	C11orf24	EpiA_Dn
287	203015_s_at	SSX2IP	EpiA_Dn
288	210821_x_at	CENPA	EpiA_Dn
289	204317_at	GTSE1	EpiA_Dn
290	206364_at	KIF14	EpiA_Dn
291	222250_s_at	INTS7	EpiA_Dn
292	203271_s_at	UNC119	EpiA_Dn
293	200625_s_at	CAP1	EpiA_Dn
294	204947_at	E2F1	EpiA_Dn
295	200021_at	CFL1	EpiA_Dn
296	200052_s_at	ILF2	EpiA_Dn
297	210527_x_at	TUBA3C	EpiA_Dn
298	218479_s_at	XPO4	EpiA_Dn
299	202869_at	OAS1	EpiA_Dn
300	208644_at	PARP1	EpiA_Dn
301	212165_at	TMEM183A /// TMEM183B	EpiA_Dn
302	214849_at	KCTD20	EpiA_Dn
303	203436_at	RPP30	EpiA_Dn
304	220721_at	ZNF614	EpiA_Dn
305	218447_at	C16orf61	EpiA_Dn
306	205085_at	ORC1L	EpiA_Dn
307	204514_at	DPH2	EpiA_Dn
308	200039_s_at	PSMB2	EpiA_Dn
309	219510_at	POLQ	EpiA_Dn
310	219502_at	NEIL3	EpiA_Dn
311	202338_at	TK1	EpiA_Dn
312	204441_s_at	POLA2	EpiA_Dn
313	218235_s_at	UTP11L	EpiA_Dn
314	211114_x_at	SIP1	EpiA_Dn
315	203213_at	CDC2	EpiA_Dn
316	216940_x_at	YBX1 /// YBX1P2	EpiA_Dn
317	211786_at	TNFRSF9	EpiA_Dn
318	206621_s_at	EIF4H	EpiA_Up
319	215462_at	PLK3	EpiA_Up
320	208078_s_at	SIK1	EpiA_Up
321	216595_at	FAM186A	EpiA_Up
322	215637_at	TSGA14	EpiA_Up
323	211419_s_at	CHN2	EpiA_Up
324	214271_x_at	RPL12	EpiA_Up
325	215386_at	---	EpiA_Up
326	214458_at	TRAF3IP1	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
327	215102_at	DPY19L1P1	EpiA_Up
328	209375_at	XPC	EpiA_Up
329	211441_x_at	CYP3A43	EpiA_Up
330	207418_s_at	DDO	EpiA_Up
331	216735_x_at	---	EpiA_Up
		HNRNPA1 /// HNRNPA1L2 /// HNRPA1L-2 /// HNRPAIP5 /// LOC100128701 /// LOC100128836 /// LOC120364 /// LOC391670 /// LOC402112 /// LOC642817 /// LOC643033 /// LOC644037 /// LOC645001 /// LOC728170 /// LOC728643 /// LOC728732 /// LOC729102 /// LOC729366 ///	
332	216497_at	LOC730246 /// RP11-569O4.6	EpiA_Up
333	202701_at	BMP1	EpiA_Up
334	219503_s_at	TMEM40	EpiA_Up
335	215284_at	---	EpiA_Up
336	206222_at	TNFRSF10C	EpiA_Up
337	200663_at	CD63	EpiA_Up
338	215892_at	ZNF440	EpiA_Up
339	214873_at	LRP5L	EpiA_Up
340	219281_at	MSRA	EpiA_Up
341	217873_at	CAB39	EpiA_Up
342	41220_at	SEPT9	EpiA_Up
343	222061_at	CD58	EpiA_Up
344	200847_s_at	TMEM66	EpiA_Up
345	211517_s_at	IL5RA	EpiA_Up
346	213922_at	TTBK2	EpiA_Up
347	211698_at	EID1	EpiA_Up
348	215624_at	TSC2	EpiA_Up
349	212726_at	PHF2	EpiA_Up
350	220497_at	ZNF214	EpiA_Up
351	204227_s_at	TK2	EpiA_Up
352	216135_at	IQCK	EpiA_Up
353	206910_x_at	CFHR2	EpiA_Up
354	210486_at	ANKMY1	EpiA_Up
355	214082_at	CA5B	EpiA_Up
356	204874_x_at	BAIAP3	EpiA_Up
357	200677_at	PTTG1IP	EpiA_Up
358	221617_at	TAF9B	EpiA_Up
359	219834_at	ALS2CR8	EpiA_Up
360	206540_at	GLB1L	EpiA_Up
361	219354_at	KLHL26	EpiA_Up
362	202561_at	TNKS	EpiA_Up

**Gene
List 2 -
EpiA**

Index	Probe	Gene	Category
363	217682_at	---	EpiA_Up
364	217107_at	---	EpiA_Up
365	206855_s_at	HYAL2	EpiA_Up
366	219135_s_at	LMF1	EpiA_Up
367	219136_s_at	LMF1	EpiA_Up
368	215626_at	---	EpiA_Up
369	212736_at	C16orf45	EpiA_Up
370	219891_at	PGPEP1	EpiA_Up
371	213848_at	---	EpiA_Up
372	220364_at	FLJ11235	EpiA_Up
373	221889_at	KCTD13	EpiA_Up
374	205271_s_at	CCRK	EpiA_Up
375	214147_at	C1orf175	EpiA_Up
376	219106_s_at	KBTD10	EpiA_Up
377	217574_at	CDH8	EpiA_Up
378	214192_at	NUP88	EpiA_Up
379	208646_at	RPS14 /// RPS14P3	EpiA_Up
380	206594_at	PASK	EpiA_Up
381	214118_x_at	PCM1	EpiA_Up
382	202419_at	KDSR	EpiA_Up
383	207785_s_at	RBPJ	EpiA_Up
384	215146_s_at	TTC28	EpiA_Up
385	216342_x_at	RPS4P13 /// RPS4P17 /// RPS4P7 /// RPS4X	EpiA_Up
386	221867_at	N4BP1	EpiA_Up
387	210129_s_at	TTLL3	EpiA_Up
388	220271_x_at	EFCAB6	EpiA_Up
389	219482_at	SETD4	EpiA_Up
390	208741_at	SAP18	EpiA_Up
391	209240_at	OGT	EpiA_Up
392	217863_at	PLAS1	EpiA_Up
393	215972_at	---	EpiA_Up
394	201132_at	HNRNPH2	EpiA_Up
395	217016_x_at	FLJ23172	EpiA_Up
396	203380_x_at	SFRS5	EpiA_Up
397	219252_s_at	GEMIN8	EpiA_Up
398	215030_at	GRSF1	EpiA_Up
399	221493_at	TSPYL1	EpiA_Up
400	220361_at	IQCH	EpiA_Up
401	221905_at	CYLD	EpiA_Up
402	204792_s_at	IFT140	EpiA_Up
403	215598_at	TTC12	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
404	221480_at	HNRNPD	EpiA_Up
405	200928_s_at	RAB14	EpiA_Up
406	220218_at	C9orf68	EpiA_Up
407	210962_s_at	AKAP9	EpiA_Up
408	209838_at	COPS2	EpiA_Up
409	213364_s_at	SNX1	EpiA_Up
410	200074_s_at	RPL14 /// RPL14P1	EpiA_Up
411	212427_at	KIAA0368	EpiA_Up
412	214045_at	LIAS	EpiA_Up
413	218517_at	PHF17	EpiA_Up
414	220614_s_at	C6orf103	EpiA_Up
415	212074_at	UNC84A	EpiA_Up
416	204276_at	TK2	EpiA_Up
417	203563_at	AFAP1	EpiA_Up
418	213838_at	NOL7	EpiA_Up
419	212710_at	CAMSAP1	EpiA_Up
420	213215_at	AP3S2	EpiA_Up
421	46142_at	LMF1	EpiA_Up
422	212826_s_at	SLC25A6	EpiA_Up
423	208796_s_at	CCNG1	EpiA_Up
424	202615_at	GNAQ	EpiA_Up
425	218396_at	VPS13C	EpiA_Up
426	211938_at	EIF4B	EpiA_Up
427	212425_at	SCAMP1	EpiA_Up
428	219973_at	ARSJ	EpiA_Up
429	206315_at	CRLF1	EpiA_Up
430	220539_at	C10orf92	EpiA_Up
431	215266_at	DNAH3	EpiA_Up
432	204662_at	CP110	EpiA_Up
433	213185_at	KIAA0556	EpiA_Up
434	213058_at	TTC28	EpiA_Up
435	212343_at	YIPF6	EpiA_Up
436	218785_s_at	RABL5	EpiA_Up
437	204055_s_at	CTAGE5	EpiA_Up
438	45653_at	KCTD13	EpiA_Up
439	202962_at	KIF13B	EpiA_Up
440	214800_x_at	BTF3	EpiA_Up
441	215185_at	---	EpiA_Up
442	204625_s_at	ITGB3	EpiA_Up
443	212179_at	SFRS18	EpiA_Up
444	217828_at	SLTM	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
445	205584_at	ALG13	EpiA_Up
446	209256_s_at	KLHDC10	EpiA_Up
447	218980_at	FHOD3	EpiA_Up
448	202174_s_at	PCM1	EpiA_Up
449	218147_s_at	GLT8D1	EpiA_Up
450	210111_s_at	KLHDC10	EpiA_Up
451	212293_at	HIPK1	EpiA_Up
452	213190_at	COG7	EpiA_Up
453	212416_at	SCAMP1	EpiA_Up
454	221476_s_at	RPL15	EpiA_Up
455	32029_at	PDPK1	EpiA_Up
456	210958_s_at	MAST4	EpiA_Up
457	214937_x_at	PCM1	EpiA_Up
458	209884_s_at	SLC4A7	EpiA_Up
459	212633_at	KIAA0776	EpiA_Up
460	221257_x_at	FBXO38	EpiA_Up
461	202163_s_at	CNOT8	EpiA_Up
462	220050_at	C9orf9	EpiA_Up
463	212221_x_at	IDS	EpiA_Up
464	90265_at	ADAP1	EpiA_Up
465	203835_at	LRRC32	EpiA_Up
466	209486_at	UTP3	EpiA_Up
467	204008_at	DNAL4	EpiA_Up
468	218976_at	DNAJC12	EpiA_Up
469	202603_at	---	EpiA_Up
470	205839_s_at	BZRAP1	EpiA_Up
471	217996_at	PHLDA1	EpiA_Up
472	219381_at	C5orf42	EpiA_Up
473	214848_at	---	EpiA_Up
474	212109_at	HN1L	EpiA_Up
475	208865_at	CSNK1A1	EpiA_Up
476	218265_at	SECISBP2	EpiA_Up
477	213024_at	TMF1	EpiA_Up
478	212936_at	FAM172A	EpiA_Up
479	213974_at	ADAMTSL3	EpiA_Up
480	217047_s_at	FAM13A	EpiA_Up
481	204703_at	IFT88	EpiA_Up
482	204958_at	PLK3	EpiA_Up
483	220344_at	C11orf16	EpiA_Up
484	208866_at	CSNK1A1	EpiA_Up
485	200066_at	IK	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
486	207698_at	C6orf123	EpiA_Up
487	222134_at	DDO	EpiA_Up
488	212140_at	PDS5A	EpiA_Up
489	209963_s_at	EPOR	EpiA_Up
490	200597_at	EIF3A	EpiA_Up
491	222322_at	---	EpiA_Up
492	219186_at	ZBTB7A	EpiA_Up
493	219957_at	RUFY2	EpiA_Up
494	219680_at	NLRX1	EpiA_Up
495	213832_at	KCND3	EpiA_Up
496	222258_s_at	SH3BP4	EpiA_Up
497	201889_at	FAM3C	EpiA_Up
498	215085_x_at	DLEC1	EpiA_Up
499	219251_s_at	WDR60	EpiA_Up
500	221103_s_at	WDR52	EpiA_Up
501	213275_x_at	CTSB	EpiA_Up
502	218471_s_at	BBS1	EpiA_Up
503	202241_at	TRIB1	EpiA_Up
504	205364_at	ACOX2	EpiA_Up
505	57739_at	DND1	EpiA_Up
506	206815_at	SPAG8	EpiA_Up
507	212912_at	RPS6KA2	EpiA_Up
508	206153_at	CYP4F11	EpiA_Up
509	219396_s_at	NEIL1	EpiA_Up
510	219332_at	MICALL2	EpiA_Up
511	201861_s_at	LRRFIP1	EpiA_Up
512	203480_s_at	OTUD4	EpiA_Up
513	205583_s_at	ALG13	EpiA_Up
514	219122_s_at	THG1L	EpiA_Up
515	211471_s_at	RAB36	EpiA_Up
516	202105_at	IGBP1	EpiA_Up
517	204577_s_at	CLUAP1	EpiA_Up
518	202973_x_at	FAM13A	EpiA_Up
519	204491_at	PDE4D	EpiA_Up
520	213626_at	CBR4	EpiA_Up
521	221773_at	ELK3	EpiA_Up
522	206798_x_at	DLEC1	EpiA_Up
523	222220_s_at	TSNAXIP1	EpiA_Up
524	209068_at	HNRPDL	EpiA_Up
525	208600_s_at	GPR39	EpiA_Up
526	201581_at	TMX4	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
527	215472_at	PACRG	EpiA_Up
528	201880_at	ARIH1	EpiA_Up
529	203348_s_at	ETV5	EpiA_Up
530	202081_at	IER2	EpiA_Up
531	205069_s_at	ARHGAP26	EpiA_Up
532	201473_at	JUNB	EpiA_Up
533	200810_s_at	CIRBP	EpiA_Up
534	220426_at	C20orf195	EpiA_Up
535	37986_at	EPOR	EpiA_Up
536	206492_at	FHIT	EpiA_Up
537	201260_s_at	SYPL1	EpiA_Up
538	221621_at	C17orf86	EpiA_Up
539	211004_s_at	ALDH3B1	EpiA_Up
540	219597_s_at	DUOX1	EpiA_Up
541	203513_at	SPG11	EpiA_Up
542	210103_s_at	FOXA2	EpiA_Up
543	206081_at	SLC24A1	EpiA_Up
544	206938_at	SRD5A2	EpiA_Up
545	220141_at	C11orf63	EpiA_Up
546	215498_s_at	MAP2K3	EpiA_Up
547	213385_at	CHN2	EpiA_Up
548	214252_s_at	CLN5	EpiA_Up
549	213792_s_at	INSR	EpiA_Up
550	204545_at	PEX6	EpiA_Up
551	204788_s_at	PPOX	EpiA_Up
552	212993_at	NACC2	EpiA_Up
553	221577_x_at	GDF15	EpiA_Up
554	213589_s_at	B3GNTL1	EpiA_Up
555	212616_at	CHD9	EpiA_Up
556	204084_s_at	CLN5	EpiA_Up
557	213895_at	EMP1	EpiA_Up
558	215130_s_at	IQCK	EpiA_Up
559	208760_at	UBE2I	EpiA_Up
560	201059_at	CTTN	EpiA_Up
561	204497_at	ADCY9	EpiA_Up
562	201501_s_at	GRSF1	EpiA_Up
563	219351_at	TRAPPC2	EpiA_Up
564	209894_at	LEPR	EpiA_Up
565	202084_s_at	SEC14L1	EpiA_Up
566	202181_at	KIAA0247	EpiA_Up
567	212927_at	SMC5	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
568	209640_at	PML	EpiA_Up
569	203763_at	DYNC2LI1	EpiA_Up
570	204576_s_at	CLUAP1	EpiA_Up
571	219916_s_at	RNF39	EpiA_Up
572	218501_at	ARHGEF3	EpiA_Up
573	203144_s_at	KIAA0040	EpiA_Up
574	219644_at	CCDC41	EpiA_Up
575	218950_at	ARAP3	EpiA_Up
576	215341_at	DNAH6	EpiA_Up
577	219109_at	SPAG16	EpiA_Up
578	201862_s_at	LRRFIP1	EpiA_Up
579	207896_s_at	DLEC1	EpiA_Up
580	207170_s_at	LETMD1	EpiA_Up
581	220500_s_at	RABL2A /// RABL2B	EpiA_Up
582	216119_s_at	SPEF1	EpiA_Up
583	201694_s_at	EGR1	EpiA_Up
584	219951_s_at	C20orf12	EpiA_Up
585	219271_at	GALNT14	EpiA_Up
586	220581_at	C6orf97	EpiA_Up
587	210345_s_at	DNAH9	EpiA_Up
588	209568_s_at	RGL1	EpiA_Up
589	201906_s_at	CTDSPL	EpiA_Up
590	201018_at	EIF1AX	EpiA_Up
591	215808_at	KLK10	EpiA_Up
592	221096_s_at	TMCO6	EpiA_Up
593	207375_s_at	IL15RA	EpiA_Up
594	208407_s_at	CTNND1	EpiA_Up
595	201939_at	PLK2	EpiA_Up
596	222348_at	MAST4	EpiA_Up
597	210612_s_at	SYNJ2	EpiA_Up
598	220389_at	CCDC81	EpiA_Up
599	206874_s_at	---	EpiA_Up
600	201693_s_at	EGR1	EpiA_Up
601	203349_s_at	ETV5	EpiA_Up
602	205011_at	VWA5A	EpiA_Up
603	213704_at	RABGGTB	EpiA_Up
604	202761_s_at	SYNE2	EpiA_Up
605	213106_at	ATP8A1	EpiA_Up
606	205856_at	SLC14A1	EpiA_Up
607	203573_s_at	RABGGTA	EpiA_Up
608	220107_s_at	FAM164C	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
609	204099_at	SMARCD3	EpiA_Up
610	222111_at	---	EpiA_Up
611	201887_at	IL13RA1	EpiA_Up
612	219686_at	STK32B	EpiA_Up
613	218328_at	COQ4	EpiA_Up
614	40016_g_at	MAST4	EpiA_Up
615	221934_s_at	DALRD3 /// LOC100133719	EpiA_Up
616	202552_s_at	CRIM1	EpiA_Up
617	218584_at	TCTN1	EpiA_Up
618	205834_s_at	PART1	EpiA_Up
619	207959_s_at	DNAH9	EpiA_Up
620	204085_s_at	CLN5	EpiA_Up
621	203897_at	LYRM1	EpiA_Up
622	215054_at	EPOR	EpiA_Up
623	205193_at	MAFF	EpiA_Up
624	201941_at	CPD	EpiA_Up
625	214919_s_at	ANKHD1-EIF4EBP3 /// EIF4EBP3	EpiA_Up
626	217645_at	COX16	EpiA_Up
627	209962_at	EPOR	EpiA_Up
628	211297_s_at	CDK7	EpiA_Up
629	219455_at	C7orf63	EpiA_Up
630	205459_s_at	NPAS2	EpiA_Up
631	204168_at	MGST2	EpiA_Up
632	203997_at	PTPN3	EpiA_Up
633	219157_at	KLHL2	EpiA_Up
634	202067_s_at	LDLR	EpiA_Up
635	203408_s_at	SATB1	EpiA_Up
636	219587_at	TTC12	EpiA_Up
637	219222_at	RBKS	EpiA_Up
638	209227_at	TUSC3	EpiA_Up
639	201408_at	PPP1CB	EpiA_Up
640	209457_at	DUSP5	EpiA_Up
641	205580_s_at	HRH1	EpiA_Up
642	209184_s_at	IRS2	EpiA_Up
643	208873_s_at	REEP5	EpiA_Up
644	201341_at	ENC1	EpiA_Up
645	205251_at	PER2	EpiA_Up
646	218931_at	RAB17	EpiA_Up
647	212321_at	SGPL1	EpiA_Up
648	212828_at	SYNJ2	EpiA_Up
649	218826_at	SLC35F2	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
650	218769_s_at	ANKRA2	EpiA_Up
651	210367_s_at	PTGES	EpiA_Up
652	214109_at	LRBA	EpiA_Up
653	221973_at	---	EpiA_Up
654	210106_at	RDH5	EpiA_Up
655	205074_at	SLC22A5 PCDHA1 /// PCDHA10 /// PCDHA11 /// PCDHA12 /// PCDHA13 /// PCDHA2 /// PCDHA3 /// PCDHA4 /// PCDHA5 /// PCDHA6 /// PCDHA7 /// PCDHA8 /// PCDHA9 /// PCDHAC1 /// PCDHAC2	EpiA_Up
656	210674_s_at	---	EpiA_Up
657	215304_at	---	EpiA_Up
658	208920_at	SRI	EpiA_Up
659	213375_s_at	N4BP2L1	EpiA_Up
660	213750_at	RSL1D1	EpiA_Up
661	214428_x_at	C4A /// C4B	EpiA_Up
662	218086_at	NPDC1	EpiA_Up
663	209185_s_at	IRS2	EpiA_Up
664	220917_s_at	WDR19	EpiA_Up
665	201042_at	TGM2	EpiA_Up
666	221489_s_at	SPRY4	EpiA_Up
667	207797_s_at	LRP2BP	EpiA_Up
668	220280_s_at	ANKMY1	EpiA_Up
669	205227_at	IL1RAP	EpiA_Up
670	209164_s_at	CYB561	EpiA_Up
671	35666_at	SEMA3F	EpiA_Up
672	211986_at	AHNAK	EpiA_Up
673	219542_at	NEK11	EpiA_Up
674	218764_at	PRKCH	EpiA_Up
675	209740_s_at	PNPLA4	EpiA_Up
676	214204_at	PACRG	EpiA_Up
677	213304_at	FAM179B	EpiA_Up
678	220520_s_at	NUP62CL	EpiA_Up
679	207517_at	LAMC2	EpiA_Up
680	218795_at	ACP6	EpiA_Up
681	220540_at	KCNK15	EpiA_Up
682	213142_x_at	PION	EpiA_Up
683	57540_at	RBKS	EpiA_Up
684	209194_at	CETN2	EpiA_Up
685	209163_at	CYB561	EpiA_Up
686	200972_at	TSPAN3	EpiA_Up
687	219151_s_at	RABL2A /// RABL2B	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
688	214235_at	CYP3A5	EpiA_Up
689	212586_at	CAST	EpiA_Up
690	201998_at	ST6GAL1	EpiA_Up
691	203143_s_at	KIAA0040	EpiA_Up
692	210168_at	C6	EpiA_Up
693	215856_at	SIGLEC15	EpiA_Up
694	203739_at	ZNF217	EpiA_Up
695	206526_at	RIBC2	EpiA_Up
696	211200_s_at	EFCAB2	EpiA_Up
697	218437_s_at	LZTFL1	EpiA_Up
698	208683_at	CAPN2	EpiA_Up
699	215033_at	TM4SF1	EpiA_Up
700	39548_at	NPAS2	EpiA_Up
701	204973_at	GJB1	EpiA_Up
702	203767_s_at	STS	EpiA_Up
703	208623_s_at	EZR	EpiA_Up
704	212231_at	FBXO21	EpiA_Up
705	205593_s_at	PDE9A	EpiA_Up
706	208451_s_at	C4A /// C4B	EpiA_Up
707	202478_at	TRIB2	EpiA_Up
708	222325_at	---	EpiA_Up
709	208322_s_at	ST3GAL1	EpiA_Up
710	40284_at	FOXA2	EpiA_Up
711	212229_s_at	FBXO21	EpiA_Up
712	216012_at	---	EpiA_Up
713	211998_at	H3F3B	EpiA_Up
714	211603_s_at	ETV4	EpiA_Up
715	212558_at	SPRY1	EpiA_Up
716	203608_at	ALDH5A1	EpiA_Up
717	209794_at	SRGAP3	EpiA_Up
718	212188_at	KCTD12	EpiA_Up
719	206076_at	LRRC23	EpiA_Up
720	220302_at	MAK	EpiA_Up
721	218541_s_at	C8orf4	EpiA_Up
722	220623_s_at	TSGA10	EpiA_Up
723	205014_at	FGFBP1	EpiA_Up
724	210026_s_at	CARD10	EpiA_Up
725	208153_s_at	FAT2	EpiA_Up
726	214222_at	DNAH7	EpiA_Up
727	207490_at	TUBA4B	EpiA_Up
728	220636_at	DNAI2	EpiA_Up

Gene
List 2 -
EpiA

Index	Probe	Gene	Category
729	219522_at	FJX1	EpiA_Up
730	213392_at	IQCK	EpiA_Up
731	213386_at	C9orf125	EpiA_Up
732	220769_s_at	WDR78	EpiA_Up
733	208140_s_at	LRRC48	EpiA_Up
734	207981_s_at	ESRRG	EpiA_Up
735	219833_s_at	EFHC1	EpiA_Up
736	211596_s_at	LRIG1	EpiA_Up
737	212538_at	DOCK9	EpiA_Up
738	214234_s_at	CYP3A5	EpiA_Up
739	205266_at	LIF	EpiA_Up
740	220390_at	AGBL2	EpiA_Up
741	219416_at	SCARA3	EpiA_Up
742	218736_s_at	PALMD	EpiA_Up
743	222125_s_at	P4HTM	EpiA_Up
744	220591_s_at	EFHC2	EpiA_Up
745	205906_at	FOXJ1	EpiA_Up
746	205709_s_at	CDS1	EpiA_Up
747	214811_at	RIMBP2	EpiA_Up
748	205640_at	ALDH3B1	EpiA_Up
749	210861_s_at	WISP3	EpiA_Up
750	221946_at	C9orf116	EpiA_Up
751	201474_s_at	ITGA3	EpiA_Up
752	207624_s_at	RPGR	EpiA_Up
753	208268_at	ADAM28	EpiA_Up
754	208893_s_at	DUSP6	EpiA_Up
755	210021_s_at	CCNO	EpiA_Up
756	205579_at	HRH1	EpiA_Up
757	203074_at	ANXA8 /// ANXA8L1 /// ANXA8L2	EpiA_Up
758	219313_at	GRAMD1C	EpiA_Up
759	220308_at	CCDC19	EpiA_Up
760	219274_at	TSPAN12	EpiA_Up
761	222068_s_at	LRRC50	EpiA_Up
762	202068_s_at	LDLR	EpiA_Up
763	212192_at	KCTD12	EpiA_Up
764	222043_at	CLU	EpiA_Up
765	213056_at	FRMD4B	EpiA_Up
766	221215_s_at	RIPK4	EpiA_Up
767	209627_s_at	OSBPL3	EpiA_Up
768	210323_at	TEKT2	EpiA_Up
769	205997_at	ADAM28	EpiA_Up

**Gene
List 2 -
EpiA**

Index	Probe	Gene	Category
770	220173_at	C14orf45	EpiA_Up
771	36711_at	MAFF	EpiA_Up
772	202827_s_at	MMP14	EpiA_Up
773	203407_at	PPL	EpiA_Up
774	219182_at	FLJ22167	EpiA_Up
775	205714_s_at	ZMYND10	EpiA_Up
776	204446_s_at	ALOX5	EpiA_Up
777	220125_at	DNAI1	EpiA_Up
778	204011_at	SPRY2	EpiA_Up
779	213572_s_at	SERPINB1	EpiA_Up
780	204989_s_at	ITGB4	EpiA_Up
781	208892_s_at	DUSP6	EpiA_Up
782	219580_s_at	TMC5	EpiA_Up
783	206483_at	LRRC6	EpiA_Up
784	208891_at	DUSP6	EpiA_Up
785	204015_s_at	DUSP4	EpiA_Up
786	59437_at	C9orf116	EpiA_Up
787	218035_s_at	RBM47	EpiA_Up
788	211026_s_at	MGLL	EpiA_Up
789	220156_at	EFCAB1	EpiA_Up
790	216663_s_at	ZMYND10	EpiA_Up
791	219115_s_at	IL20RA	EpiA_Up
792	201596_x_at	KRT18	EpiA_Up
793	203585_at	ZNF185	EpiA_Up
794	64900_at	FLJ22167	EpiA_Up
795	205334_at	S100A1	EpiA_Up
796	219866_at	CLIC5	EpiA_Up
797	205680_at	MMP10	EpiA_Up
798	204526_s_at	TBC1D8	EpiA_Up
799	205016_at	TGFA	EpiA_Up
800	205668_at	LY75	EpiA_Up
801	218211_s_at	MLPH	EpiA_Up
802	209386_at	TM4SF1	EpiA_Up
803	205765_at	CYP3A5	EpiA_Up
804	204124_at	SLC34A2	EpiA_Up
805	219857_at	C10orf81	EpiA_Up
806	203661_s_at	TMOD1	EpiA_Up
807	220168_at	CASC1	EpiA_Up
808	209114_at	TSPAN1	EpiA_Up
809	205896_at	SLC22A4	EpiA_Up
810	213285_at	TMEM30B	EpiA_Up

**Gene
List 2 -
EpiA**

Index	Probe	Gene	Category
811	202267_at	LAMC2	EpiA_Up
812	213462_at	NPAS2	EpiA_Up
813	206884_s_at	SCEL	EpiA_Up
814	203662_s_at	TMOD1	EpiA_Up
815	211429_s_at	SERPINA1	EpiA_Up
816	204990_s_at	ITGB4	EpiA_Up
817	212560_at	SORL1	EpiA_Up
818	39549_at	NPAS2	EpiA_Up
819	218966_at	MYO5C	EpiA_Up
820	203726_s_at	LAMA3	EpiA_Up
821	206859_s_at	PAEP	EpiA_Up
822	202504_at	TRIM29	EpiA_Up
823	204014_at	DUSP4	EpiA_Up
824	205597_at	SLC44A4	EpiA_Up
825	204542_at	ST6GALNAC2	EpiA_Up
826	202834_at	AGT	EpiA_Up
827	201012_at	ANXA1	EpiA_Up
828	209292_at	ID4	EpiA_Up
829	218876_at	TPPP3	EpiA_Up
830	221530_s_at	BHLHE41	EpiA_Up
831	208792_s_at	CLU	EpiA_Up
832	206197_at	NME5	EpiA_Up
833	208791_at	CLU	EpiA_Up
834	220269_at	ZBBX	EpiA_Up
835	204591_at	CHL1	EpiA_Up
836	222271_at	---	EpiA_Up
837	213432_at	MUC5B	EpiA_Up
838	219230_at	TMEM100	EpiA_Up
839	213317_at	CLIC5	EpiA_Up
840	212909_at	LYPD1	EpiA_Up
841	219836_at	ZBED2	EpiA_Up
842	220979_s_at	ST6GALNAC5	EpiA_Up
843	209792_s_at	KLK10	EpiA_Up
844	213994_s_at	SPON1	EpiA_Up
845	204733_at	KLK6	EpiA_Up
846	212531_at	LCN2	EpiA_Up
847	218963_s_at	KRT23	EpiA_Up
848	213993_at	SPON1	EpiA_Up
849	205328_at	CLDN10	EpiA_Up
850	220196_at	MUC16	EpiA_Up

Gene
List 2 -
EpiB

Index	Probe	Gene	Category
1	203417_at	MFAP2	EpiB_Dn
2	201505_at	LAMB1	EpiB_Dn
3	202976_s_at	RHOBTB3	EpiB_Dn
4	217996_at	PHLDA1	EpiB_Dn
5	202975_s_at	RHOBTB3	EpiB_Dn
6	211651_s_at	LAMB1	EpiB_Dn
7	217997_at	PHLDA1	EpiB_Dn
8	201939_at	PLK2	EpiB_Dn
9	204011_at	SPRY2	EpiB_Dn
10	212158_at	SDC2	EpiB_Dn
11	204955_at	SRPX	EpiB_Dn
12	202149_at	NEDD9	EpiB_Dn
13	212386_at	TCF4	EpiB_Dn
14	205990_s_at	WNT5A	EpiB_Dn
15	212651_at	RHOBTB1	EpiB_Dn
16	201310_s_at	C5orf13	EpiB_Dn
17	202336_s_at	PAM	EpiB_Dn
18	217897_at	FXVD6	EpiB_Dn
19	208712_at	CCND1	EpiB_Dn
20	208782_at	FSTL1	EpiB_Dn
21	209118_s_at	TUBA1A	EpiB_Dn
22	202007_at	NID1	EpiB_Dn
23	201426_s_at	VIM	EpiB_Dn
24	212233_at	MAP1B	EpiB_Dn
25	212958_x_at	PAM	EpiB_Dn
26	213891_s_at	TCF4	EpiB_Dn
27	210220_at	FZD2	EpiB_Dn
28	203355_s_at	PSD3	EpiB_Dn
29	212382_at	TCF4	EpiB_Dn
30	200907_s_at	PALLD	EpiB_Dn
31	222146_s_at	TCF4	EpiB_Dn
32	200897_s_at	PALLD	EpiB_Dn
33	212558_at	SPRY1	EpiB_Dn
34	212364_at	MYO1B	EpiB_Dn
35	212387_at	TCF4	EpiB_Dn
36	203753_at	TCF4	EpiB_Dn
37	219179_at	DACT1	EpiB_Dn
38	212372_at	MYH10	EpiB_Dn
39	218613_at	PSD3	EpiB_Dn
40	201417_at	SOX4	EpiB_Dn
41	222101_s_at	DCHS1	EpiB_Dn

Gene
List 2 -
EpiB

Index	Probe	Gene	Category
42	214620_x_at	PAM	EpiB_Dn
43	204451_at	FZD1	EpiB_Dn
44	213668_s_at	SOX4	EpiB_Dn
45	218181_s_at	MAP4K4	EpiB_Dn
46	208891_at	DUSP6	EpiB_Dn
47	208711_s_at	CCND1	EpiB_Dn
48	209082_s_at	COL18A1	EpiB_Dn
49	208892_s_at	DUSP6	EpiB_Dn
50	203627_at	IGF1R	EpiB_Dn
51	209288_s_at	CDC42EP3	EpiB_Dn
52	212792_at	DPY19L1	EpiB_Dn
53	203477_at	COL15A1	EpiB_Dn
54	201416_at	SOX4	EpiB_Dn
55	203349_s_at	ETV5	EpiB_Dn
56	214953_s_at	APP	EpiB_Dn
57	222258_s_at	SH3BP4	EpiB_Dn
58	221489_s_at	SPRY4	EpiB_Dn
59	200602_at	APP	EpiB_Dn
60	209081_s_at	COL18A1	EpiB_Dn
61	200771_at	LAMC1 PCDHGA1 /// PCDHGA10 /// PCDHGA11 /// PCDHGA12 /// PCDHGA2 /// PCDHGA3 /// PCDHGA4 /// PCDHGA5 /// PCDHGA6 /// PCDHGA7 /// PCDHGA8 /// PCDHGA9 /// PCDHGB1 /// PCDHGB2 /// PCDHGB3 /// PCDHGB4 /// PCDHGB5 /// PCDHGB6 /// PCDHGB7 /// PCDHGC3 /// PCDHGC4 /// PCDHGC5	EpiB_Dn
62	211066_x_at	CHSY1	EpiB_Dn
63	203044_at	ZNF167	EpiB_Dn
64	206314_at	GPRASP1	EpiB_Dn
65	204793_at	---	EpiB_Dn
66	212812_at	PCDHGA1 /// PCDHGA10 /// PCDHGA11 /// PCDHGA12 /// PCDHGA2 /// PCDHGA3 /// PCDHGA4 /// PCDHGA5 /// PCDHGA6 /// PCDHGA7 /// PCDHGA8 /// PCDHGA9 /// PCDHGB1 /// PCDHGB2 /// PCDHGB3 /// PCDHGB4 /// PCDHGB5 /// PCDHGB6 /// PCDHGB7 /// PCDHGC3 /// PCDHGC4 /// PCDHGC5	EpiB_Dn
67	215836_s_at	CDC42EP3	EpiB_Dn
68	209286_at	ABL1	EpiB_Dn
69	202123_s_at	C4orf31	EpiB_Dn
70	219747_at	HES1	EpiB_Dn
71	203394_s_at	PKD2	EpiB_Dn
72	203688_at		

Gene
List 2 -
EpiB

Index	Probe	Gene	Category
		PCDHGA1 /// PCDHGA10 /// PCDHGA11 /// PCDHGA12 /// PCDHGA2 /// PCDHGA3 /// PCDHGA4 /// PCDHGA5 /// PCDHGA6 /// PCDHGA7 /// PCDHGA8 /// PCDHGA9 /// PCDHGB1 /// PCDHGB2 /// PCDHGB3 /// PCDHGB4 /// PCDHGB5 /// PCDHGB6 /// PCDHGB7 /// PCDHGC3 /// PCDHGC4 /// PCDHGC5	
73	209079_x_at		EpiB_Dn
74	212842_x_at	RGPD4 /// RGPD5 /// RGPD6 /// RGPD8	EpiB_Dn
75	212071_s_at	SPTBN1	EpiB_Dn
76	201307_at		EpiB_Dn
77	202457_s_at	PPP3CA	EpiB_Dn
78	203763_at	DYNC2LI1	EpiB_Dn
79	219631_at	LRP12	EpiB_Dn
		PCDHGA1 /// PCDHGA10 /// PCDHGA11 /// PCDHGA12 /// PCDHGA2 /// PCDHGA3 /// PCDHGA4 /// PCDHGA5 /// PCDHGA6 /// PCDHGA7 /// PCDHGA8 /// PCDHGA9 /// PCDHGB1 /// PCDHGB2 /// PCDHGB3 /// PCDHGB4 /// PCDHGB5 /// PCDHGB6 /// PCDHGB7 /// PCDHGC3 /// PCDHGC4 /// PCDHGC5	
80	205717_x_at		EpiB_Dn
81	214629_x_at	RTN4	EpiB_Dn
82	211509_s_at	RTN4	EpiB_Dn
83	221542_s_at	ERLIN2	EpiB_Dn
84	202084_s_at	SEC14L1	EpiB_Dn
85	200603_at	PRKAR1A	EpiB_Dn
86	201375_s_at	PPP2CB	EpiB_Dn
87	213278_at	MTMR9	EpiB_Dn
88	213626_at	CBR4	EpiB_Dn
89	219432_at	EVC	EpiB_Dn
90	200847_s_at	TMEM66	EpiB_Dn
91	203097_s_at	RAPGEF2	EpiB_Dn
92	208669_s_at	EID1	EpiB_Dn
93	211698_at	EID1	EpiB_Dn
94	208030_s_at	ADD1	EpiB_Dn
95	41220_at		EpiB_Dn
96	203343_at	UGDH	EpiB_Dn
97	200595_s_at	EIF3A	EpiB_Dn
98	216727_at	STK38	EpiB_Up
99	214634_at	HIST1H4B	EpiB_Up
100	219893_at	CCDC71	EpiB_Up
101	210557_x_at	CSF1	EpiB_Up
102	215579_at	APOBEC3G	EpiB_Up
103	209587_at	PITX1	EpiB_Up

Gene
List 2 -
EpiB

Index	Probe	Gene	Category
104	220033_at	---	EpiB_Up
105	204789_at	FMNL1	EpiB_Up
106	204514_at	DPH2	EpiB_Up
107	216583_x_at	NHP2	EpiB_Up
108	207727_s_at	MUTYH	EpiB_Up
109	214084_x_at	LOC648998	EpiB_Up
110	213297_at	RMND5B	EpiB_Up
111	209477_at	EMD	EpiB_Up
112	211920_at	CFB	EpiB_Up
113	219690_at	TMEM149	EpiB_Up
114	218539_at	FBXO34	EpiB_Up
115	221600_s_at	C11orf67	EpiB_Up
116	221680_s_at	ETV7	EpiB_Up
117	213127_s_at	MED8	EpiB_Up
118	218080_x_at	FAF1	EpiB_Up
119	202849_x_at	GRK6	EpiB_Up
120	201678_s_at	C3orf37	EpiB_Up
121	218488_at	EIF2B3	EpiB_Up
122	202883_s_at	PPP2R1B	EpiB_Up
123	215633_x_at	LST1	EpiB_Up
124	213735_s_at	COX5B	EpiB_Up
125	217329_x_at	---	EpiB_Up
126	207485_x_at	BTN3A1	EpiB_Up
127	210212_x_at	MTCP1NB	EpiB_Up
128	216862_s_at	MTCP1NB	EpiB_Up
129	211025_x_at	COX5B	EpiB_Up
130	203805_s_at	FANCA	EpiB_Up
131	204922_at	C11orf80	EpiB_Up
132	202855_s_at	SLC16A3	EpiB_Up
133	209770_at	BTN3A1	EpiB_Up
134	211063_s_at	NCK1	EpiB_Up
135	219275_at	PDCD5	EpiB_Up
136	205671_s_at	HLA-DOB	EpiB_Up
137	203960_s_at	HSPB11	EpiB_Up
138	213539_at	CD3D	EpiB_Up
139	208502_s_at	PITX1	EpiB_Up
140	205317_s_at	SLC15A2	EpiB_Up
141	202110_at	COX7B	EpiB_Up
142	209716_at	CSF1	EpiB_Up
143	57163_at	ELOVL1	EpiB_Up
144	208967_s_at	AK2	EpiB_Up

**Gene
List 2 -
EpiB**

Index	Probe	Gene	Category
145	201625_s_at	INSIG1	EpiB_Up
146	1294_at	UBA7	EpiB_Up
147	208012_x_at	SP110	EpiB_Up
148	218028_at	ELOVL1	EpiB_Up
149	220094_s_at	CCDC90A	EpiB_Up
150	200814_at	PSME1	EpiB_Up
151	202864_s_at	SP100	EpiB_Up
152	212174_at	AK2	EpiB_Up
153	203689_s_at	FMR1	EpiB_Up
154	202074_s_at	OPTN	EpiB_Up
155	205101_at	CHTA	EpiB_Up
156	219566_at	PLEKHF1	EpiB_Up
157	201587_s_at	IRAK1	EpiB_Up
158	204820_s_at	BTN3A2 /// BTN3A3	EpiB_Up
159	218746_at	TAPBPL	EpiB_Up
160	219593_at	SLC15A3	EpiB_Up
161	201762_s_at	PSME2	EpiB_Up
162	208829_at	TAPBP	EpiB_Up
163	211671_s_at	NR3C1	EpiB_Up
164	221978_at	HLA-F	EpiB_Up
165	221087_s_at	APOL3	EpiB_Up
166	219132_at	PELI2	EpiB_Up
167	200629_at	WARS	EpiB_Up
168	206011_at	CASP1	EpiB_Up
169	211367_s_at	CASP1	EpiB_Up
170	202481_at	DHRS3	EpiB_Up
171	204821_at	BTN3A3	EpiB_Up
172	205316_at	SLC15A2	EpiB_Up
173	205379_at	CBR3	EpiB_Up
174	214058_at	MYCL1	EpiB_Up
175	218747_s_at	TAPBPL	EpiB_Up
176	204769_s_at	TAP2	EpiB_Up
177	218543_s_at	PARP12	EpiB_Up
178	209970_x_at	CASP1	EpiB_Up
179	211366_x_at	CASP1	EpiB_Up
180	202446_s_at	PLSCR1	EpiB_Up
181	202659_at	PSMB10	EpiB_Up
182	208296_x_at	TNFAIP8	EpiB_Up
183	206247_at	MICB	EpiB_Up
184	201649_at	UBE2L6	EpiB_Up
185	213523_at	CCNE1	EpiB_Up

**Gene
List 2 -
EpiB**

Index	Probe	Gene	Category
186	202531_at	IRF1	EpiB_Up
187	211368_s_at	CASP1	EpiB_Up
188	200862_at	DHCR24	EpiB_Up
189	209969_s_at	STAT1	EpiB_Up
190	209040_s_at	PSMB8	EpiB_Up
191	202307_s_at	TAP1	EpiB_Up
192	202270_at	GBP1	EpiB_Up
193	209644_x_at	CDKN2A	EpiB_Up
194	219684_at	RTP4	EpiB_Up
195	202269_x_at	GBP1	EpiB_Up
196	202357_s_at	C2 /// CFB	EpiB_Up
197	207039_at	CDKN2A	EpiB_Up
198	204279_at	PSMB9	EpiB_Up
199	204070_at	RARRES3	EpiB_Up
200	204533_at	CXCL10	EpiB_Up

**Gene
List 2 -
Mes**

Index	Probe	Gene Symbol	Category
1	203325_s_at	COL5A1	Mes_Up
2	213125_at	OLFML2B	Mes_Up
3	212489_at	COL5A1	Mes_Up
4	212488_at	COL5A1	Mes_Up
5	209365_s_at	ECM1	Mes_Up
6	202952_s_at	ADAM12	Mes_Up
7	221541_at	CRISPLD2	Mes_Up
8	221729_at	COL5A2	Mes_Up
9	221019_s_at	COLEC12	Mes_Up
10	203876_s_at	MMP11	Mes_Up
11	221730_at	COL5A2	Mes_Up
12	205479_s_at	PLAU	Mes_Up
13	203878_s_at	MMP11	Mes_Up
14	203083_at	THBS2	Mes_Up
15	210511_s_at	INHBA	Mes_Up
16	209955_s_at	FAP	Mes_Up
17	213909_at	LRRC15	Mes_Up
18	202450_s_at	CTSK	Mes_Up
19	205941_s_at	COL10A1	Mes_Up
20	218468_s_at	GREM1	Mes_Up
21	217428_s_at	COL10A1	Mes_Up
22	218469_at	GREM1	Mes_Up
23	210809_s_at	POSTN	Mes_Up
24	204320_at	COL11A1	Mes_Up
25	37892_at	COL11A1	Mes_Up

Gene
List 2 -
StemA

Index	Probe	Gene Symbol	Category
1	202237_at	NNMT	StemA_Dn
2	219630_at	PDZK1IP1	StemA_Dn
3	217478_s_at	HLA-DMA	StemA_Dn
4	209619_at	CD74	StemA_Dn
5	202804_at	ABCC1	StemA_Dn
6	217995_at	SQRDL	StemA_Dn
7	202748_at	GBP2	StemA_Dn
8	202659_at	PSMB10	StemA_Dn
9	214211_at	FTH1	StemA_Dn
10	202180_s_at	MVP	StemA_Dn
11	200904_at	HLA-E	StemA_Dn
12	203281_s_at	UBA7	StemA_Dn
13	219319_at	HIF3A	StemA_Up
14	218457_s_at	DNMT3A	StemA_Up
15	205741_s_at	DTNA	StemA_Up
16	204612_at	PKIA	StemA_Up
17	205123_s_at	TMEFF1	StemA_Up
18	213283_s_at	SALL2	StemA_Up
19	221016_s_at	TCF7L1	StemA_Up
20	209757_s_at	MYCN	StemA_Up
21	204915_s_at	SOX11	StemA_Up
22	205122_at	TMEFF1	StemA_Up
23	205347_s_at	TMSB15A	StemA_Up
24	204914_s_at	SOX11	StemA_Up
25	204913_s_at	SOX11	StemA_Up

Gene
List 2 -
StemB

Index	Probe	Gene	Category
1	221950_at	EMX2	StemB_Dn
2	213317_at	CLIC5	StemB_Dn
3	202207_at	ARL4C	StemB_Dn
4	212909_at	LYPD1	StemB_Dn
5	219836_at	ZBED2	StemB_Dn
6	202206_at	ARL4C	StemB_Dn
7	204069_at	MEIS1	StemB_Dn
8	220979_s_at	ST6GALNAC5	StemB_Dn
9	204733_at	KLK6	StemB_Dn
10	219866_at	CLIC5	StemB_Dn
11	204885_s_at	MSLN	StemB_Dn
12	202524_s_at	SPOCK2	StemB_Dn
13	202208_s_at	ARL4C	StemB_Dn
14	40093_at	BCAM	StemB_Dn
15	208978_at	CRIP2	StemB_Dn
16	204783_at	MLF1	StemB_Dn
17	213201_s_at	TNNT1	StemB_Dn
18	206067_s_at	WT1	StemB_Dn
19	201324_at	EMP1	StemB_Dn
20	212148_at	PBX1	StemB_Dn
21	203009_at	BCAM	StemB_Dn
22	205334_at	S100A1	StemB_Dn
23	201325_s_at	EMP1	StemB_Dn
24	203632_s_at	GPRC5B	StemB_Dn
25	204784_s_at	MLF1	StemB_Dn
26	219416_at	SCARA3	StemB_Dn
27	209437_s_at	SPON1	StemB_Dn
28	205227_at	IL1RAP	StemB_Dn
29	201998_at	ST6GAL1	StemB_Dn
30	209436_at	SPON1	StemB_Dn
31	216953_s_at	WT1	StemB_Dn
32	213993_at	SPON1	StemB_Dn
33	218176_at	MAGEF1	StemB_Dn
34	203661_s_at	TMOD1	StemB_Dn
35	203662_s_at	TMOD1	StemB_Dn
36	213994_s_at	SPON1	StemB_Dn
37	209596_at	MXRA5	StemB_Dn
38	205778_at	KLK7	StemB_Dn
39	220274_at	IQCA1	StemB_Dn

Gene
List 2 -
StemB

Index	Probe	Gene	Category
40	213135_at	TIAM1	StemB_Dn
41	213518_at	PRKCI	StemB_Dn
42	215716_s_at	ATP2B1	StemB_Dn
43	221530_s_at	BHLHE41	StemB_Dn
44	219229_at	SLCO3A1	StemB_Dn
45	204457_s_at	GAS1	StemB_Dn
46	210115_at	RPL39L	StemB_Dn
47	204369_at	PIK3CA	StemB_Dn
48	209899_s_at	PUF60	StemB_Dn
49	212430_at	RBM38	StemB_Dn
50	213669_at	FCHO1	StemB_Dn
51	203853_s_at	GAB2	StemB_Dn
52	205481_at	ADORA1	StemB_Dn
53	207076_s_at	ASS1	StemB_Dn
54	215108_x_at	TOX3	StemB_Dn
55	215813_s_at	PTGS1	StemB_Dn
56	212816_s_at	CBS	StemB_Dn
57	206125_s_at	KLK8	StemB_Dn
58	216623_x_at	TOX3	StemB_Dn
59	205128_x_at	PTGS1	StemB_Dn
60	209195_s_at	ADCY6	StemB_Dn
61	213698_at	ZMYM6	StemB_Up
62	214771_x_at	MPRIIP	StemB_Up
63	213913_s_at	TBC1D30	StemB_Up
64	211885_x_at	FUT6	StemB_Up
65	212197_x_at	MPRIIP	StemB_Up
66	45526_g_at	NAT15	StemB_Up
67	204633_s_at	RPS6KA5	StemB_Up
68	206043_s_at	ATP2C2	StemB_Up
69	201128_s_at	ACLY	StemB_Up
70	216518_at	---	StemB_Up
71	221173_at	USH1C	StemB_Up
72	213358_at	KIAA0802	StemB_Up
73	205042_at	GNE	StemB_Up
74	212383_at	ATP6V0A1	StemB_Up
75	213143_at	C2orf72	StemB_Up
76	205137_x_at	USH1C	StemB_Up
77	221636_s_at	MOSC2	StemB_Up
78	205848_at	GAS2	StemB_Up
79	219570_at	KIF16B	StemB_Up
80	214307_at	HGD	StemB_Up

Gene
List 2 -
StemB

Index	Probe	Gene	Category
81	212071_s_at	SPTBN1	StemB_Up
82	205857_at	SLC18A2	StemB_Up
83	204394_at	SLC43A1	StemB_Up
84	202211_at	ARFGAP3	StemB_Up
85	211889_x_at	CEACAM1	StemB_Up
86	213744_at	ATRNL1	StemB_Up
87	214308_s_at	HGD	StemB_Up
88	209426_s_at	AMACR /// C1QTNF3	StemB_Up
89	211184_s_at	USH1C	StemB_Up
90	205776_at	FMO5	StemB_Up
91	209395_at	CHI3L1	StemB_Up
92	219405_at	TRIM68	StemB_Up
93	209396_s_at	CHI3L1	StemB_Up
94	213707_s_at	DLX5	StemB_Up
95	213324_at	SRC	StemB_Up
96	208096_s_at	COL21A1	StemB_Up
97	206245_s_at	IVNS1ABP	StemB_Up
98	203343_at	UGDH	StemB_Up
99	214825_at	FAM155A	StemB_Up
100	218763_at	STX18	StemB_Up
101	202851_at	FLJ11506	StemB_Up
102	206286_s_at	TDGF1 /// TDGF3	StemB_Up
103	204389_at	MAOA	StemB_Up
104	205278_at	GAD1	StemB_Up
105	202699_s_at	TMEM63A	StemB_Up
106	208209_s_at	C4BPB	StemB_Up
107	211883_x_at	CEACAM1	StemB_Up
108	206576_s_at	CEACAM1	StemB_Up
109	204388_s_at	MAOA	StemB_Up
110	205771_s_at	AKAP7	StemB_Up
111	207357_s_at	GALNT10	StemB_Up
112	219142_at	RASL11B	StemB_Up
113	215447_at	TFPI	StemB_Up
114	215983_s_at	UBXN8	StemB_Up
115	205513_at	TCN1	StemB_Up
116	206204_at	GRB14	StemB_Up
117	206756_at	CHST7	StemB_Up
118	213036_x_at	ATP2A3	StemB_Up
119	205221_at	HGD	StemB_Up
120	202908_at	WFS1	StemB_Up
121	202786_at	STK39	StemB_Up

**Gene
List 2 -
StemB**

Index	Probe	Gene	Category
122	204687_at	DKFZP564O0823	StemB_Up
123	219478_at	WFDC1	StemB_Up
124	203467_at	PMM1	StemB_Up
125	204818_at	HSD17B2	StemB_Up
126	203059_s_at	PAPSS2	StemB_Up
127	204793_at	GPRASP1	StemB_Up
128	212096_s_at	MTUS1	StemB_Up
129	203303_at	DYNLT3	StemB_Up
130	219747_at	C4orf31	StemB_Up
131	209498_at	CEACAM1	StemB_Up
132	211657_at	CEACAM6	StemB_Up
133	213745_at	ATRNL1	StemB_Up
134	209847_at	CDH17	StemB_Up
135	203757_s_at	CEACAM6. UGT1A1 /// UGT1A10 /// UGT1A3 /// UGT1A4 /// UGT1A5 /// UGT1A6 /// UGT1A7 /// UGT1A8 ///	StemB_Up
136	208596_s_at	UGT1A9	StemB_Up
137	204579_at	FGFR4	StemB_Up
138	205894_at	ARSE	StemB_Up
139	209892_at	FUT4	StemB_Up
140	205141_at	ANG	StemB_Up
141	207414_s_at	PCSK6	StemB_Up
142	201819_at	SCARB1	StemB_Up
143	202742_s_at	PRKACB	StemB_Up
144	213059_at	CREB3L1	StemB_Up
145	204272_at	LGALS4	StemB_Up
146	209513_s_at	HSDL2	StemB_Up
147	205799_s_at	SLC3A1	StemB_Up
148	205158_at	RNASE4	StemB_Up
149	219263_at	RNF128	StemB_Up
150	205517_at	GATA4	StemB_Up
151	208510_s_at	PPARG	StemB_Up
152	202741_at	PRKACB	StemB_Up
153	212741_at	MAOA	StemB_Up
154	209890_at	TSPAN5	StemB_Up
155	202975_s_at	RHOBTB3	StemB_Up
156	201809_s_at	ENG	StemB_Up
157	213397_x_at	RNASE4	StemB_Up
158	220102_at	FOXL2	StemB_Up
159	211651_s_at	LAMB1	StemB_Up
160	219179_at	DACT1	StemB_Up

**Gene
List 2 -
StemB**

Index	Probe	Gene	Category
161	204304_s_at	PROM1	StemB_Up
162	210664_s_at	TFPI	StemB_Up
163	206167_s_at	ARHGAP6	StemB_Up
164	201505_at	LAMB1	StemB_Up
165	203058_s_at	PAPSS2	StemB_Up
166	204548_at	STAR	StemB_Up
167	204931_at	TCF21	StemB_Up
168	205466_s_at	HS3ST1	StemB_Up
169	212224_at	ALDH1A1	StemB_Up
170	204351_at	S100P	StemB_Up
171	202609_at	EPS8	StemB_Up
172	209243_s_at	PEG3 /// ZIM2	StemB_Up
173	203060_s_at	PAPSS2	StemB_Up
174	204719_at	ABCA8	StemB_Up
175	203824_at	TSPAN8	StemB_Up

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
201130_s_at	CDH1	Epithelial
201131_s_at	CDH1	Epithelial
201650_at	KRT19	Epithelial
202005_at	ST14	Epithelial
202890_at	MAP7	Epithelial
203256_at	CDH3	Epithelial
203287_at	LAD1	Epithelial
204503_at	EVPL	Epithelial
205490_x_at	GJB3	Epithelial
205709_s_at	CDS1	Epithelial
209873_s_at	PKP3	Epithelial
210715_s_at	SPINT2	Epithelial
211778_s_at	OVOL2	Epithelial
215243_s_at	GJB3	Epithelial
216641_s_at	LAD1	Epithelial
216905_s_at	ST14	Epithelial
218792_s_at	BSPRY	Epithelial
219121_s_at	ESRP1	Epithelial
219388_at	GRHL2	Epithelial
219395_at	ESRP2	Epithelial
201839_s_at	EPCAM	Epithelial
202826_at	SPINT1	Epithelial
206043_s_at	ATP2C2	Epithelial
209872_s_at	PKP3	Epithelial
219850_s_at	EHF	Epithelial
203726_s_at	LAMA3	Epithelial
90265_at	ADAP1	Epithelial
206884_s_at	SCEL	Epithelial
202489_s_at	FXYP3	Epithelial
212543_at	AIM1	Epithelial
212925_at	C19orf21	Epithelial
201428_at	CLDN4	Epithelial
204740_at	CNKSR1	Epithelial
205016_at	TGFA	Epithelial
220638_s_at	CBLC	Epithelial
210827_s_at	ELF3	Epithelial
218966_at	MYO5C	Epithelial
219150_s_at	ADAP1	Epithelial
208190_s_at	LSR	Epithelial
203407_at	PPL	Epithelial
209163_at	CYB561	Epithelial
203713_s_at	LLGL2	Epithelial
204989_s_at	ITGB4	Epithelial

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
200752_s_at	CAPN1	Epithelial
201778_s_at	KIAA0494	Epithelial
208083_s_at	ITGB6	Epithelial
31846_at	RHOD	Epithelial
91826_at	EPS8L1	Epithelial
201015_s_at	JUP	Epithelial
204733_at	KLK6	Epithelial
213307_at	SHANK2	Epithelial
219856_at	C1orf116	Epithelial
202525_at	PRSS8	Epithelial
221215_s_at	RIPK4	Epithelial
202889_x_at	MAP7	Epithelial
207291_at	PRRG4	Epithelial
209114_at	TSPAN1	Epithelial
215471_s_at	MAP7	Epithelial
218779_x_at	EPS8L1	Epithelial
219476_at	C1orf116	Epithelial
219513_s_at	SH2D3A	Epithelial
202790_at	CLDN7	Epithelial
204765_at	ARHGEF5	Epithelial
205014_at	EGFEBP1	Epithelial
218960_at	TMPRSS4	Epithelial
203953_s_at	CLDN3	Epithelial
210761_s_at	GRB7	Epithelial
212531_at	LCN2	Epithelial
218186_at	RAB25	Epithelial
203954_x_at	CLDN3	Epithelial
214734_at	EXPH5	Epithelial
218677_at	S100A14	Epithelial
204990_s_at	ITGB4	Epithelial
206683_at	ZNF165	Epithelial
201510_at	ELF3	Epithelial
202454_s_at	ERBB3	Epithelial
205015_s_at	TGFA	Epithelial
205466_s_at	HS3ST1	Epithelial
205780_at	BIK	Epithelial
213308_at	SHANK2	Epithelial
221665_s_at	EPS8L1	Epithelial
209164_s_at	CYB561	Epithelial
219241_x_at	SSH3	Epithelial
33323_r_at	SFN	Epithelial
51192_at	SSH3	Epithelial
205455_at	MST1R	Epithelial
214493_s_at	INADL	Epithelial

**Gene List 3. EMT-signature genes in
cultured cell lines**

Probe	Gene Symbol	Category
220144_s_at	ANKRD5	Epithelial
202286_s_at	TACSTD2	Epithelial
213929_at	EXPH5	Epithelial
209260_at	SFN	Epithelial
214798_at	ATP2C2	Epithelial
217939_s_at	AFTPH	Epithelial
209008_x_at	KRT8	Epithelial
209885_at	RHOD	Epithelial
33322_i_at	SFN	Epithelial
208084_at	ITGB6	Epithelial
209792_s_at	KLK10	Epithelial
207540_s_at	SYK	Epithelial
217681_at	WNT7B	Epithelial
219919_s_at	SSH3	Epithelial
202358_s_at	SNX19	Epithelial
211905_s_at	ITGB4	Epithelial
202546_at	VAMP8	Epithelial
208779_x_at	DDR1	Epithelial
210136_at	MBP	Epithelial
1007_s_at	DDR1	Epithelial
203005_at	LTBR	Epithelial
204014_at	DUSP4	Epithelial
207169_x_at	DDR1	Epithelial
211258_s_at	TGFA	Epithelial
209173_at	AGR2	Epithelial
210749_x_at	DDR1	Epithelial
219936_s_at	GPR87	Epithelial
221655_x_at	EPS8L1	Epithelial
201596_x_at	KRT18	Epithelial
211661_x_at	PTAFR	Epithelial
214705_at	INADL	Epithelial
217200_x_at	CYB561	Epithelial
218309_at	CAMK2N1	Epithelial
203397_s_at	GALNT3	Epithelial
214355_x_at	CTAGE4	Epithelial
207986_x_at	CYB561	Epithelial
221081_s_at	DENND2D	Epithelial
203453_at	SCNN1A	Epithelial
209211_at	KLF5	Epithelial
215549_x_at	CTAGE4	Epithelial
205847_at	PRSS22	Epithelial
209369_at	ANXA3	Epithelial
213618_at	ARAP2	Epithelial
219648_at	MREG	Epithelial

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
202295_s_at	CTSH	Epithelial
212657_s_at	IL1RN	Epithelial
202688_at	TNFSF10	Epithelial
205617_at	PRRG2	Epithelial
207717_s_at	PKP2	Epithelial
210058_at	MAPK13	Epithelial
203535_at	S100A9	Epithelial
218693_at	TSPAN15	Epithelial
201079_at	SYNGR2	Epithelial
202687_s_at	TNFSF10	Epithelial
203110_at	PTK2B	Epithelial
209502_s_at	BAIAP2	Epithelial
201776_s_at	KIAA0494	Epithelial
209016_s_at	KRT7	Epithelial
203317_at	PSD4	Epithelial
204019_s_at	SH3YL1	Epithelial
205977_s_at	EPHA1	Epithelial
206200_s_at	ANXA11	Epithelial
208862_s_at	CTNND1	Epithelial
215729_s_at	VGLL1	Epithelial
218180_s_at	EPS8L2	Epithelial
204015_s_at	DUSP4	Epithelial
208407_s_at	CTNND1	Epithelial
219058_x_at	TINAGL1	Epithelial
35148_at	TJP3	Epithelial
202597_at	IRF6	Epithelial
203216_s_at	MYO6	Epithelial
205239_at	AREG	Epithelial
221664_s_at	F11R	Epithelial
203108_at	GPRC5A	Epithelial
204856_at	B3GNT3	Epithelial
209269_s_at	SYK	Epithelial
215923_s_at	PSD4	Epithelial
216568_x_at	---	Epithelial
218035_s_at	RBM47	Epithelial
218928_s_at	SLC37A1	Epithelial
211599_x_at	MET	Epithelial
212444_at	---	Epithelial
220030_at	STYK1	Epithelial
201531_at	ZFP36	Epithelial
204505_s_at	EPB49	Epithelial
205032_at	ITGA2	Epithelial
209212_s_at	KLF5	Epithelial
216243_s_at	IL1RN	Epithelial

**Gene List 3. EMT-signature genes in
cultured cell lines**

Probe	Gene Symbol	Category
201775_s_at	KIAA0494	Epithelial
213085_s_at	WWC1	Epithelial
204855_at	SERPINB5	Epithelial
205074_at	SLC22A5	Epithelial
206109_at	FUT1	Epithelial
209529_at	PPAP2C	Epithelial
218849_s_at	PPP1R13L	Epithelial
200660_at	S100A11	Epithelial
218780_at	HOOK2	Epithelial
211240_x_at	CTNND1	Epithelial
214329_x_at	TNFSF10	Epithelial
203510_at	MET	Epithelial
204679_at	KCNK1	Epithelial
208650_s_at	CD24	Epithelial
213807_x_at	MET	Epithelial
220945_x_at	MANSC1	Epithelial
204363_at	F3	Epithelial
204678_s_at	KCNK1	Epithelial
206595_at	CST6	Epithelial
209772_s_at	CD24	Epithelial
210059_s_at	MAPK13	Epithelial
200872_at	S100A10	Epithelial
205980_s_at	ARHGAP8	Epithelial
266_s_at	CD24	Epithelial
200804_at	TMBIM6	Epithelial
204341_at	TRIM16	Epithelial
206295_at	IL18	Epithelial
209126_x_at	KRT6B	Epithelial
221696_s_at	STYK1	Epithelial
202071_at	SDC4	Epithelial
208540_x_at	S100A11	Epithelial
208949_s_at	LGALS3	Epithelial
202267_at	LAMC2	Epithelial
203918_at	PCDH1	Epithelial
208651_x_at	CD24	Epithelial
209771_x_at	CD24	Epithelial
214783_s_at	ANXA11	Epithelial
202720_at	TES	Epithelial
208009_s_at	ARHGEF16	Epithelial
214088_s_at	FUT3	Epithelial
216074_x_at	WWC1	Epithelial
216379_x_at	CD24	Epithelial
219976_at	HOOK1	Epithelial
220318_at	EPN3	Epithelial

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
219696_at	DENND1B	Epithelial
203780_at	MPZL2	Epithelial
218931_at	RAB17	Epithelial
38766_at	SRCAP	Epithelial
201005_at	CD9	Epithelial
206125_s_at	KLK8	Epithelial
209190_s_at	DIAPH1	Epithelial
209222_s_at	OSBPL2	Epithelial
213667_at	SRCAP	Epithelial
219215_s_at	SLC39A4	Epithelial
37117_at	ARHGAP8	Epithelial
200606_at	DSP	Epithelial
217109_at	MUC4	Epithelial
217149_x_at	TNK1	Epithelial
218019_s_at	PDXK	Epithelial
221610_s_at	STAP2	Epithelial
210816_s_at	CYB561	Epithelial
212338_at	MYO1D	Epithelial
217744_s_at	PERP	Epithelial
202719_s_at	TES	Epithelial
204927_at	RASSF7	Epithelial
207525_s_at	GIPC1	Epithelial
208890_s_at	PLXNB2	Epithelial
210314_x_at	TNFSF13	Epithelial
221927_s_at	ABHD11	Epithelial
219858_s_at	MFSD6	Epithelial
40359_at	RASSF7	Epithelial
201242_s_at	ATP1B1	Epithelial
207549_x_at	CD46	Epithelial
208783_s_at	CD46	Epithelial
219411_at	ELMO3	Epithelial
219450_at	C4orf19	Epithelial
204254_s_at	VDR	Epithelial
213412_at	TJP3	Epithelial
204952_at	LYPD3	Epithelial
222333_at	ALS2CL	Epithelial
212242_at	TUBA4A	Epithelial
217730_at	TMBIM1	Epithelial
218942_at	PIP4K2C	Epithelial
222354_at	F11R	Epithelial
201188_s_at	ITPR3	Epithelial
202481_at	DHRS3	Epithelial
210085_s_at	ANXA9	Epithelial
219127_at	ATAD4	Epithelial

**Gene List 3. EMT-signature genes in
cultured cell lines**

Probe	Gene Symbol	Category
201189_s_at	ITPR3	Epithelial
217875_s_at	PMEPA1	Epithelial
217979_at	TSPAN13	Epithelial
204328_at	TMC6	Epithelial
206414_s_at	ASAP2	Epithelial
211574_s_at	CD46	Epithelial
217110_s_at	MUC4	Epithelial
219946_x_at	MYH14	Epithelial
221841_s_at	KLF4	Epithelial
203180_at	ALDH1A3	Epithelial
210480_s_at	MYO6	Epithelial
211712_s_at	ANXA9	Epithelial
202704_at	TOBI	Epithelial
203779_s_at	MPZL2	Epithelial
204734_at	KRT15	Epithelial
205258_at	INHBB	Epithelial
211004_s_at	ALDH3B1	Epithelial
202820_at	AHR	Epithelial
203028_s_at	CYBA	Epithelial
209221_s_at	OSBPL2	Epithelial
209499_x_at	TNFSF12	Epithelial
202149_at	NEDD9	Epithelial
202510_s_at	TNFAIP2	Epithelial
205403_at	IL1R2	Epithelial
206831_s_at	ARSD	Epithelial
200878_at	EPAS1	Epithelial
206687_s_at	PTPN6	Epithelial
210117_at	SPAG1	Epithelial
210150_s_at	LAMA5	Epithelial
213050_at	COBL	Epithelial
214154_s_at	PKP2	Epithelial
219916_s_at	RNF39	Epithelial
202150_s_at	NEDD9	Epithelial
216918_s_at	DST	Epithelial
221666_s_at	PYCARD	Epithelial
202359_s_at	SNX19	Epithelial
204455_at	DST	Epithelial
207935_s_at	KRT13	Epithelial
212255_s_at	ATP2C1	Epithelial
218261_at	AP1M2	Epithelial
205487_s_at	VGLL1	Epithelial
205640_at	ALDH3B1	Epithelial
212312_at	BCL2L1	Epithelial
206048_at	OVOL2	Epithelial

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
218066_at	SLC12A7	Epithelial
203143_s_at	KIAA0040	Epithelial
204446_s_at	ALOX5	Epithelial
208156_x_at	EPPK1	Epithelial
208510_s_at	PPARG	Epithelial
219836_at	ZBED2	Epithelial
220196_at	MUC16	Epithelial
65517_at	AP1M2	Epithelial
207992_s_at	AMPD3	Epithelial
201243_s_at	ATP1B1	Epithelial
205469_s_at	IRF5	Epithelial
201328_at	ETS2	Epithelial
201329_s_at	ETS2	Epithelial
203215_s_at	MYO6	Epithelial
205293_x_at	BAIAP2	Epithelial
217901_at	DSG2	Epithelial
207178_s_at	FRK	Epithelial
208078_s_at	SIK1	Epithelial
212339_at	EPB41L1	Epithelial
202699_s_at	TMEM63A	Epithelial
209270_at	LAMB3	Epithelial
202023_at	EFNA1	Epithelial
202531_at	IRF1	Epithelial
203072_at	MYO1E	Epithelial
204168_at	MGST2	Epithelial
219010_at	C1orf106	Epithelial
220056_at	IL22RA1	Epithelial
209500_x_at	TNFSF12	Epithelial
210237_at	ARTN	Epithelial
211372_s_at	IL1R2	Epithelial
213816_s_at	MET	Epithelial
201474_s_at	ITGA3	Epithelial
202085_at	TJP2	Epithelial
208161_s_at	ABCC3	Epithelial
219622_at	RAB20	Epithelial
205465_x_at	HS3ST1	Epithelial
205668_at	LY75	Epithelial
213076_at	ITPKC	Epithelial
202504_at	TRIM29	Epithelial
220907_at	GPR110	Epithelial
203038_at	PTPRK	Epithelial
203236_s_at	LGALS9	Epithelial
204255_s_at	VDR	Epithelial
204542_at	ST6GALNAC2	Epithelial

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
220266_s_at	KLF4	Epithelial
204681_s_at	RAPGEF5	Epithelial
206277_at	P2RY2	Epithelial
202430_s_at	PLSCR1	Epithelial
202833_s_at	SERPINA1	Epithelial
203021_at	SLPI	Epithelial
206482_at	PTK6	Epithelial
216581_at	---	Epithelial
220149_at	C2orf54	Epithelial
220998_s_at	UNC93B1	Epithelial
200666_s_at	DNAJB1	Epithelial
205093_at	PLEKHA6	Epithelial
206665_s_at	BCL2L1	Epithelial
202609_at	EPS8	Epithelial
202488_s_at	FXYP3	Epithelial
202869_at	OAS1	Epithelial
207180_s_at	HTATIP2	Epithelial
217534_at	FAM49B	Epithelial
218342_s_at	ERMP1	Epithelial
200923_at	LGALS3BP	Epithelial
201798_s_at	MYOF	Epithelial
209448_at	HTATIP2	Epithelial
213393_at	MFSD9	Epithelial
218816_at	LRRC1	Epithelial
60474_at	FERMT1	Epithelial
203892_at	WFDC2	Epithelial
209373_at	MALL	Epithelial
217995_at	SQRDL	Epithelial
219229_at	SLCO3A1	Epithelial
201260_s_at	SYPL1	Epithelial
202506_at	SSFA2	Epithelial
206604_at	OVOL1	Epithelial
211488_s_at	ITGB8	Epithelial
203759_at	ST3GAL4	Epithelial
208690_s_at	PDLIM1	Epithelial
209360_s_at	RUNX1	Epithelial
203074_at	ANXA8	Epithelial
213279_at	DHRS1	Epithelial
218796_at	FERMT1	Epithelial
218840_s_at	NADSYN1	Epithelial
205769_at	SLC27A2	Epithelial
209468_at	LRP5	Epithelial
206747_at	GPRIN2	Epithelial
209040_s_at	PSMB8	Epithelial

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
211864_s_at	MYOF	Epithelial
208817_at	COMT	Epithelial
215037_s_at	BCL2L1	Epithelial
210248_at	WNT7A	Epithelial
210367_s_at	PTGES	Epithelial
201953_at	CIB1	Epithelial
212089_at	LMNA	Epithelial
220603_s_at	MCTP2	Epithelial
205816_at	ITGB8	Epithelial
211429_s_at	SERPINA1	Epithelial
212717_at	PLEKHM1	Epithelial
212727_at	DLG3	Epithelial
218963_s_at	KRT23	Epithelial
219580_s_at	TMC5	Epithelial
203324_s_at	CAV2	Epithelial
207517_at	LAMC2	Epithelial
219332_at	MICALL2	Epithelial
219735_s_at	TFCP2L1	Epithelial
220468_at	ARL14	Epithelial
203066_at	GALNAC4S-6ST	Epithelial
208623_s_at	EZR	Epithelial
212660_at	PHF15	Epithelial
214786_at	MAP3K1	Epithelial
217728_at	S100A6	Epithelial
222362_at	AGFG2	Epithelial
200766_at	CTSD	Epithelial
215189_at	KRT86	Epithelial
218706_s_at	GRAMD3	Epithelial
218810_at	ZC3H12A	Epithelial
205968_at	KCNS3	Epithelial
212070_at	GPR56	Epithelial
214958_s_at	TMC6	Epithelial
222303_at	---	Epithelial
201286_at	SDC1	Epithelial
204895_x_at	MUC4	Epithelial
205645_at	REPS2	Epithelial
205768_s_at	SLC27A2	Epithelial
205807_s_at	TUFT1	Epithelial
215808_at	KLK10	Epithelial
217947_at	CMTM6	Epithelial
218451_at	CDCP1	Epithelial
218856_at	TNFRSF21	Epithelial
219045_at	RHOF	Epithelial

**Gene List 3. EMT-signature genes in
cultured cell lines**

Probe	Gene Symbol	Category
202838_at	FUCA1	Epithelial
205552_s_at	OAS1	Epithelial
209326_at	SLC35A2	Epithelial
217835_x_at	C20orf24	Epithelial
219844_at	C10orf118	Epithelial
39249_at	AQP3	Epithelial
204942_s_at	ALDH3B2	Epithelial
216052_x_at	ARTN	Epithelial
203833_s_at	TGOLN2	Epithelial
218322_s_at	ACSL5	Epithelial
219115_s_at	IL20RA	Epithelial
201368_at	ZFP36L2	Epithelial
217351_at	---	Epithelial
219503_s_at	TMEM40	Epithelial
201032_at	BLCAP	Epithelial
212560_at	SORL1	Epithelial
213317_at	CLIC5	Epithelial
213839_at	CLMN	Epithelial
218543_s_at	PARP12	Epithelial
205190_at	PLS1	Epithelial
212285_s_at	AGRN	Epithelial
216060_s_at	DAAM1	Epithelial
222173_s_at	TBC1D2	Epithelial
205793_x_at	TNK1	Epithelial
207675_x_at	ARTN	Epithelial
213716_s_at	SECTM1	Epithelial
220073_s_at	PLEKHG6	Epithelial
220948_s_at	ATP1A1	Epithelial
200879_s_at	EPAS1	Epithelial
206542_s_at	SMARCA2	Epithelial
214581_x_at	TNFRSF21	Epithelial
220484_at	MCOLN3	Epithelial
201777_s_at	KIAA0494	Epithelial
203323_at	CAV2	Epithelial
208600_s_at	GPR39	Epithelial
217419_x_at	AGRN	Epithelial
220289_s_at	AIM1L	Epithelial
222154_s_at	LOC26010	Epithelial
31845_at	ELF4	Epithelial
218018_at	PDXXK	Epithelial
204068_at	STK3	Epithelial
212336_at	EPB41L1	Epithelial
202086_at	MX1	Epithelial
206722_s_at	LPAR2	Epithelial

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
217707_x_at	SMARCA2	Epithelial
219751_at	SETD6	Epithelial
200748_s_at	FTH1	Epithelial
201983_s_at	EGFR	Epithelial
203509_at	SORL1	Epithelial
207196_s_at	TNIP1	Epithelial
212640_at	PTPLB	Epithelial
65086_at	YIPF2	Epithelial
210365_at	RUNX1	Epithelial
202287_s_at	TACSTD2	Epithelial
207126_x_at	UGT1A1	Epithelial
211495_x_at	TNFSF12	Epithelial
215125_s_at	UGT1A1	Epithelial
219296_at	ZDHHC13	Epithelial
36936_at	TSTA3	Epithelial
200774_at	FAM120A	Epithelial
209641_s_at	ABCC3	Epithelial
209800_at	KRT16	Epithelial
210582_s_at	LIMK2	Epithelial
211628_x_at	FTHP1	Epithelial
202193_at	LIMK2	Epithelial
208622_s_at	EZR	Epithelial
212975_at	DENND3	Epithelial
215732_s_at	DTX2	Epithelial
217551_at	LOC441453	Epithelial
218154_at	GSDMD	Epithelial
219352_at	HERC6	Epithelial
220734_s_at	GLTPD1	Epithelial
201984_s_at	EGFR	Epithelial
201125_s_at	ITGB5	Epithelial
213514_s_at	DIAPH1	Epithelial
202145_at	LY6E	Epithelial
208908_s_at	CAST	Epithelial
211320_s_at	PTPRU	Epithelial
212823_s_at	PLEKHG3	Epithelial
214763_at	ACOT11	Epithelial
215411_s_at	TRAF3IP2	Epithelial
217837_s_at	VPS24	Epithelial
218776_s_at	TMEM62	Epithelial
202744_at	SLC20A2	Epithelial
206082_at	HCP5	Epithelial
208818_s_at	COMT	Epithelial
202949_s_at	FHL2	Epithelial
203490_at	ELF4	Epithelial

**Gene List 3. EMT-signature genes in
cultured cell lines**

Probe	Gene Symbol	Category
204537_s_at	GABRE	Epithelial
218631_at	AVPI1	Epithelial
218844_at	ACSF2	Epithelial
219474_at	C3orf52	Epithelial
221042_s_at	CLMN	Epithelial
218804_at	ANO1	Epithelial
204908_s_at	BCL3	Epithelial
210740_s_at	ITPK1	Epithelial
214657_s_at	NCRNA00084	Epithelial
219716_at	APOL6	Epithelial
203942_s_at	MARK2	Epithelial
208829_at	TAPBP	Epithelial
212297_at	ATP13A3	Epithelial
212807_s_at	SORT1	Epithelial
218065_s_at	TMEM9B	Epithelial
200601_at	ACTN4	Epithelial
203747_at	AQP3	Epithelial
204070_at	RARRES3	Epithelial
207467_x_at	CAST	Epithelial
208596_s_at	UGT1A1	Epithelial
210984_x_at	EGFR	Epithelial
217853_at	TNS3	Epithelial
220174_at	LRRC8E	Epithelial
218159_at	DDRKG1	Epithelial
204250_s_at	CEP164	Mesenchymal
206538_at	MRAS	Mesenchymal
209825_s_at	UCK2	Mesenchymal
211787_s_at	EIF4A1	Mesenchymal
212371_at	PPPDE1	Mesenchymal
212422_at	PDCD11	Mesenchymal
216850_at	SNRPN	Mesenchymal
220576_at	PGAP1	Mesenchymal
222344_at	---	Mesenchymal
201342_at	SNRPC	Mesenchymal
201763_s_at	DAXX	Mesenchymal
202224_at	CRK	Mesenchymal
202332_at	CSNK1E	Mesenchymal
202578_s_at	DDX19A	Mesenchymal
206583_at	ZNF673	Mesenchymal
206853_s_at	MAP3K7	Mesenchymal
207939_x_at	RNPS1	Mesenchymal
209049_s_at	ZMYND8	Mesenchymal
213631_x_at	DHODH	Mesenchymal
214999_s_at	RAB11FIP3	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
220040_x_at	ZC4H2	Mesenchymal
217779_s_at	PNRC2	Mesenchymal
203373_at	SOCS2	Mesenchymal
203958_s_at	ZBTB40	Mesenchymal
203959_s_at	ZBTB40	Mesenchymal
204320_at	COL11A1	Mesenchymal
209776_s_at	SLC19A1	Mesenchymal
218889_at	NOC3L	Mesenchymal
219098_at	MYBBP1A	Mesenchymal
200593_s_at	HNRNPU	Mesenchymal
202268_s_at	NAE1	Mesenchymal
202875_s_at	PBX2	Mesenchymal
208984_x_at	RBM10	Mesenchymal
213186_at	DZIP3	Mesenchymal
215470_at	GTF2H2B	Mesenchymal
219968_at	ZNF589	Mesenchymal
203187_at	DOCK1	Mesenchymal
205331_s_at	REEP2	Mesenchymal
211536_x_at	MAP3K7	Mesenchymal
211714_x_at	TUBB	Mesenchymal
212615_at	CHD9	Mesenchymal
221505_at	ANP32E	Mesenchymal
204402_at	RHBDD3	Mesenchymal
200775_s_at	HNRNPK	Mesenchymal
202405_at	TIAL1	Mesenchymal
205412_at	ACAT1	Mesenchymal
212910_at	THAP11	Mesenchymal
215285_s_at	PHTF1	Mesenchymal
217949_s_at	VKORC1	Mesenchymal
219002_at	FASTKD1	Mesenchymal
204788_s_at	PPOX	Mesenchymal
208939_at	SEPHS1	Mesenchymal
214862_x_at	---	Mesenchymal
218045_x_at	PTMS	Mesenchymal
217221_x_at	RBM10	Mesenchymal
221910_at	ETV1	Mesenchymal
201530_x_at	EIF4A1	Mesenchymal
202725_at	POLR2A	Mesenchymal
204208_at	RNGTT	Mesenchymal
220650_s_at	SLC9A5	Mesenchymal
221699_s_at	DDX50	Mesenchymal
202806_at	DBN1	Mesenchymal
204436_at	PLEKHO2	Mesenchymal
206852_at	EPHA7	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
207268_x_at	ABI2	Mesenchymal
207754_at	RASSF8	Mesenchymal
211071_s_at	MLLT11	Mesenchymal
213176_s_at	LTBP4	Mesenchymal
214951_at	SLC26A10	Mesenchymal
200746_s_at	GNB1	Mesenchymal
200959_at	FUS	Mesenchymal
200982_s_at	ANXA6	Mesenchymal
209883_at	GLT25D2	Mesenchymal
219578_s_at	CPEB1	Mesenchymal
34764_at	LARS2	Mesenchymal
201396_s_at	SGTA	Mesenchymal
202754_at	R3HDM1	Mesenchymal
209200_at	MEF2C	Mesenchymal
209856_x_at	ABI2	Mesenchymal
210672_s_at	C16orf35	Mesenchymal
212348_s_at	KDM1	Mesenchymal
212490_at	DNAJC8	Mesenchymal
206241_at	KPNA5	Mesenchymal
203322_at	ADNP2	Mesenchymal
204560_at	FKBP5	Mesenchymal
212104_s_at	RBM9	Mesenchymal
212618_at	ZNF609	Mesenchymal
219782_s_at	ZNF771	Mesenchymal
220797_at	METT10D	Mesenchymal
200626_s_at	MATR3	Mesenchymal
201072_s_at	SMARCC1	Mesenchymal
201718_s_at	EPB41L2	Mesenchymal
203079_s_at	CUL2	Mesenchymal
205652_s_at	TTLL1	Mesenchymal
209483_s_at	NSL1	Mesenchymal
212984_at	ATF2	Mesenchymal
217631_at	GTPBP4	Mesenchymal
219006_at	NDUFAF4	Mesenchymal
220298_s_at	SPATA6	Mesenchymal
214363_s_at	MATR3	Mesenchymal
215718_s_at	PHF3	Mesenchymal
220992_s_at	C1orf25	Mesenchymal
208591_s_at	PDE3B	Mesenchymal
200995_at	IPO7	Mesenchymal
203782_s_at	POLRMT	Mesenchymal
205817_at	SIX1	Mesenchymal
207232_s_at	DZIP3	Mesenchymal
44563_at	WRAP53	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
203537_at	PRPSAP2	Mesenchymal
204230_s_at	SLC17A7	Mesenchymal
209208_at	MPDU1	Mesenchymal
209375_at	XPC	Mesenchymal
209556_at	NCDN	Mesenchymal
212309_at	CLASP2	Mesenchymal
213218_at	ZNF187	Mesenchymal
210171_s_at	CREM	Mesenchymal
218909_at	RPS6KC1	Mesenchymal
201138_s_at	SSB	Mesenchymal
209265_s_at	METTL3	Mesenchymal
209484_s_at	NSL1	Mesenchymal
216098_s_at	HTR7	Mesenchymal
216305_s_at	C2orf3	Mesenchymal
217987_at	ASNSD1	Mesenchymal
219575_s_at	COG8	Mesenchymal
219688_at	BBS7	Mesenchymal
91682_at	---	Mesenchymal
203151_at	MAP1A	Mesenchymal
208765_s_at	HNRNPR	Mesenchymal
208802_at	SRP72	Mesenchymal
208910_s_at	C1QBP	Mesenchymal
219260_s_at	C17orf81	Mesenchymal
200873_s_at	CCT8	Mesenchymal
201802_at	SLC29A1	Mesenchymal
212852_s_at	TROVE2	Mesenchymal
214214_s_at	C1QBP	Mesenchymal
217061_s_at	ETV1	Mesenchymal
219306_at	KIF15	Mesenchymal
37433_at	PIAS2	Mesenchymal
201667_at	GJA1	Mesenchymal
203871_at	SENP3	Mesenchymal
208786_s_at	MAP1LC3B	Mesenchymal
213220_at	NCRNA00081	Mesenchymal
219295_s_at	PCOLCE2	Mesenchymal
221540_x_at	GTF2H2	Mesenchymal
336_at	TBXA2R	Mesenchymal
201706_s_at	PEX19	Mesenchymal
203861_s_at	ACTN2	Mesenchymal
207127_s_at	HNRNPH3	Mesenchymal
207153_s_at	GLMN	Mesenchymal
209048_s_at	ZMYND8	Mesenchymal
213604_at	TCEB3	Mesenchymal
48580_at	CXXC1	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
201801_s_at	SLC29A1	Mesenchymal
201935_s_at	EIF4G3	Mesenchymal
212303_x_at	KHSRP	Mesenchymal
221912_s_at	CCDC28B	Mesenchymal
204442_x_at	LTBP4	Mesenchymal
204796_at	EML1	Mesenchymal
210588_x_at	HNRNPH3	Mesenchymal
212880_at	WDR7	Mesenchymal
214881_s_at	UBTF	Mesenchymal
218058_at	CXXC1	Mesenchymal
218587_s_at	KTELC1	Mesenchymal
219170_at	FSD1	Mesenchymal
202432_at	PPP3CB	Mesenchymal
203264_s_at	ARHGEF9	Mesenchymal
203441_s_at	CDH2	Mesenchymal
204042_at	WASF3	Mesenchymal
206233_at	B4GALT6	Mesenchymal
213632_at	DHODH	Mesenchymal
201528_at	RPA1	Mesenchymal
206854_s_at	MAP3K7	Mesenchymal
210438_x_at	TROVE2	Mesenchymal
217025_s_at	DBN1	Mesenchymal
218222_x_at	ARNT	Mesenchymal
202401_s_at	SRF	Mesenchymal
202557_at	HSPA13	Mesenchymal
208673_s_at	SFRS3	Mesenchymal
41397_at	ZNF821	Mesenchymal
201516_at	SRM	Mesenchymal
202502_at	ACADM	Mesenchymal
203092_at	TIMM44	Mesenchymal
204300_at	PET112L	Mesenchymal
204992_s_at	PFN2	Mesenchymal
206147_x_at	SCML2	Mesenchymal
207559_s_at	ZMYM3	Mesenchymal
208447_s_at	PRPS1	Mesenchymal
213306_at	MPDZ	Mesenchymal
213474_at	KCTD7	Mesenchymal
216693_x_at	HDGFRP3	Mesenchymal
221825_at	ANGEL2	Mesenchymal
200744_s_at	GNB1	Mesenchymal
200815_s_at	PAFAH1B1	Mesenchymal
212674_s_at	DHX30	Mesenchymal
212817_at	DNAJB5	Mesenchymal
215991_s_at	KIAA0090	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
217951_s_at	PHF3	Mesenchymal
221606_s_at	NSBP1	Mesenchymal
35776_at	ITSN1	Mesenchymal
203520_s_at	ZNF318	Mesenchymal
203940_s_at	VASH1	Mesenchymal
208682_s_at	MAGED2	Mesenchymal
212739_s_at	NME4	Mesenchymal
204819_at	FGD1	Mesenchymal
200041_s_at	BAT1	Mesenchymal
202397_at	NUTF2	Mesenchymal
206663_at	SP4	Mesenchymal
209440_at	PRPS1	Mesenchymal
209693_at	ASTN2	Mesenchymal
213627_at	MAGED2	Mesenchymal
212855_at	DCUN1D4	Mesenchymal
219708_at	NT5M	Mesenchymal
44654_at	G6PC3	Mesenchymal
200813_s_at	PAFAH1B1	Mesenchymal
208799_at	PSMB5	Mesenchymal
209490_s_at	PPT2	Mesenchymal
219820_at	SLC6A16	Mesenchymal
202465_at	PCOLCE	Mesenchymal
200083_at	USP22	Mesenchymal
205830_at	CLGN	Mesenchymal
58780_s_at	FLJ10357	Mesenchymal
205493_s_at	DPYSL4	Mesenchymal
207006_s_at	CCDC106	Mesenchymal
210875_s_at	ZEB1	Mesenchymal
221554_at	STRADA	Mesenchymal
201936_s_at	EIF4G3	Mesenchymal
203223_at	RABEP1	Mesenchymal
204797_s_at	EML1	Mesenchymal
213312_at	C6orf162	Mesenchymal
201309_x_at	C5orf13	Mesenchymal
204355_at	DHX30	Mesenchymal
208986_at	TCF12	Mesenchymal
217952_x_at	PHF3	Mesenchymal
218607_s_at	SDAD1	Mesenchymal
220143_x_at	LUC7L	Mesenchymal
208670_s_at	EID1	Mesenchymal
209947_at	UBAP2L	Mesenchymal
218336_at	PFDN2	Mesenchymal
219781_s_at	ZNF771	Mesenchymal
216271_x_at	SYDE1	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
200053_at	SPAG7	Mesenchymal
201081_s_at	PIP4K2B	Mesenchymal
202564_x_at	ARL2	Mesenchymal
204483_at	ENO3	Mesenchymal
204735_at	PDE4A	Mesenchymal
213469_at	PGAP1	Mesenchymal
201310_s_at	C5orf13	Mesenchymal
203146_s_at	GABBR1	Mesenchymal
205079_s_at	MPDZ	Mesenchymal
209526_s_at	HDGFRP3	Mesenchymal
212635_at	TNPO1	Mesenchymal
204372_s_at	KHSRP	Mesenchymal
209657_s_at	HSF2	Mesenchymal
218529_at	CD320	Mesenchymal
205021_s_at	FOXP3	Mesenchymal
205347_s_at	TMSB15A	Mesenchymal
205407_at	RECK	Mesenchymal
207808_s_at	PROS1	Mesenchymal
212738_at	ARHGAP19	Mesenchymal
213677_s_at	PMS1	Mesenchymal
214297_at	CSPG4	Mesenchymal
202179_at	BLMH	Mesenchymal
204557_s_at	DZIP1	Mesenchymal
212887_at	SEC23A	Mesenchymal
200000_s_at	PRPF8	Mesenchymal
202123_s_at	ABL1	Mesenchymal
203884_s_at	RAB11FIP2	Mesenchymal
207822_at	FGFR1	Mesenchymal
220326_s_at	FLJ10357	Mesenchymal
203093_s_at	TIMM44	Mesenchymal
204592_at	DLG4	Mesenchymal
200060_s_at	RNPS1	Mesenchymal
209524_at	HDGFRP3	Mesenchymal
213278_at	MTMR9	Mesenchymal
213314_at	C6orf162	Mesenchymal
221786_at	C6orf120	Mesenchymal
204344_s_at	SEC23A	Mesenchymal
210250_x_at	ADSL	Mesenchymal
214878_at	ZNF37A	Mesenchymal
201529_s_at	RPA1	Mesenchymal
213262_at	SACS	Mesenchymal
215113_s_at	SENP3	Mesenchymal
218641_at	LOC65998	Mesenchymal
220565_at	CCR10	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
206506_s_at	SUPT3H	Mesenchymal
211537_x_at	MAP3K7	Mesenchymal
37577_at	ARHGAP19	Mesenchymal
205408_at	MLLT10	Mesenchymal
207541_s_at	EXOSC10	Mesenchymal
213234_at	KIAA1467	Mesenchymal
213489_at	MAPRE2	Mesenchymal
217812_at	YTHDF2	Mesenchymal
220258_s_at	WRAP53	Mesenchymal
220993_s_at	GPR63	Mesenchymal
202967_at	GSTA4	Mesenchymal
203263_s_at	ARHGEF9	Mesenchymal
204900_x_at	SAP30	Mesenchymal
218759_at	DVL2	Mesenchymal
201725_at	CDC123	Mesenchymal
215407_s_at	ASTN2	Mesenchymal
216551_x_at	PLCG1	Mesenchymal
218148_at	CENPT	Mesenchymal
35201_at	HNRNPL	Mesenchymal
206902_s_at	EXOG	Mesenchymal
209525_at	HDGFRP3	Mesenchymal
210232_at	CDC42	Mesenchymal
221911_at	ETV1	Mesenchymal
202072_at	HNRNPL	Mesenchymal
203874_s_at	SMARCA1	Mesenchymal
204104_at	SNAPC2	Mesenchymal
203883_s_at	RAB11FIP2	Mesenchymal
215058_at	DENND5B	Mesenchymal
219240_s_at	C10orf88	Mesenchymal
220938_s_at	GMEB1	Mesenchymal
219205_at	SRR	Mesenchymal
209118_s_at	TUBA1A	Mesenchymal
218380_at	NLRP1	Mesenchymal
52169_at	STRADA	Mesenchymal
209092_s_at	GLOD4	Mesenchymal
209967_s_at	CREM	Mesenchymal
212736_at	C16orf45	Mesenchymal
217053_x_at	ETV1	Mesenchymal
217815_at	SUPT16H	Mesenchymal
201312_s_at	SH3BGRL	Mesenchymal
202144_s_at	ADSL	Mesenchymal
216506_x_at	MLLT10	Mesenchymal
203875_at	SMARCA1	Mesenchymal
209174_s_at	QRICH1	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
214230_at	CDC42	Mesenchymal
202576_s_at	DDX19A	Mesenchymal
202577_s_at	DDX19A	Mesenchymal
200097_s_at	HNRNPK	Mesenchymal
207219_at	ZNF643	Mesenchymal
210288_at	KLRG1	Mesenchymal
212551_at	CAP2	Mesenchymal
219204_s_at	SRR	Mesenchymal
201311_s_at	SH3BGRL	Mesenchymal
207937_x_at	FGFR1	Mesenchymal
218152_at	HMG20A	Mesenchymal
218993_at	RNMTL1	Mesenchymal
212554_at	CAP2	Mesenchymal
215294_s_at	SMARCA1	Mesenchymal
218196_at	OSTM1	Mesenchymal
35617_at	MAPK7	Mesenchymal
203172_at	FXR2	Mesenchymal
214582_at	PDE3B	Mesenchymal
206501_x_at	ETV1	Mesenchymal
220278_at	KDM4D	Mesenchymal
214508_x_at	CREM	Mesenchymal
207630_s_at	CREM	Mesenchymal
219446_at	RIC8B	Mesenchymal
202260_s_at	STXBP1	Mesenchymal
213194_at	ROBO1	Mesenchymal
211089_s_at	NEK3	Mesenchymal
212813_at	JAM3	Mesenchymal
213118_at	UHRF1BP1L	Mesenchymal
218025_s_at	PECI	Mesenchymal
205521_at	EXOG	Mesenchymal
207830_s_at	PPP1R8	Mesenchymal
212265_at	QKI	Mesenchymal
212962_at	SYDE1	Mesenchymal
57532_at	DVL2	Mesenchymal
213434_at	STX2	Mesenchymal
201426_s_at	VIM	Mesenchymal
214552_s_at	RABEP1	Mesenchymal
218223_s_at	PLEKHO1	Mesenchymal
219479_at	KDELC1	Mesenchymal
222317_at	PDE3B	Mesenchymal
213116_at	NEK3	Mesenchymal
207292_s_at	MAPK7	Mesenchymal
209406_at	BAG2	Mesenchymal
221759_at	G6PC3	Mesenchymal

Gene List 3. EMT-signature genes in cultured cell lines

Probe	Gene Symbol	Category
205215_at	RNF2	Mesenchymal
211038_s_at	CROCCL1	Mesenchymal
211602_s_at	TRPC1	Mesenchymal
35265_at	FXR2	Mesenchymal
203388_at	ARRB2	Mesenchymal
212262_at	QKI	Mesenchymal
214724_at	DIXDC1	Mesenchymal
218517_at	PHF17	Mesenchymal
202789_at	PLCG1	Mesenchymal
205803_s_at	TRPC1	Mesenchymal
212263_at	QKI	Mesenchymal
212624_s_at	CHN1	Mesenchymal
203011_at	IMPA1	Mesenchymal
204065_at	CHST10	Mesenchymal
201980_s_at	RSU1	Mesenchymal
203278_s_at	PHF21A	Mesenchymal
211535_s_at	FGFR1	Mesenchymal
219317_at	POLI	Mesenchymal
214543_x_at	QKI	Mesenchymal
217650_x_at	ST3GAL2	Mesenchymal
212512_s_at	CARM1	Mesenchymal
218974_at	SOBP	Mesenchymal
204899_s_at	SAP30	Mesenchymal
204795_at	PRR3	Mesenchymal
204432_at	SOX12	Mesenchymal
204854_at	LEPREL2	Mesenchymal
212764_at	ZEB1	Mesenchymal
205545_x_at	DNAJC8	Mesenchymal
207346_at	STX2	Mesenchymal
220977_x_at	EPB41L5	Mesenchymal
210151_s_at	DYRK3	Mesenchymal
219731_at	---	Mesenchymal
204392_at	CAMK1	Mesenchymal
209537_at	EXTL2	Mesenchymal
212758_s_at	ZEB1	Mesenchymal
205802_at	TRPC1	Mesenchymal
210973_s_at	FGFR1	Mesenchymal
216503_s_at	MLLT10	Mesenchymal
212491_s_at	DNAJC8	Mesenchymal
205346_at	ST3GAL2	Mesenchymal
204521_at	C12orf24	Mesenchymal
65493_at	HEATR6	Mesenchymal
209407_s_at	DEAF1	Mesenchymal
219400_at	CNTNAP1	Mesenchymal

**Gene List 3. EMT-signature genes in
cultured cell lines**

Probe	Gene Symbol	Category
219469_at	DYNC2H1	Mesenchymal
216272_x_at	SYDE1	Mesenchymal
218991_at	HEATR6	Mesenchymal
216873_s_at	ATP8B2	Mesenchymal
221078_s_at	CCDC88A	Mesenchymal
213302_at	PFAS	Mesenchymal
44702_at	SYDE1	Mesenchymal
212413_at	Sep6	Mesenchymal
212414_s_at	N-PAC	Mesenchymal
204165_at	WASF1	Mesenchymal
214298_x_at	Sep6	Mesenchymal
202921_s_at	ANK2	Mesenchymal
215146_s_at	TTC28	Mesenchymal
209210_s_at	FERMT2	Mesenchymal
213058_at	TTC28	Mesenchymal
209209_s_at	FERMT2	Mesenchymal
219387_at	CCDC88A	Mesenchymal
220750_s_at	LEPRE1	Mesenchymal
207719_x_at	CEP170	Mesenchymal
212746_s_at	CEP170	Mesenchymal
214212_x_at	FERMT2	Mesenchymal
202920_at	ANK2	Mesenchymal
212561_at	DENND5A	Mesenchymal

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
1007_s_at	DDR1	Epithelial
1487_at	ESRRA	Epithelial
200601_at	ACTN4	Epithelial
200632_s_at	NDRG1	Epithelial
200639_s_at	YWHAZ	Epithelial
200660_at	S100A11	Epithelial
200752_s_at	CAPN1	Epithelial
200767_s_at	FAM120A	Epithelial
200774_at	FAM120A	Epithelial
200824_at	GSTP1	Epithelial
200916_at	TAGLN2	Epithelial
201015_s_at	JUP	Epithelial
201059_at	CTTN	Epithelial
201079_at	SYNGR2	Epithelial
201131_s_at	CDH1	Epithelial
201188_s_at	ITPR3	Epithelial
201189_s_at	ITPR3	Epithelial
201201_at	CSTB	Epithelial
201331_s_at	STAT6	Epithelial
201349_at	SLC9A3R1	Epithelial
201373_at	PLEC1	Epithelial
201412_at	LRP10	Epithelial
201428_at	CLDN4	Epithelial
201467_s_at	NQO1	Epithelial
201468_s_at	NQO1	Epithelial
201510_at	ELF3	Epithelial
201596_x_at	KRT18	Epithelial
201644_at	TSTA3	Epithelial
201650_at	KRT19	Epithelial
201674_s_at	AKAP1	Epithelial
201690_s_at	TPD52	Epithelial
201704_at	ENTPD6	Epithelial
201769_at	CLINT1	Epithelial
201827_at	SMARCD2	Epithelial
201839_s_at	EPCAM	Epithelial
201925_s_at	CD55	Epithelial
201926_s_at	CD55	Epithelial
201941_at	CPD	Epithelial
201953_at	CIB1	Epithelial
202005_at	ST14	Epithelial
202023_at	EFNA1	Epithelial
202067_s_at	LDLR	Epithelial
202068_s_at	LDLR	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
202071_at	SDC4	Epithelial
202085_at	TJP2	Epithelial
202096_s_at	TSPO	Epithelial
202180_s_at	MVP	Epithelial
202187_s_at	PPP2R5A	Epithelial
202267_at	LAMC2	Epithelial
202286_s_at	TACSTD2	Epithelial
202387_at	BAG1	Epithelial
202454_s_at	ERBB3	Epithelial
202481_at	DHRS3	Epithelial
202488_s_at	FXYP3	Epithelial
202489_s_at	FXYP3	Epithelial
202504_at	TRIM29	Epithelial
202506_at	SSFA2	Epithelial
202525_at	PRSS8	Epithelial
202528_at	GALE	Epithelial
202545_at	PRKCD	Epithelial
202546_at	VAMP8	Epithelial
202597_at	IRF6	Epithelial
202659_at	PSMB10	Epithelial
202699_s_at	TMEM63A	Epithelial
202700_s_at	TMEM63A	Epithelial
202702_at	TRIM26	Epithelial
202712_s_at	CKMT1A	Epithelial
202740_at	ACY1	Epithelial
202790_at	CLDN7	Epithelial
202826_at	SPINT1	Epithelial
202833_s_at	SERPINA1	Epithelial
202889_x_at	MAP7	Epithelial
202890_at	MAP7	Epithelial
202962_at	KIF13B	Epithelial
202996_at	POLD4	Epithelial
203014_x_at	SGSM3	Epithelial
203021_at	SLPI	Epithelial
203028_s_at	CYBA	Epithelial
203108_at	GPRC5A	Epithelial
203215_s_at	MYO6	Epithelial
203216_s_at	MYO6	Epithelial
203287_at	LAD1	Epithelial
203397_s_at	GALNT3	Epithelial
203407_at	PPL	Epithelial
203411_s_at	LMNA	Epithelial
203430_at	HEBP2	Epithelial
203431_s_at	RICS	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
203453_at	SCNN1A	Epithelial
203458_at	SPR	Epithelial
203509_at	SORL1	Epithelial
203593_at	CD2AP	Epithelial
203652_at	MAP3K11	Epithelial
203669_s_at	DGAT1	Epithelial
203713_s_at	LLGL2	Epithelial
203726_s_at	LAMA3	Epithelial
203757_s_at	CEACAM6	Epithelial
203779_s_at	MPZL2	Epithelial
203780_at	MPZL2	Epithelial
203904_x_at	CD82	Epithelial
203918_at	PCDH1	Epithelial
203942_s_at	MARK2	Epithelial
203953_s_at	CLDN3	Epithelial
203954_x_at	CLDN3	Epithelial
203974_at	HDHD1A	Epithelial
203997_at	PTPN3	Epithelial
204034_at	ETHE1	Epithelial
204124_at	SLC34A2	Epithelial
204166_at	SBNO2	Epithelial
204168_at	MGST2	Epithelial
204231_s_at	FAAH	Epithelial
204351_at	S100P	Epithelial
204398_s_at	EML2	Epithelial
204401_at	KCNN4	Epithelial
204480_s_at	C9orf16	Epithelial
204494_s_at	C15orf39	Epithelial
204503_at	EVPL	Epithelial
204519_s_at	PLLP	Epithelial
204526_s_at	TBC1D8	Epithelial
204547_at	RAB40B	Epithelial
204578_at	HISPPD2A	Epithelial
204608_at	ASL	Epithelial
204632_at	RPS6KA4	Epithelial
204656_at	SHB	Epithelial
204734_at	KRT15	Epithelial
204757_s_at	C2CD2L	Epithelial
204856_at	B3GNT3	Epithelial
204875_s_at	GMDS	Epithelial
204922_at	C11orf80	Epithelial
204927_at	RASSF7	Epithelial
204942_s_at	ALDH3B2	Epithelial
204973_at	GJB1	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
204975_at	EMP2	Epithelial
204981_at	SLC22A18	Epithelial
204989_s_at	ITGB4	Epithelial
204990_s_at	ITGB4	Epithelial
205011_at	VWA5A	Epithelial
205014_at	FGFBP1	Epithelial
205016_at	TGFA	Epithelial
205019_s_at	VIPR1	Epithelial
205068_s_at	ARHGAP26	Epithelial
205093_at	PLEKHA6	Epithelial
205172_x_at	CLTB	Epithelial
205190_at	PLS1	Epithelial
205193_at	MAFF	Epithelial
205263_at	BCL10	Epithelial
205266_at	LIF	Epithelial
205328_at	CLDN10	Epithelial
205349_at	GNA15	Epithelial
205455_at	MST1R	Epithelial
205459_s_at	NPAS2	Epithelial
205460_at	NPAS2	Epithelial
205487_s_at	VGLL1	Epithelial
205490_x_at	GJB3	Epithelial
205538_at	CORO2A	Epithelial
205597_at	SLC44A4	Epithelial
205617_at	PRRG2	Epithelial
205622_at	SMPD2	Epithelial
205634_x_at	ZDHHC24	Epithelial
205640_at	ALDH3B1	Epithelial
205668_at	LY75	Epithelial
205709_s_at	CDS1	Epithelial
205759_s_at	SULT2B1	Epithelial
205765_at	CYP3A5	Epithelial
205780_at	BIK	Epithelial
205807_s_at	TUFT1	Epithelial
205847_at	PRSS22	Epithelial
205977_s_at	EPHA1	Epithelial
205980_s_at	ARHGAP8	Epithelial
206043_s_at	ATP2C2	Epithelial
206048_at	OVOL2	Epithelial
206153_at	CYP4F11	Epithelial
206200_s_at	ANXA11	Epithelial
206277_at	P2RY2	Epithelial
206284_x_at	CLTB	Epithelial
206482_at	PTK6	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
206576_s_at	CEACAM1	Epithelial
206599_at	LOC100133772	Epithelial
206600_s_at	LOC100133772	Epithelial
206628_at	SLC5A1	Epithelial
206698_at	XK	Epithelial
206770_s_at	SLC35A3	Epithelial
207109_at	POU2F3	Epithelial
207169_x_at	DDR1	Epithelial
207180_s_at	HTATIP2	Epithelial
207291_at	PRRG4	Epithelial
207517_at	LAMC2	Epithelial
207525_s_at	GIPC1	Epithelial
207667_s_at	MAP2K3	Epithelial
207847_s_at	MUC1	Epithelial
207949_s_at	ICA1	Epithelial
207986_x_at	CYB561	Epithelial
208009_s_at	ARHGEF16	Epithelial
208083_s_at	ITGB6	Epithelial
208084_at	ITGB6	Epithelial
208161_s_at	ABCC3	Epithelial
208165_s_at	PRSS16	Epithelial
208190_s_at	LSR	Epithelial
208505_s_at	FUT2	Epithelial
208540_x_at	S100A11	Epithelial
208613_s_at	FLNB	Epithelial
208622_s_at	EZR	Epithelial
208623_s_at	EZR	Epithelial
208650_s_at	CD24	Epithelial
208651_x_at	CD24	Epithelial
208779_x_at	DDR1	Epithelial
208817_at	COMT	Epithelial
208818_s_at	COMT	Epithelial
208862_s_at	CTNND1	Epithelial
208890_s_at	PLXNB2	Epithelial
208928_at	POR	Epithelial
208949_s_at	LGALS3	Epithelial
209008_x_at	KRT8	Epithelial
209016_s_at	KRT7	Epithelial
209114_at	TSPAN1	Epithelial
209126_x_at	KRT6B	Epithelial
209163_at	CYB561	Epithelial
209164_s_at	CYB561	Epithelial
209173_at	AGR2	Epithelial
209190_s_at	DIAPH1	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
209211_at	KLF5	Epithelial
209212_s_at	KLF5	Epithelial
209260_at	SFN	Epithelial
209270_at	LAMB3	Epithelial
209275_s_at	CLN3	Epithelial
209354_at	TNFRSF14	Epithelial
209367_at	STXBP2	Epithelial
209373_at	MALL	Epithelial
209386_at	TM4SF1	Epithelial
209387_s_at	TM4SF1	Epithelial
209448_at	HTATIP2	Epithelial
209498_at	CEACAM1	Epithelial
209499_x_at	TNFSF12- TNFSF13	Epithelial
209500_x_at	TNFSF12- TNFSF13	Epithelial
209502_s_at	BAIAP2	Epithelial
209529_at	PPAP2C	Epithelial
209587_at	PITX1	Epithelial
209605_at	TST	Epithelial
209626_s_at	OSBPL3	Epithelial
209627_s_at	OSBPL3	Epithelial
209641_s_at	ABCC3	Epithelial
209771_x_at	CD24	Epithelial
209772_s_at	CD24	Epithelial
209803_s_at	PHLDA2	Epithelial
209872_s_at	PKP3	Epithelial
209873_s_at	PKP3	Epithelial
210010_s_at	SLC25A1	Epithelial
210058_at	MAPK13	Epithelial
210059_s_at	MAPK13	Epithelial
210117_at	SPAG1	Epithelial
210205_at	B3GALT4	Epithelial
210301_at	XDH	Epithelial
210314_x_at	TNFSF13	Epithelial
210397_at	DEFB1	Epithelial
210480_s_at	MYO6	Epithelial
210519_s_at	NQO1	Epithelial
210547_x_at	ICA1	Epithelial
210592_s_at	SAT1	Epithelial
210608_s_at	FUT2	Epithelial
210652_s_at	TTC39A	Epithelial
210678_s_at	AGPAT2	Epithelial
210740_s_at	ITPK1	Epithelial
210749_x_at	DDR1	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
210761_s_at	GRB7	Epithelial
210791_s_at	RICS	Epithelial
210827_s_at	ELF3	Epithelial
210859_x_at	CLN3	Epithelial
211002_s_at	TRIM29	Epithelial
211043_s_at	CLTB	Epithelial
211240_x_at	CTNND1	Epithelial
211429_s_at	SERPINA1	Epithelial
211628_x_at	FTHP1	Epithelial
211657_at	CEACAM6	Epithelial
211695_x_at	MUC1	Epithelial
211778_s_at	OVOL2	Epithelial
211883_x_at	CEACAM1	Epithelial
211889_x_at	CEACAM1	Epithelial
212053_at	PDXDC1	Epithelial
212070_at	GPR56	Epithelial
212089_at	LMNA	Epithelial
212127_at	RANGAP1	Epithelial
212268_at	SERPINB1	Epithelial
212339_at	EPB41L1	Epithelial
212443_at	NBEAL2	Epithelial
212444_at	---	Epithelial
212456_at	KIAA0664	Epithelial
212527_at	PPPDE2	Epithelial
212531_at	LCN2	Epithelial
212543_at	AIM1	Epithelial
212560_at	SORL1	Epithelial
212659_s_at	IL1RN	Epithelial
212727_at	DLG3	Epithelial
212841_s_at	PPFIBP2	Epithelial
212925_at	C19orf21	Epithelial
213050_at	COBL	Epithelial
213076_at	ITPKC	Epithelial
213078_x_at	LPCAT4	Epithelial
213085_s_at	WWC1	Epithelial
213172_at	TTC9	Epithelial
213174_at	TTC9	Epithelial
213191_at	TICAM1	Epithelial
213230_at	CDR2L	Epithelial
213242_x_at	KIAA0284	Epithelial
213285_at	TMEM30B	Epithelial
213308_at	SHANK2	Epithelial
213412_at	TJP3	Epithelial
213432_at	MUC5B	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
213441_x_at	SPDEF	Epithelial
213462_at	NPAS2	Epithelial
213506_at	F2RL1	Epithelial
213542_at	ZNF710	Epithelial
213572_s_at	SERPINB1	Epithelial
213590_at	LOC100133772	Epithelial
213667_at	SRCAP	Epithelial
213693_s_at	MUC1	Epithelial
213929_at	EXPH5	Epithelial
214070_s_at	ATP10B	Epithelial
214088_s_at	FUT3	Epithelial
214106_s_at	GMDS	Epithelial
214234_s_at	CYP3A5	Epithelial
214235_at	CYP3A5	Epithelial
214404_x_at	SPDEF	Epithelial
214665_s_at	CHP	Epithelial
214734_at	EXPH5	Epithelial
214779_s_at	SGSM3	Epithelial
214783_s_at	ANXA11	Epithelial
214924_s_at	TRAK1	Epithelial
215034_s_at	TM4SF1	Epithelial
215243_s_at	GJB3	Epithelial
215471_s_at	MAP7	Epithelial
215498_s_at	MAP2K3	Epithelial
215499_at	MAP2K3	Epithelial
215729_s_at	VGLL1	Epithelial
215732_s_at	DTX2	Epithelial
216010_x_at	FUT3	Epithelial
216074_x_at	WWC1	Epithelial
216251_s_at	TTL12	Epithelial
216379_x_at	CD24	Epithelial
216568_x_at	---	Epithelial
216641_s_at	LAD1	Epithelial
216836_s_at	ERBB2	Epithelial
216905_s_at	ST14	Epithelial
217109_at	MUC4	Epithelial
217110_s_at	MUC4	Epithelial
217149_x_at	TNK1	Epithelial
217200_x_at	CYB561	Epithelial
217551_at	LOC441453	Epithelial
217728_at	S100A6	Epithelial
217730_at	TMBIM1	Epithelial
217744_s_at	PERP	Epithelial
217751_at	GSTK1	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
217794_at	PRR13	Epithelial
217867_x_at	BACE2	Epithelial
217939_s_at	AFTPH	Epithelial
217995_at	SQRDL	Epithelial
218028_at	ELOVL1	Epithelial
218035_s_at	RBM47	Epithelial
218144_s_at	INF2	Epithelial
218161_s_at	CLN6	Epithelial
218180_s_at	EPS8L2	Epithelial
218186_at	RAB25	Epithelial
218211_s_at	MLPH	Epithelial
218261_at	AP1M2	Epithelial
218301_at	RNPEPL1	Epithelial
218451_at	CDCP1	Epithelial
218498_s_at	ERO1L	Epithelial
218500_at	C8orf55	Epithelial
218644_at	PLEK2	Epithelial
218677_at	S100A14	Epithelial
218693_at	TSPAN15	Epithelial
218776_s_at	TMEM62	Epithelial
218779_x_at	EPS8L1	Epithelial
218792_s_at	BSPRY	Epithelial
218806_s_at	VAV3	Epithelial
218807_at	VAV3	Epithelial
218810_at	ZC3H12A	Epithelial
218840_s_at	NADSYN1	Epithelial
218856_at	TNFRSF21	Epithelial
218858_at	DEPDC6	Epithelial
218885_s_at	GALNT12	Epithelial
218900_at	CNNM4	Epithelial
218921_at	SIGIRR	Epithelial
218928_s_at	SLC37A1	Epithelial
218931_at	RAB17	Epithelial
218960_at	TMPRSS4	Epithelial
218963_s_at	KRT23	Epithelial
218966_at	MYO5C	Epithelial
219010_at	C1orf106	Epithelial
219121_s_at	ESRP1	Epithelial
219127_at	ATAD4	Epithelial
219150_s_at	ADAP1	Epithelial
219188_s_at	MACROD1	Epithelial
219215_s_at	SLC39A4	Epithelial
219241_x_at	SSH3	Epithelial
219274_at	TSPAN12	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
219313_at	GRAMD1C	Epithelial
219327_s_at	GPRC5C	Epithelial
219332_at	MICALL2	Epithelial
219360_s_at	TRPM4	Epithelial
219388_at	GRHL2	Epithelial
219395_at	ESRP2	Epithelial
219411_at	ELMO3	Epithelial
219429_at	FA2H	Epithelial
219461_at	PAK6	Epithelial
219476_at	C1orf116	Epithelial
219508_at	GCNT3	Epithelial
219513_s_at	SH2D3A	Epithelial
219517_at	ELL3	Epithelial
219518_s_at	ELL3	Epithelial
219580_s_at	TMC5	Epithelial
219622_at	RAB20	Epithelial
219630_at	PDZK1IP1	Epithelial
219681_s_at	RAB11FIP1	Epithelial
219716_at	APOL6	Epithelial
219749_at	SH2D4A	Epithelial
219756_s_at	POF1B	Epithelial
219768_at	VTCN1	Epithelial
219850_s_at	EHF	Epithelial
219856_at	C1orf116	Epithelial
219857_at	C10orf81	Epithelial
219916_s_at	RNF39	Epithelial
219919_s_at	SSH3	Epithelial
219946_x_at	MYH14	Epithelial
220030_at	STYK1	Epithelial
220161_s_at	EPB41L4B	Epithelial
220174_at	LRRC8E	Epithelial
220192_x_at	SPDEF	Epithelial
220196_at	MUC16	Epithelial
220312_at	FAM83E	Epithelial
220475_at	SLC28A3	Epithelial
220638_s_at	CBLC	Epithelial
220945_x_at	MANSC1	Epithelial
220948_s_at	ATP1A1	Epithelial
220964_s_at	RAB1B	Epithelial
220998_s_at	UNC93B1	Epithelial
221042_s_at	CLMN	Epithelial
221081_s_at	DENND2D	Epithelial
221122_at	HRASLS2	Epithelial
221215_s_at	RIPK4	Epithelial

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
221256_s_at	HDHD3	Epithelial
221610_s_at	STAP2	Epithelial
221655_x_at	EPS8L1	Epithelial
221656_s_at	ARHGEF10L	Epithelial
221664_s_at	F11R	Epithelial
221665_s_at	EPS8L1	Epithelial
221696_s_at	STYK1	Epithelial
221764_at	C19orf22	Epithelial
221880_s_at	FAM174B	Epithelial
221927_s_at	ABHD11	Epithelial
222126_at	AGFG2	Epithelial
222165_x_at	C9orf16	Epithelial
222333_at	ALS2CL	Epithelial
222362_at	AGFG2	Epithelial
266_s_at	CD24	Epithelial
32837_at	AGPAT2	Epithelial
33322_i_at	SFN	Epithelial
33323_r_at	SFN	Epithelial
35148_at	TJP3	Epithelial
36711_at	MAFF	Epithelial
36936_at	TSTA3	Epithelial
37117_at	ARHGAP8	Epithelial
38766_at	SRCAP	Epithelial
39548_at	NPAS2	Epithelial
39549_at	NPAS2	Epithelial
39891_at	ZNF710	Epithelial
40359_at	RASSF7	Epithelial
40472_at	LPCAT4	Epithelial
41047_at	C9orf16	Epithelial
51158_at	FAM174B	Epithelial
51192_at	SSH3	Epithelial
52940_at	SIGIRR	Epithelial
57163_at	ELOVL1	Epithelial
64486_at	CORO1B	Epithelial
65517_at	AP1M2	Epithelial
90265_at	ADAP1	Epithelial
91826_at	EPS8L1	Epithelial
200783_s_at	STMN1	Mesenchymal
200953_s_at	CCND2	Mesenchymal
200975_at	PPT1	Mesenchymal
200982_s_at	ANXA6	Mesenchymal
201054_at	HNRNPA0	Mesenchymal
201116_s_at	CPE	Mesenchymal
201117_s_at	CPE	Mesenchymal

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
201147_s_at	TIMP3	Mesenchymal
201148_s_at	TIMP3	Mesenchymal
201149_s_at	TIMP3	Mesenchymal
201150_s_at	TIMP3	Mesenchymal
201272_at	AKR1B1	Mesenchymal
201309_x_at	C5orf13	Mesenchymal
201310_s_at	C5orf13	Mesenchymal
201387_s_at	UCHL1	Mesenchymal
201426_s_at	VIM	Mesenchymal
201518_at	CBX1	Mesenchymal
201539_s_at	FHL1	Mesenchymal
201540_at	FHL1	Mesenchymal
201560_at	CLIC4	Mesenchymal
201564_s_at	FSCN1	Mesenchymal
201669_s_at	MARCKS	Mesenchymal
202141_s_at	COPS8	Mesenchymal
202142_at	COPS8	Mesenchymal
202143_s_at	COPS8	Mesenchymal
202179_at	BLMH	Mesenchymal
202302_s_at	RSRC2	Mesenchymal
202557_at	HSPA13	Mesenchymal
202558_s_at	HSPA13	Mesenchymal
202732_at	PKIG	Mesenchymal
202789_at	PLCG1	Mesenchymal
202976_s_at	RHOBTB3	Mesenchymal
203044_at	CHSY1	Mesenchymal
203184_at	FBN2	Mesenchymal
203188_at	B3GNT1	Mesenchymal
203217_s_at	ST3GAL5	Mesenchymal
203296_s_at	ATP1A2	Mesenchymal
203417_at	MFAP2	Mesenchymal
203440_at	CDH2	Mesenchymal
203441_s_at	CDH2	Mesenchymal
203688_at	PKD2	Mesenchymal
203706_s_at	FZD7	Mesenchymal
203753_at	TCF4	Mesenchymal
203813_s_at	SLIT3	Mesenchymal
203874_s_at	SMARCA1	Mesenchymal
203919_at	TCEA2	Mesenchymal
204065_at	CHST10	Mesenchymal
204140_at	TPST1	Mesenchymal
204165_at	WASF1	Mesenchymal
204173_at	MYL6B	Mesenchymal
204400_at	EFS	Mesenchymal

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
204466_s_at	SNCA	Mesenchymal
204521_at	C12orf24	Mesenchymal
204528_s_at	NAP1L1	Mesenchymal
204556_s_at	DZIP1	Mesenchymal
204557_s_at	DZIP1	Mesenchymal
204589_at	NUAK1	Mesenchymal
204612_at	PKIA	Mesenchymal
204749_at	NAP1L3	Mesenchymal
204759_at	RCBTB2	Mesenchymal
204773_at	IL11RA	Mesenchymal
204795_at	PRR3	Mesenchymal
204915_s_at	SOX11	Mesenchymal
205031_at	EFNB3	Mesenchymal
205079_s_at	MPDZ	Mesenchymal
205122_at	TMEFF1	Mesenchymal
205123_s_at	TMEFF1	Mesenchymal
205303_at	KCNJ8	Mesenchymal
205304_s_at	KCNJ8	Mesenchymal
205347_s_at	TMSB15A	Mesenchymal
205407_at	RECK	Mesenchymal
205525_at	CALD1	Mesenchymal
205545_x_at	DNAJC8	Mesenchymal
205741_s_at	DTNA	Mesenchymal
205794_s_at	NOVA1	Mesenchymal
205802_at	TRPC1	Mesenchymal
205803_s_at	TRPC1	Mesenchymal
205933_at	SETBP1	Mesenchymal
205961_s_at	PSIP1	Mesenchymal
206314_at	ZNF167	Mesenchymal
206580_s_at	EFEMP2	Mesenchymal
207030_s_at	CSRP2	Mesenchymal
207068_at	ZFP37	Mesenchymal
207719_x_at	CEP170	Mesenchymal
207781_s_at	ZNF711	Mesenchymal
207876_s_at	FLNC	Mesenchymal
208752_x_at	NAP1L1	Mesenchymal
208753_s_at	NAP1L1	Mesenchymal
208782_at	FSTL1	Mesenchymal
208848_at	ADH5	Mesenchymal
208962_s_at	FADS1	Mesenchymal
208963_x_at	FADS1	Mesenchymal
208964_s_at	FADS1	Mesenchymal
209087_x_at	MCAM	Mesenchymal
209118_s_at	TUBA1A	Mesenchymal

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
209197_at	SYT11	Mesenchymal
209198_s_at	SYT11	Mesenchymal
209209_s_at	FERMT2	Mesenchymal
209210_s_at	FERMT2	Mesenchymal
209285_s_at	C3orf63	Mesenchymal
209337_at	PSIP1	Mesenchymal
209440_at	PRPS1	Mesenchymal
209674_at	CRY1	Mesenchymal
209866_s_at	LPHN3	Mesenchymal
209867_s_at	LPHN3	Mesenchymal
210105_s_at	FYN	Mesenchymal
210220_at	FZD2	Mesenchymal
210298_x_at	FHL1	Mesenchymal
210299_s_at	FHL1	Mesenchymal
210852_s_at	AASS	Mesenchymal
210875_s_at	ZEB1	Mesenchymal
210882_s_at	TRO	Mesenchymal
210933_s_at	FSCN1	Mesenchymal
210973_s_at	FGFR1	Mesenchymal
211071_s_at	MLLT11	Mesenchymal
211126_s_at	CSRP2	Mesenchymal
211276_at	TCEAL2	Mesenchymal
211535_s_at	FGFR1	Mesenchymal
211602_s_at	TRPC1	Mesenchymal
211700_s_at	TRO	Mesenchymal
211701_s_at	TRO	Mesenchymal
211958_at	IGFBP5	Mesenchymal
211959_at	IGFBP5	Mesenchymal
212233_at	MAP1B	Mesenchymal
212262_at	QKI	Mesenchymal
212263_at	QKI	Mesenchymal
212265_at	QKI	Mesenchymal
212358_at	CLIP3	Mesenchymal
212382_at	TCF4	Mesenchymal
212385_at	TCF4	Mesenchymal
212386_at	TCF4	Mesenchymal
212387_at	TCF4	Mesenchymal
212413_at	SEP6	Mesenchymal
212414_s_at	N-PAC	Mesenchymal
212486_s_at	FYN	Mesenchymal
212491_s_at	DNAJC8	Mesenchymal
212561_at	DENND5A	Mesenchymal
212624_s_at	CHN1	Mesenchymal
212651_at	RHOBTB1	Mesenchymal

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
212713_at	MFAP4	Mesenchymal
212746_s_at	CEP170	Mesenchymal
212758_s_at	ZEB1	Mesenchymal
212764_at	ZEB1	Mesenchymal
212854_x_at	NBPFI0	Mesenchymal
212915_at	PDZRN3	Mesenchymal
212967_x_at	NAPIL1	Mesenchymal
212977_at	CXCR7	Mesenchymal
212982_at	ZDHHHC17	Mesenchymal
213110_s_at	COL4A5	Mesenchymal
213170_at	GPX7	Mesenchymal
213218_at	ZNF187	Mesenchymal
213262_at	SACS	Mesenchymal
213283_s_at	SALL2	Mesenchymal
213306_at	MPDZ	Mesenchymal
213316_at	KIAA1462	Mesenchymal
213329_at	SRGAP2	Mesenchymal
213340_s_at	KIAA0495	Mesenchymal
213348_at	CDKN1C	Mesenchymal
213411_at	---	Mesenchymal
213434_at	STX2	Mesenchymal
213666_at	SEP6	Mesenchymal
213864_s_at	NAPIL1	Mesenchymal
213891_s_at	TCF4	Mesenchymal
213992_at	COL4A6	Mesenchymal
214023_x_at	TUBB2B	Mesenchymal
214043_at	PTPRD	Mesenchymal
214051_at	TMSB15B	Mesenchymal
214212_x_at	FERMT2	Mesenchymal
214505_s_at	FHL1	Mesenchymal
214761_at	ZNF423	Mesenchymal
214913_at	ADAMTS3	Mesenchymal
214954_at	SUSD5	Mesenchymal
215143_at	DPY19L2P2	Mesenchymal
216033_s_at	FYN	Mesenchymal
216048_s_at	RHOBTB3	Mesenchymal
216873_s_at	ATP8B2	Mesenchymal
217714_x_at	STMN1	Mesenchymal
217820_s_at	ENAH	Mesenchymal
217897_at	FXVD6	Mesenchymal
218025_s_at	PECI	Mesenchymal
218032_at	SNN	Mesenchymal
218127_at	NFYB	Mesenchymal
218181_s_at	MAP4K4	Mesenchymal

Gene List 4. EMT-signature genes in clinical samples

Probe	Gene	Category
218223_s_at	PLEKHO1	Mesenchymal
218236_s_at	PRKD3	Mesenchymal
218263_s_at	ZBED5	Mesenchymal
218332_at	BEX1	Mesenchymal
218338_at	PHC1	Mesenchymal
218370_s_at	S100BP	Mesenchymal
218380_at	NLRP1	Mesenchymal
218573_at	MAGEH1	Mesenchymal
218646_at	C4orf27	Mesenchymal
218675_at	SLC22A17	Mesenchymal
218694_at	ARMCX1	Mesenchymal
218824_at	PNMAL1	Mesenchymal
219213_at	JAM2	Mesenchymal
219304_s_at	PDGFD	Mesenchymal
219372_at	IFT81	Mesenchymal
219387_at	CCDC88A	Mesenchymal
219410_at	TMEM45A	Mesenchymal
219479_at	KDELC1	Mesenchymal
219532_at	ELOVL4	Mesenchymal
219534_x_at	CDKN1C	Mesenchymal
219670_at	BEND5	Mesenchymal
219740_at	VASH2	Mesenchymal
219825_at	CYP26B1	Mesenchymal
219855_at	NUDT11	Mesenchymal
219972_s_at	C14orf135	Mesenchymal
220040_x_at	ZC4H2	Mesenchymal
220750_s_at	LEPRE1	Mesenchymal
221016_s_at	TCF7L1	Mesenchymal
221078_s_at	CCDC88A	Mesenchymal
221234_s_at	BACH2	Mesenchymal
221261_x_at	MAGED4	Mesenchymal
221959_at	FAM110B	Mesenchymal
222101_s_at	DCHS1	Mesenchymal
222146_s_at	TCF4	Mesenchymal
222164_at	FGFR1	Mesenchymal

CLAIMS

1. A method of generating a scheme allowing classification of a cancer of an individual patient for estimating a clinical outcome for said patient, wherein the method comprises:

- 5 a) identifying subtype clusters of a cancer type based on comparison of a set of gene expression data derived from clinical cancer samples of multiple test subjects suffering from said cancer type; wherein clinical samples are divided into subtype clusters of said cancer type based on the similarity of their gene expression data;
- 10 b) correlating the subtype clusters identified under a) to a specific clinical outcome of cancer;
- c) determining an epithelial-mesenchymal transition (EMT) signature, comprising:
- 15 i) determining a quantitative expression of at least two markers characteristic for each subtype clusters identified under a), wherein each of these markers is either characteristic for a mesenchymal cell phenotype or for an epithelial cell phenotype,
- ii) subjecting the results of the quantitative expression of the at least two markers to a regression analysis to thereby determine said epithelial-mesenchymal transition (EMT) signature,
- 20 iii) correlating the epithelial mesenchymal transition (EMT) signature to the specific clinical outcome of cancer identified in b);
- and
- d) estimating the outcome of a patient suffering from said cancer by:
1. assigning the set of gene expression data of said patient sample to any one of the subtype clusters according to a) and b), and
- 25 2. assigning the patient's epithelial-mesenchymal transition (EMT) score by determining the quantitative expression of the at least two markers in said patient sample and comparing it with the epithelial-mesenchymal transition (EMT) signature under c) to assign an epithelial-mesenchymal transition (EMT) score for said patient sample to correlate the EMT score to the specific clinical outcome of cancer.

2. The method of claim 1, wherein identifying the subtype clusters according to a) comprises:
- 35

- a') selecting a subset of genes which are most variably expressed across all set of gene expression data;
- b') subjecting the most variably expressed genes determined under a') to clustering to identify said subtypes of said cancer type.

5

- 3. The method of claim 2, wherein a gene is considered most variably expressed across all sets of gene expression data of all clinical samples referred to under a') if the standard deviation of the gene expression is higher across all sets of gene expression data in comparison to the standard deviation of any other gene.

10

- 4. The method of claim 2, wherein a gene is considered most variably expressed across all sets of gene expression data of all clinical samples referred to under a') if said gene has a higher variability in expression among all sets of expression data obtained from the clinical samples.

15

- 5. The method of claim 3 or 4, wherein the most 500 or 600 or 700 or 800 or 900 or 1000 variably expressed genes across all sets of gene expression data will be selected.

20

- 6. The method of claim 2, wherein the clustering algorithm for clustering according to b') is a hierarchical clustering with agglomerative linkage.

25

- 7. The method of claim 2, wherein the clustering algorithm for consensus clustering according to b') is a hierarchical clustering with agglomerative linkage with Euclidean distance and with a sub-sampling ratio of between about 0.5 to 0.9, preferably 0.8, for 1000 iterations.

30

- 8. The method of any one of claims 1 to 7, wherein assigning the set of gene expression data of said patient sample to a subtype cluster referred to under d) is carried out by

- selecting a set of gene expression data from test subjects which correlate the best with the cancer phenotype assigned to each of the subtype clusters under b) for a given subtype cluster;
- subdividing said set of gene expression data of a clinical sample selected from all subtype clusters equally into at least two training groups;
- determining gene expression signatures within the at least two training groups which are characteristic for each of the subtype clusters previously determined; and

35

- comparing the set of gene expression data of a patient sample with the expression signatures for determining to which subtype cluster the patient sample is to be assigned.

- 5 9. The method of claim 8, wherein an at least 50% or 60% or 70% or 75% match of the gene expression data of the patient sample with the expression signature of one of the subtype clusters assigns the patient sample to the respective subtype cluster.
- 10 10. The method of claim 8, wherein silhouette analysis is used to select sets of gene expression data from test subjects which correlate the best with the cancer phenotype assigned to each of the subtype clusters for a given subtype cluster.
- 15 11. The method of claim 10, wherein expression profiles having the highest silhouette values are selected from all subtype clusters to be subdivided into the at least two training groups.
- 20 12. The method of claim 8, wherein a regression model is used to determine gene expression signatures within one or both of the at least two training groups which are characteristic for each of the subtype clusters previously determined.
- 25 13. The method of claim 8, wherein a Bayesian probit regression model is used to assign the patient sample to one of the subtype clusters.
- 30 14. The method of any one of claims 1 to 13, wherein correlating the subtype clusters identified under a) to a specific clinical outcome of cancer is carried out by comparing the single samples assigned to any one of the subtype clusters with the clinical development of the test subject from which the respective set of gene expression data is obtained.
- 35 15. The method of any one of claims 1 to 14, wherein the cancer is selected from the group consisting of epithelial ovarian cancer (EOC), breast carcinoma, hepatocarcinoma, pancreatic carcinoma, glioblastoma multiforme (GBM), lung carcinoma, colorectal cancer and bladder carcinoma.
16. The method of any one of claims 1 to 14, wherein the cancer is a solid tumor type cancer.

17. A method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (EOC) wherein the method comprises:

a) providing a set of expression data in a patient sample obtained from a patient suffering from epithelial ovarian cancer (EOC);

b) assigning the set of expression data derived from said patient sample to one of five subtype clusters for epithelial ovarian cancer (EOC),

wherein the first of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 – Epi A;

wherein the second of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - EpiB;

wherein the third of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - Mes;

wherein the fourth of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - StemA;

wherein the fifth of the five subtype clusters of epithelial ovarian cancer (EOC) is characterized by the genes referred to in Gene List 2 - StemB;

c) determining an EMT score for the patient sample by

i) computing an enrichment score by integration of the difference between the empirical cumulative distribution functions of genes from Gene List 3 and genes not in Gene List 3 for each set of expression data from the individual patient samples to determine the epithelial rank or mesenchymal rank of a sample;

ii) determining the EMT score by subtracting the value for the epithelial rank from the value for the mesenchymal rank

d) estimating the clinical outcome depending on any one of the five subtype clusters and the EMT score to which the patient sample is assigned.

18. The method of claim 17, wherein assigning the set of expression data derived from said patient sample to one of five subtype clusters for epithelial ovarian cancer (EOC) is carried out either

a') by clustering the expression data derived from the patient sample together with the expression data which make up said five different subtype clusters of epithelial ovarian cancer (EOC) to determine to which group the expression data of the patient sample belongs; or

b') by subjecting the expression data obtained from the patient sample together with the expression data which make up said five different subtype clusters of epithelial ovarian cancer (EOC) to a regression analysis.

5 19. The method of claim 17 or 18, wherein the EMT score referred to under c) for a patient cancer sample is determined by:

g) computing an enrichment score by integration of the difference between the empirical cumulative distribution functions of genes from Gene List 4 and genes not in Gene List 4 for each set of expression data from the individual patient cancer sample to determine the epithelial rank or mesenchymal rank of a sample;

10 h) determining an EMT score by subtracting the value for the epithelial rank from the value for the mesenchymal rank.

15 20. The method of claim 18 or 19, wherein integration of the difference between the empirical cumulative distribution functions of genes from Gene List 3 or Gene List 4 and genes not in Gene List 3 or Gene List 4, respectively, for each set of expression data from the individual patient cancer sample to determine the epithelial rank or mesenchymal rank of a sample is carried out using single sample enrichment analysis.

20 21. A method of determining whether the epithelial mesenchymal score of a patient suffering from a cancer can be changed by administering an EMT reversal agent to increase patients susceptibility for an anti-cancer treatment, wherein the method comprises classifying a tumor sample of said patient using a method of any one of claims 1 to 20 to determine the cancer subtype and EMT score; after determining the cancer subtype and EMT score determining whether a treatment with an EMT reversal agent is necessary to

25 sensitize said patient to anti-cancer treatment.

22. The method of claim 21, wherein the anti-cancer treatment is any one of administering an anti-cancer drug, surgery, radiation therapy, chemotherapy, or hormonal therapy.

30 23. A cluster characterized in that it comprises at least one subtype cluster selected from the group consisting of subtype clusters shown in Gene List 2 - Epi A, subtype cluster shown in Gene List 2 Epi-B, subtype cluster shown in Gene List 2 - Mes, subtype cluster shown in Gene List 2 - Stem A and subtype cluster shown in Gene List 2 -Stem B.

35

24. A computer readable medium having stored therein a computer program comprising a set of executable instructions, when executed by a computer processor, controls the processor to perform the method according to any one of claims 1 to 16 or 17 to 20.
- 5 25. A computer program comprising a set of executable instructions, when executed by a computer processor, controls the processor to perform the method according to any one of claims 1 to 17 or 18 to 22.